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Asthma is a chronic inflammatory disease of the airways, affecting 
5.4 million people in the UK. Asthma pathology is characterised by 
airway hyper-responsiveness, bronchoconstriction, and airway 
remodelling. Airway remodelling is particularly prominent in severe 
asthma and describes structural changes within the airways 
including, ASM hyperplasia and hypertrophy, subepithelial fibrosis, 
mucus gland hyperplasia, and angiogenesis. The pleiotropic cytokine 
TGFβ is plays a central role in the development of all airway 
remodelling characteristics and is found to have increased activation 
in asthmatics versus non-asthmatics. Previous studies in ASM cells 
has shown that the integrin αvβ5 and the actin cytoskeleton is 
essential for TGFβ activation. Moreover, the heterotrimeric G-
proteins Gαq/11 have been implicated in TGFβ activation in murine 
embryonic fibroblasts and epithelial cells. However, the class of 
heterotrimeric G-protein required for TGFβ activation in ASM has not 
been established. The hypothesis of this thesis is that the 
heterotrimeric G-proteins Gαq/11 are required for TGFβ activation in 
ASM cells. 
The methodology of this thesis uses the GPCR agonist 
lysophosphatidic acid (LPA) and cyclical mechanical stretch as a 
stimulus to activate TGFβ in vitro. TGFβ activation has been primarily 
measured through western blotting of phospho-Smad2 (pSmad2). 
Inhibiting heterotrimeric G-protein activation has been carried out 
using a small molecule inhibitor of Gαq/11/14, YM-254890, and siRNA.  
The results in this thesis demonstrate, for the first time, that Gαq/11 
are not required for either LPA- or stretch-induced TGFβ activation in 
ASM cells. The serine/threonine kinase, Rho kinase (ROCKI/II), has 
been shown as central to LPA- and stretch-induced TGFβ activation 




been shown for the first time to be regulated Gα12/13, but not Gαq/11, 
in response to LPA in ASM cells. However, inhibition Gα12/13 by siRNA 
had no effect on LPA-induced pSmad2, therefore implying that LPA-
induced TGFβ activation may require ROCKI/II, but not RhoA. Finally, 
inhibition of both Gαq/11 and Gα12 did not reduce LPA-induced TGFβ 
activation, however, the role of Gα13 cannot be discounted due to 
incomplete knockdown.  
Collectively, these data disprove the hypothesis that the 
heterotrimeric G-proteins Gαq/11 are required for TGFβ activation in 
ASM cells. Moreover, they show that LPA- and stretch-induced TGFβ 
activation in ASM cells does not require either Gαq/11 or Gα12 signalling. 
The fascinating possibility that ROCKI/II, but not RhoA, is required 
for LPA-induced TGFβ in ASM cells requires further investigation. If 
this hypothesis proves to be true it could unlock new opportunities 
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1 Chapter 1: Introduction 
1.1 Asthma 
Asthma is a chronic inflammatory disease of the airways, resulting in 
185 people to be admitted to hospital every day in the UK because 
of exacerbation (2). Asthma pathology is characterised by airway 
hyper-responsiveness, bronchoconstriction, and airway remodelling. 
There are 5.4 million people in the UK who suffer from asthma with 
1.1 million children and 4.3 million adults (2). Asthma is more 
prevalent in developed countries, however the gap between 
countries is narrowing as it plateaus in high income countries and 
rises in low and middle income countries due to lifestyle and 
environmental changes such as a rise in pollution (3). Worldwide 
there are an estimated 300 million people with asthma and this 
number is expected to rise by more than 100 million by 2025. In the 
UK 1 in 12 adults and 1 in 11 children suffer from asthma equating 
to a total of 5.5 million individuals (AsthmaUK). There are presently 
no cures for the disease, however a combination of an inhaled short- 
or long-β2-adrenergic agonist and corticosteroid can control the 
disease in many patients. Approximately 10% of patients with 
asthma have a severe form of the disease that is refractory to 
corticosteroid treatment, resulting in frequent and uncontrolled 
exacerbation that lead to a long term reduction in lung function due 
to narrowing of the airway. 
Classically asthma has been characterised into two distinct types. 
Allergic (atopic) asthma occurs due to sensitisation to inhaled 
allergens such as house dust mite (HDM), animal dander, pollen and 
fungal spores, and can be detected by a positive skin prick test or 
IgE reactivity to these allergens (4). Atopic asthma is the 
predominant form seen in children and accounts for roughly half of 




triggered by a specific allergen and has no obvious involvement with 
the adaptive immune system (4). These patients are often resistant 
to steroid treatment and often suffer from more severe symptoms. 
Defining asthma as atopic or non-atopic is now seen as an 
oversimplification and it has been accepted that many factors 
contribute to varying degrees, resulting in a very heterogeneous 




Airway hyper responsiveness to inhaled allergens and pollutants 
present in the atmosphere is a key hallmark of asthma, particularly 
atopic asthma. Epithelial cells line the airway and are the first cells 
to come into contact with inhaled allergens. Dendritic cells migrate 
to the epithelial cell surface where they phagocytose the antigen. The 
antigen is broken down into short peptide fragments and presented 
on the dendritic cell surface as an antigen-major histocompatibility 
complex (MHC). The antigen-MHC is presented to naïve T helper cells 
(Th), also known as CD4+ cells, which differentiate into Type 1 helper 
(Th1) or Type 2 helper (Th2) cells. Increased IL-4 in the lung of 
asthmatic patients tips the balance of Th cell differentiation toward 
Th2 cells (6). Th2 effector cells include B lymphocytes which produce 
antigen-specific IgE antibodies that bind to the cell surface of mast 
cells, basophils, B lymphocytes, and eosinophils. This process of 
sensitisation results in the presence of immune cells that become 





1.1.2 Early and Late Asthmatic response 
Allergens that an asthma patient has been sensitised to can trigger 
an ‘exacerbation’ when inhaled, characterised by airway obstruction 
and a drop in forced expiratory volume in 1 second (FEV1). The 
response to an inhaled allergen can be broken into an early asthmatic 
response (EAR) and a late asthmatic response (LAR). 
Inhaled allergens bind to, and cross-link, IgE on the surface of mast 
cells and basophils. Subsequent degranulation of mast cells releases 
intracellular stores of histamine, tryptase, chemotactic factors, and 
activates signalling pathways that synthesise signalling lipids such as 
prostaglandins (PG). These mediators are responsible for initiating 
constriction of the bronchial airways (bronchoconstriction), 
stimulating mucus secretion, increasing permeability and dilation of 
the pulmonary blood vessels. EAR develops within 10-15 minutes of 
allergen inhalation, peaks at 30 minutes and resolves by 1-3 hours 
(7).  
The LAR is characterised as an eosinophilic inflammatory response 
that typically occurs 4 to 8 hours after the initial allergen exposure 
and results in bronchoconstriction. LAR is the result of an influx of 
active eosinophils and CD4+ TH cells (8, 9). Moreover, transfer of TH 
cells from ovalbumin sensitised mice, a model of asthma, into control 





1.2 Airway Inflammation 
1.2.1 Mast Cells 
Mast cells are a type of granulocyte originating from hematopoietic 
stem and are typically found in tissues exposed to the external 
environment. They play an important role in the inflammatory 
response seen in asthma. Within mast cells are granules containing 
heparin, proteases including chymase and tryptase, histamine, IL-4, 
IL-5, IL-6, and tumour necrosis factor (TNFα) (11, 12). They are 
stimulated by allergens, physical injury and pathogens by 
recognising damage-associated molecular patterns (DAMPS) and 
pathogen associated molecular patterns (PAMPS) respectively. In 
healthy patients mast cells are typically found surrounding blood 
vessels, however in asthmatic patients they migrate into airway 
structures. In the asthmatic airway mast cells are increased in the 
airway epithelium and mucous glands, but are predominantly found 
in airway smooth muscle (13). Bronchial biopsy of patients with 
asthma, eosinophilic bronchitis, and healthy controls found mast cells 
to be significantly higher in the smooth muscle of asthma patients 
than either control group (14). Moreover, an increase in mast cells is 
seen in the distal airways in histological sections from asthma 
patients versus healthy controls, with the greatest increase found in 
smooth muscle and mucous glands (15). Coculture of mast cells with 
ASM cells has been shown to increase TGFβ1 expression in ASM, 
caused by release of tryptase. This results in increased α-smooth 
muscle actin (αSMA) and cell contractility and has been suggested to 
switch ASM cells to a more contractile phenotype (16). Further, 
biopsy of the asthmatic bronchial mucosa shows αSMA staining 
intensity to correlate to the number of mast cells within or adjacent 




Mice that have mast cells genetically knocked out do not exhibit LAR. 
However, transfer of mast cells into these mice or intranasal 
administration of TNFα restores the LAR (17). Mast cells express the 
high affinity IgE receptor FcεRI. Upon binding of IgE, degranulation 
of mast cells occurs rapidly and releases histamine, serotonin, 
proteoglycans and proteases such as tryptase. This contributes to 
the EAR. Synthesis of cytokines and chemokines occurs which are 
released hours after the initial IgE binding, resulting in the LAR (18). 
Moreover, a humanized anti-IgE antibody, omalizumab, 
administered to patients with moderate-to-severe or severe asthma, 
attenuated inflammatory markers including IL-2, IL-4, IL5 and IL-13 
(19). 
In summary, mast cells migrate to the airway smooth muscle where 
they play a key role in mediating both the early and late asthmatic 
response in allergic asthma. 
 
1.2.2 T-lymphocytes 
T cells are a type of lymphocyte that have a T cell receptor on their 
surface and mature in the thymus. They can be divided in four 
subgroups; cytotoxic T cells (TC), helper T cells (TH), memory T cells, 
and regulatory T cells (Treg). Tc cells are also known as CD8+ due to 
the presence of this glycoprotein on their cell surface. They bind to 
infected or damaged cells to induce apoptosis via antigen associated 
to MHC class I that is expressed on all nucleated cells. TH cells are 
also known as CD4+ T cells and are involved in the adaptive immune 
system. They play a central role in activation of TC cells and in B cell 
antibody class switching. TH cell activation occurs upon antigen 
presentation by MHC class II molecules present on the surface of 
antigen presenting cells (APCs), such as dendritic cells, 




proliferate by releasing IL-2 and will polarise into either TH1 or TH2 
cells. The cytokine environment determines the polarisation of a TH 
cell. It is accepted that IL-4 induces TH2 polarisation once a threshold 
has been reached (20). In contrast, TH1 polarisation is induced by 
IL-12 and IL-18, which are predominantly released by dendritic cells 
and macrophages (21).  
There are several subtypes of TH cells grouped by the variety of 
cytokines and chemokines secreted. TH1 cells are involved in cell 
mediated immunity and secretes the cytokines interferon-γ (IFN-γ), 
interleukin-2 (IL-2), and tumour necrosis factor-β (TNF-β) (22). On 
the other hand, TH2 secrete interleukin-4 (IL-4), interleukin-5 (IL-5), 
interleukin-6 (IL-6), interleukin-9 (IL-9), interleukin-10 (IL-10), and 
interleukin-13 (IL-) (23, 24). GM-CSF and tumour necrosis factor-α 
(TNF-α) are cytokines secreted by both TH1 and TH2 cells. Asthma is 
considered to be a TH2 disease. Genetic depletion of CD4+ T cells 
ablates key asthma features, in contrast transfer of TH2 cells from 
OVA sensitised mice in null mice resulted in induction of asthma 
features (25, 26).  
Memory T cells are long lasting antigen specific cells that can 
circulate throughout the body or reside in tissues that are exposed 
to the environment and are able respond rapidly to repeated 
exposure of antigens (27). Treg cells, also known as suppressor T 
cells, can develop in the thymus or be induced peripherally. Briefly, 
in the lung Treg cells function to suppress immune response to 
antigens that may be continually inhaled and will be discussed in 
more detail later.   
1.2.3 Eosinophilic Asthma 
‘Asthma’ is a blanket term that describes an inflammatory disease of 
the airway that causes symptoms such as shortness of breath, 




phenotypic groups based on clinical characteristics (28). Eosinophilic 
asthma is viewed as a TH2 disorder, defined when induced sputum 
eosinophil count is greater than 2% of the total cell count (29). 
Eosinophils contain an array of pre-synthesised mediators in 
secondary granules that are thought to be implicated in asthma 
pathogenesis. Many cytotoxic mediators are contained within 
secondary granules, including eosinophil peroxidase (EPO), major 
basic protein (MBP), and eosinophil cationic protein (ECP), which are 
able to puncture the cell membrane, ultimately inducing cell lysis 
(30). Eosinophils are also a source of many pro-inflammatory 
cytokines including IL-4, IL-5, IL-6, IL-8, GM-CSF, and TNFα (31). 
Eosinophils stimulated with IFN-γ were able to induce apoptosis in 
cultured epithelial cells, an effect that was inhibited by pre-treatment 
with an anti-TNFα antibody (32). The release of mediators from 
eosinophils causes damage to the epithelium, a key feature of airway 
remodelling in asthma that will be discussed in more detail later. 
Moreover, mast cells are able to be reactivated, and release 
histamine, by a combination of MBP and eosinophil sonicate, 
suggesting a role for eosinophils contributing to the LAR (33).  
TH2 cells play an essential role in recruitment of eosinophils to the 
lung. Eosinophils migrate in response to cytokines, chemokines, and 
adhesion molecules. The cytokines IL-4 and IL-5 are released by TH2 
cells and are involved in IgE production and allergic sensitisation, 
and eosinophil survival respectively (23). IL-5 is an eosinophil 
chemoattractant. Levels of IL-5 have been correlated with eosinophil 
count in the BAL of both topic and atopic asthma (34). Vascular cell 
adhesion molecule-1 (VCAM-1) is an adhesion molecule that is 
essential for eosinophil tethering and rolling during recruitment to 
the lung. CD4+ deficient mice subjected to OVA sensitisation and 




inability to upregulate VCAM-1, and therefore prevent eosinophil 
migration (35). Moreover, addition of recombinant IL-13 to murine 
airways induces AHR and influx of eosinophils in BAL (24). IL-13, 
released by TH2 cells, binds to the IL-4 receptor. Both ablation of IL-
13 and blockade of the IL-4 receptor reverse AHR in a murine model 
of allergic asthma, however this effect was independent of airway 
eosinophilia (24). Goblet cell metaplasia is a process where epithelial 
cells transdifferentiate to produce mucus that blocks the airway 
lumen. The TH2 cytokines IL-4 and IL-13 are primarily responsible 
for goblet cell metaplasia and will be discussed in more detail later 
(23, 24, 36).   
A study of 42 patients with mild to moderate asthma found two 
distinct subtypes of asthma, classified as TH2hi and TH2lo. These 
groups were differentiated by expression of IL-5 and IL-33, which 
was significantly higher in TH2hi versus TH2lo groups (36). The TH2hi 
group had a significantly higher eosinophil count in both peripheral 
blood and BAL. Moreover, airway hyper-responsiveness in TH2hi 
group was significantly worst.  
Clinical trials have been carried out using drugs designed to block 
TH2 cytokine signalling. Dupilumab is an inhibitor of the IL-4 
receptor, thus blocking IL-4 and IL-13 signalling. Patients with 
moderate to severe asthma that presented with increased blood 
eosinophil count were treated with dupilumab. Treatment resulted in 
an improvement in lung function and reduced exacerbation 
frequency (37). IL-5 has been targeted directly by the development 
of mepolizumab. Asthma patients presenting with frequent 
exacerbations and eosinophilic inflammation had a significantly 
reduced exacerbation rate and increased lung function after 
treatment with mepolizumab (38, 39). The national institute for 




mepolizumab as an add-on therapy for patients with severe 
refractory eosinophilic asthma.  
In summary, TH2 cell polarisation is required for the recruitment of 
eosinophils to the airways in asthma. Eosinophil activation may play 
a role in the LAR, and recent clinical trials targeting TH2 cytokine 
signalling have been successful in reducing the frequency of 
exacerbation in patients with eosinophilic asthma. 
 
1.2.4 Neutrophilic Asthma 
A subset of asthma patients have a high neutrophil count and are 
described as having ‘neutrophilic asthma’. Reversible airflow 
obstruction in this subset of asthma is often incomplete and 
associated with corticosteroid resistance. Neutrophilic asthma has 
been shown to have a 30% prevalence in studies analysing bronchial 
biopsies and induced sputum samples (40, 41).  
Immunostaining of bronchial biopsies have identified markers of the 
IL-17 pathway to be present in neutrophilic asthma. A 3-fold increase 
in IL-17F+ positive cells was observed in patients with neutrophil-
high asthma (40). Increased expression of IL-17A, IL-17F, IL-22, 
and IL-23 have also been identified within the neutrophilic asthma 
subset (40).  IL-17 is increased in the airways of severe asthmatics 
and has been correlated to neutrophil count and airway hyper-
responsiveness (42). Moreover, treatment of murine tracheal rings 
and lung slices with IL-17A enhanced smooth muscle contraction. In 
human tracheal smooth muscle cells this was shown to occur because 
of an upregulation of ROCKII and increased phosphorylation of 
myosin light chain kinase (43). IL-17RA or IL-17A deficient mice 
have significantly reduced neutrophil recruitment to the lung after 




17 TH2 in a murine model of asthma showed that there was an 
increased influx of inflammatory cells, and exacerbated features of 
asthma, compared to classical TH2 cells (45). Additionally, adoptive 
transfer of TH17, the primary source of IL-17A and IL-17F, into mice 
subjected to OVA challenge increased recruitment of neutrophils 
(46).  
Phenotypic analysis of adults and children with acute asthma showed 
that asthma was typically eosinophilic in children and neutrophilic in 
adults (47). Moreover, patients with neutrophilic asthma also have 
eosinophils present within the mucosa. This raises the possibility that 
neutrophilic asthma may arise in patients with progressive severe 
asthma. A clinical trial has used the anti-IL-17 monoclonal antibody 
brodalumab, which inhibits both IL-17A and IL-17F, in asthmatics 
(48). The trial failed with no overall benefit to the asthma cohort, 
however, this study did not select patients based on the presence of 
IL-17, but rather on clinical status. These studies identify the IL-17 
pathway as a key feature of neutrophilic asthma and is associated 





1.3 Airway Remodelling 
Airway remodelling broadly describes the structural changes that 
occur within the small and large airways of asthmatic patients. 
Common features include epithelial damage, angiogenesis, mucous 
gland hyperplasia, ASM hypertrophy and hyperplasia, and 
subepithelial fibrosis. Airway remodelling is associated with an 
accelerated loss of lung function that is greater in asthmatic patients 
when compared to healthy patients (49, 50). Moreover, there has 
been an association of asthma severity with airway remodelling (51). 
There is a consensus that airway remodelling is a secondary event to 
inflammation (52). Overexpression mouse models of the TH2 
cytokines IL-4, IL-5, IL-9, and IL-13 result in spontaneous airway 
inflammation, airway hyper-responsiveness, increased mucus 
secretion, and airway remodelling (53-56). Cytokines IL-4 and IL-5 
play a key role in eosinophil infiltration into the lung and have been 
discussed in detail above. The effects of IL-9 in the asthmatic lung 
require the presence of IL-13 (57). However, IL-13 does directly 
affect structural changes in the lung, including goblet cell metaplasia, 
by acting directly on epithelial cells (58). The pleiotropic cytokine 
transforming growth factor-beta (TGFβ) also plays a central role in 
airway remodelling in asthma. This chapter will discuss the features 
of airway remodelling, and the mechanistic process that drives them 






1.3.1 Airway Epithelium 
The epithelial layer acts as a barrier between the external 
environment and the internal structure of the airways. It is, 
therefore, frequently in contact with inhaled foreign bodies. The 
epithelium plays an essential role in maintaining healthy airways but 
in asthma the integrity of the epithelium is disrupted. This is known 
as epithelial shedding, a process that is widely accepted as an early, 
or initial, step in asthma pathogenesis (52). Moreover, biopsies of 
asthmatic bronchoscopy demonstrate that there is significant loss of 
epithelium when compared to the controls (59). In turn, the degree 
of epithelial shedding has been associated with airway reactivity 
(60). Susceptibility to epithelial shedding has been linked with a 
reduction of E-cadherin in the epithelium of asthmatics, which can 
be induced by house dust mites (61, 62). Immunostaining of the 
epithelial damage marker, epidermal growth factor receptor (EGFR), 
is increased in bronchial biopsies of asthmatics (63). TGFβ is able to 
initiate epithelial cell apoptosis and promote epithelial mesenchymal 
transition in the airway epithelium of asthmatic patients (64, 65).  
Damage to the airway epithelium in asthma is accompanied by 
reduced ability to regenerative capability (66). Consequently, 




damage to the epithelium increases exposure in inhaled agents, 
airway hyper-responsiveness, and sensitivity to oxidants (67). An 
increase in mucous is observed in the airway of asthmatics, due to 
goblet cell and mucous gland hyperplasia. Increased mucous 
production reduced the lumen area and is prominent in fatal asthma 
(68).  
 
1.3.2 Subepithelial Fibrosis 
The subepithelial layer is formed of ECM proteins including collagens, 
fibronectin, tenascin, and proteoglycan. Subepithelial fibrosis 
describes the process of basement membrane thickening and 
reduced elasticity of the airways due to deposition of fibrous proteins 
below the epithelium.  Although subepithelial fibrosis has been 
reported in all severities of asthma, there is an association between 
asthma severity and thickness of the basement membrane (69, 70). 
An increase in collagen I, III and VII, fibronectin, lumican, and 
tenascin are seen in the asthmatic airway, most significant in 
individuals with severe asthma (71-73). Transcription of these genes 
can be induced by TGFβ, which is found at elevated levels within the 
airway of asthmatic patients (74).  
Deposition of the extracellular matrix (ECM) is primarily controlled 
by fibroblasts and myofibroblasts (75). In fibrotic airways fibroblasts 
can polarise to myofibroblasts and have a greater presence in the 
airways of asthmatic versus healthy patients and in uncontrolled 
versus controlled asthmatics (76-78). TGFβ promotes fibroblast to 
myofibroblasts differentiation and proliferation by inducing release of 
fibroblast growth factor-2 (FGF-2) (79, 80). The number of activated 
fibroblasts and myofibroblasts are increased in the airways post 
allergen challenge, suggesting that exacerbation increases ECM 




that repeated exacerbation increased airway resistance associated 
with collagen deposition (82). TGFβ also induces expression of matrix 
metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs), which are essential regulators of ECM 
structure (83). Ultimately subepithelial fibrosis induces structural 
changes in the lung that make breathing more difficult for a severe 
asthma by contributing to airway narrowing and resistance (84). 
 
1.3.3 Airway Smooth Muscle Hyperplasia & Hypertrophy  
The ASM mass in the large and small asthmatic airways is greater 
than healthy patients. It has been associated with disease duration 
and severity (85, 86), and is attributed to both hyperplasia and 
hypertrophy, which are in turn associated with an increase in ECM 
(87-90). This contributes to stiffness of the airways as well as 
narrowing and persistent airway obstruction. Moreover, the larger 
ASM bundle undergo more forceful contractions during exacerbation 
and therefore increases the likelihood of complete occlusion of the 
airways.  
The relative contribution of hypertrophy and hyperplasia to the ASM 
bundle is a matter of debate and can vary depending on the location 
of the airway. Hypertrophy is a natural process that occurs when 
muscle is put under repeated stress, however hypertrophy has been 
observed in children with asthma, suggesting that there is a 
pathologic process occurring rather than a homeostatic one (89). The 
evidence of hypertrophy is limited because there are more 
opportunities to introduce experimental artefact and cell size is more 
difficult to quantify. Measurement of ASM cell size in biopsies of 
patients with asthma have shown them to be larger than control 
patients (87, 89). Conversely, a study of ASM in biopsies of patients 




higher compared to control patients and there was no evidence of 
hypertrophy or gene expression changes (88). Moreover, cells 
cultured from explants of asthmatic lungs have a faster proliferation 
rate than those from healthy controls (91). In the asthmatic airway 
there are a plethora of inflammatory cytokines that modulate cell 
activity, some of which induce ASM cell hypertrophy, including 
angiotensin and TGFβ (92, 93). Many of these also promote cell 
proliferation, including TGFβ, tryptase, sphingosine-1-phosphate 
(S1P) (94-96).  
In addition to hyperplasia and hypertrophy, cell migration has been 
implicated in enlarged ASM mass. There is evidence that ASM cells 
can migrate in response to platelet derived growth factor (PDGF) and 
TGFβ in culture, however this is yet to be shown in human asthma 
(97). Myofibroblasts are contractile cells that are responsible for ECM 
deposition and have been found to migrate to the airways after 
allergen challenge, where it has been suggested that they could 
transdifferentiate to ASM cells, although this has not yet been proven 
(81, 98). Fibrocytes are mesenchymal precursors that circulate in the 
peripheral blood. In asthma there is not only an increase in 
circulating fibrocytes, but also an increase in the number of 
fibrocytes within the ASM bundle (99, 100). Moreover, fibrocytes 
have been shown to migrate to the airway of asthma patients after 
allergen challenge where they are able to adopt a contractile 
phenotype (101). These highlight the mechanisms, including 
hypertrophy, hyperplasia, and migration, that contribute to an 







Angiogenesis describes the process of forming new blood vessels, a 
process involving the migration, growth and differentiation of 
endothelial cells. Increased vascularisation both in terms of the 
number and area covered has been observed in the airway wall in 
fatal asthma (102). Analysis of biopsies from the asthmatic airway 
identified that both the number and size of blood vessels are 
increased compared to healthy controls (103, 104). Angiogenesis 
however, is not limited to patients with severe fatal asthma. Biopsies 
from patients with mild asthma showed that both the number and 
size of the blood vessels were increased when compared to healthy 
controls (105).  
Angiogenesis is stimulated by inflammatory mediators such as 
vascular endothelial growth factor (VEGF) and plasminogen activator 
inhibitor-1 (PAI1). VEGF is a potent activator of endothelial cell 
growth and vascular permeability (106).  The number of VEGF 
positive cells within the airway has been correlated to vascular area 
(107).  VEGF is increased in the airways of asthmatics and can be 
secreted by a range of cells, including eosinophils and macrophages, 
fibroblasts, and ASM (108). The TH2 cytokines IL-4, IL-5, IL-13 and 
TGFβ enhance VEGF production by fibroblasts and ASM cells (109, 
110). VEGF can also upregulate the expression of metalloproteinase-
9 (MMP-9), which plays a critical role in ECM turnover, suggesting 
angiogenesis can directly alter the ECM (111).  Moreover, PAI1 is one 
of the genes that is regulated by TGFβ and contributes to airway 
remodelling (112). Overall, angiogenesis contributes to reduced 
airway lumen size due to oedema from permeable blood vessels, and 




1.3.5 Goblet cell and mucous gland hyperplasia 
There is clear evidence of goblet cell and mucous gland hyperplasia 
in asthmatic biopsies, most prominent in cases of fatal asthma (68, 
113). The consequence of mucous gland hyperplasia is that more 
mucous is secreted into the airway of asthmatics. Not only is there 
an increase in the amount of mucous but mucociliary clearance is 
also impaired in asthmatics due to a damaged epithelium (114). 
Mucins are the major component of mucous. In human patients 
MUC5AC is the primary expressed mucin, and is found to be higher 
in asthmatic patients versus healthy patients (115). MUC5AC is 
thought to impair mucociliary clearance by tethering mucous to 
epithelial cells, thus increasing the probability of airway plugging 
(116). TGFβ2 has been shown to induce synthesis of mucins in 
airway epithelial cells (117). Mice subjected to the OVA model of 
asthma have increased goblet cells and mucous production, which is 
attenuated by an anti-TGFβ antibody (118). There is limited evidence 
behind mechanism of goblet cell hyperplasia in asthma. However, it 
is clear that mucous production is increased and clearance is reduced 
in the airways of asthmatic patients. Consequently, the lumen area 






1.4 Airway Smooth Muscle 
ASM cells are spindle shaped mesenchymal cells that play an 
important structural role within the lung and collectively form a 
contractile bundle. They are described as having a “hill and valley” 
formation when fully confluent in tissue culture (119). As described 
in section 1.1.3 airway smooth muscle mass is greatly increased in 
the lungs of asthmatic patients. This is critical because airway hyper-
responsiveness to external stimuli is a key characteristic of asthma 
and ASM cell contraction results in bronchoconstriction during acute 
exacerbation. Smooth muscle cells also contribute to the 
inflammatory milieu by secreting cytokines, growth factors, and 
inflammatory mediators. Moreover, ASM cells exhibit phenotype 
plasticity allowing them to switch between contractile and secretory 
phenotypes in response to mitogens and changes to the ECM (120-
122)  
 
1.4.1 ASM Cell Contraction 
 
Figure 1.2 Overview of signalling pathways that induce smooth muscle 




There are two distinct pathways that are involved in ASM cell 
contraction, which I will refer to as calcium-dependent and calcium-
independent. It has been suggested that calcium-dependent cells 
contraction is rapid, whereas calcium-independent contraction is 
longer and sustained (123). The first step of transducing extracellular 
stimuli to cellular contraction requires a heterotrimeric G-protein 
coupled receptor (GPCR). They are composed of α, β, and γ subunits, 
where β and γ (βγ) are perpetually bound. Upon ligand binding there 
is a conformational change, prompting GDP to GTP exchange in the 
α subunit and therefore releasing βγ dimer.  
In the calcium-dependent pathway, all four members of the Gαq 
family bind directly to PLCβ on the cytosolic side of the cell 
membrane (124). Activated PLCβ hydrolyses phosphatidylinositol-
4,5-bisphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG), which both play independent roles in smooth 
muscle contraction. IP3 binds to the IP3 receptor on the sarcoplasmic 
reticulum, opening Ca2+ channels and resulting in efflux of Ca2+ from 
the sarcoplasmic reticulum into the cytosol. Intracellular Ca2+ binds 
to calmodulin inducing a conformational change that in turn allows it 
to bind and activate myosin light chain kinase (MLCK). 
Phosphorylation of Ser20 of the regulatory MLC by MLCK results in 
myosin cross bridge cycling and cellular contraction. DAG, on the 
other hand, binds to the serine/threonine kinase PKC along with Ca2+ 
and directly phosphorylates MLCK (125).  
The calcium-independent pathway involves activation of the small 
GTPase RhoA. The heterotrimeric G-proteins Gα12 and Gα13 have 
classically been linked to RhoA and involved in stress fibre formation, 
however recent evidence has also linked Gαq and Gα11 to RhoA 
activation (126-128). RhoGEFs (Rho guanine nucleotide exchange 




activation and allowing it to bind its effectors ROCKI/II, which are 
serine/threonine kinases (129). ROCKI/II phosphorylates the 
myosin-binding subunit of myosin light chain phosphatase (MLCP) at 
Thr696 and Thr853, inactivating its phosphatase activity and 
preventing interaction with MLC (130). This results in sustained 
contraction and induces calcium sensitivity. ROCKI/II also play a role 
in stress fibre formation. Stress fibres are composed of 10-30 actin 
filaments, cross-linked by α-actinin, and bind to focal adhesions that 
anchor the cytoskeleton to the ECM (131). Stress fibres can transmit 
intracellular force to the focal adhesions, which subsequently activate 
mechanosensitive proteins such as talin and integrins (132). This is 
of particular importance in airway remodelling because the αvβ5 
integrin activates TGFβ (133). ROCKI/II promote stress fibre 
formation by phosphorylating the actin binding kinases, LIM kinases 
1 and 2, which in turn phosphorylate and inactivate the actin-
depolymerising factor cofilin (134). Inhibition of ROCKI/II causes 
stress fibres and focal adhesions to disassemble in fibroblasts (123). 
The result of ROCKI/II activation is that actin dynamics are tipped in 
favour of assembly and stable actin stress fibres form. 
The contractile apparatus of ASM are composed of thick myosin 
filaments and thin actin filaments. Contraction occurs when the actin 
and myosin filaments slide across each other by the well described 
‘sliding filament mechanism’. Phosphorylation of the MLC by MLCK 
leads to a conformational change in the myosin head and induces 
ATPase activity in the myosin head. Subsequently the myosin head 
binds to the thin actin filaments forming a cross-bridge and inducing 
cross-bridge cycling. Termination of ASM contraction requires 
dephosphorylation of MLC, which is carried out by MLCP. A study 




found that it was increased in asthmatics, suggesting that this could 
contribute to airway hyper-responsiveness and contractility (135). 
Blocking Ca2+ channels has been trialled as a treatment for asthma 
to prevent exacerbation and ASM contraction. Trials using diltiazem, 
nifedipine, and verapamil, found that exercise-induced 
bronchospasm was inhibited, however they did not inhibit contraction 
induced by external stimuli and were limited by potency and side 
effects (136). Current bronchodilator drugs such as salbutamol and 
formoterol target β2-receptors that activate cAMP and subsequently 
protein kinase A (PKA), which reduces cytosolic Ca2+ and directly 
activates MLCP (137). There is however, a population of severe 
asthmatics, which constitute 10% of the total asthmatic population, 
whom do not respond to β2-agonists and suffer from frequent and 
uncontrolled exacerbation. 
In summary, two distinct mechanisms of ASM cell contraction have 
been described, both of which induce contraction with slightly 
different outcomes. Despite being distinct there is cross-talk between 
these pathways at the point of MLC regulation, with the calcium-
dependent pathway activating MLCK and promoting contraction and 
the calcium-independent pathway inhibiting MLCP activity thus 
preventing negative regulation of contraction. In asthma there is 
particular interest in the calcium-independent pathway because of 






1.5 Heterotrimeric G-proteins 
G-protein coupled receptors (GPCRs), also known as seven 
transmembrane receptors, are the largest and most diverse family 
of membrane receptors found in eukaryotic cells (138). GPCRs are 
coupled to heterotrimeric G-proteins, composed of Gα and βγ 
subunits, which bind to a pocket on the cytosolic side of the receptor. 
The Gα subunit contains a GTP binding pocket and has inherently low 
GTPase activity. The βγ subunits are permanently coupled and do not 
disassociate from one another. When GDP is bound the Gα and βγ 
form an inactive trimer; upon exchange of GDP for GTP, βγ 
disassociate from the Gα subunit to initiate signalling.  
Upon ligand binding to the receptor there is a conformational change 
in the transmembrane helices 3 and 6 which alter the shape of the 
binding pocket in which the G-protein trimer is coupled (139). This 
induces the exchange of GDP to GTP in the Gα subunit. Gα<GTP> 
dissociates from the βγ dimer becoming catalytically active to induce 
its target signalling pathways. Heterotrimeric G-proteins are divided 
into 4 classes and are based on sequence homology of the 
catalytically active Gα subunit; Gαs, Gαi/o, Gαq/11, Gα12/13. The inherent 
GTPase activity of the Gα subunit is low, therefore GTPase-activating 
proteins (GAPs) are the primary negative regulators of G-protein 
signalling, increasing the rate of hydrolysis 50-fold (138). 
 
1.5.1 Gαq/11 signalling 
The Gαq/11 family comprises 4 alpha subunits; Gαq, Gα11, Gα14, Gα16. 
Gαq/11 are ubiquitously expressed, Gα14 is expressed in the lung, liver, 
and kidney, Gα16 is only found in hematopoietic cells. The GPCRs 
coupled to Gαq/11 include but are not limited to, the M1, M3, and M5 
muscarinic receptors, angiotensin II type 1 receptor, and LPA 




binding causing the releasing of an auto-inhibitory loop and allowing 
it to catalyse PIP2 to IP3 and DAG (141). As discussed in the previous 
section, this leads to Ca2+-dependent contraction. The α subunit has 
intrinsic GTPase activity, however PLCβ acts as a GTPase-activating 
protein (GAP) thereby increasing GTPase activity by more than 50-
fold and acting as a negative regulator of Gαq/11 (142). 
More recently, there has been emerging evidence that Gαq/11 are able 
to activate more than just PLCβ. One of these targets include 
p63RhoGEF, known to activate the small G-protein RhoA, and 
interestingly is also a target of Gα12/13 (143). Another target, 
leukemia-associated RhoGEF (LARG) has also been linked with RhoA 
activation via Gαq (144).  Despite both of these heterotrimeric G-
protein families being able to activate RhoA, Gαq/11 has been shown 
to do so at a lower potency than Gα12/13 in mouse embryonic 
fibroblasts (145). This provides evidence that there is cross-talk 
between heterotrimeric G-protein signalling pathways that may be 
regulated based on the compliment of RhoGEFs within certain cell 
types. Indeed, mechanical ventilation-induced TGFβ activation, 
thought to involve RhoA, in the murine lung is abolished when 
epithelial Gαq/11 is genetically absent (127). Gαq/11 are also able to 
activate MAPK and ERK signalling pathways in both a PLCβ-
independent and PLCβ-dependent manner. In epithelial cells ERK 
signalling has been shown to activate inflammatory molecules, 
including IL-8, which increased ASM cell proliferation and may 
contribute to ASM hypertrophy (146).   
 
1.5.2 Gα12/13 signalling 
Gα12/13 are expressed ubiquitously. GPCR receptors coupled to Gα12/13 
include, angiotensin II type 1 receptor, endothelin, S1P, and LPA 1, 




Gαq/11, suggesting that activation of these pathways may occur in 
tandem. Gα12/13 are activated by GPCRs in the same manner 
described for Gαq/11. Upon activation of Gα12/13 and the Gα<GTP> can 
be bound by the RhoGEFS p115RhoGEF, PDZ-RhoGEF, and LARG 
(148, 149). These RhoGEFS contain an RH domain that binds to 
Gα12/13 and functions as a GAP, thus enhancing GTP hydrolysis and 
acting as a negative regulator of signalling. Moreover, they contain 
a Dbl-homology (DH)/pleckstrin-homology (PH) domain that directly 
interacts with RhoA and exhibits GEF activity to induce a 
conformational change resulting in exchange of GDP to GTP (150). 
RhoGEF localisation to the plasma membrane is thought to be 
regulated by the PH and RH domains thus ensuring close proximity 
to the heterotrimeric G-proteins (151). Activated RhoA 
phosphorylates its primary effector ROCKI/II, which in turn inhibits 
MLCP, promoting contraction. Studies on vascular smooth muscle 
cells have shown that upon treatment with a range of 
vasoconstrictors there is a dual role for Gαq/11 and Gα12/13 coupling to 
GPCRs and regulating phosphorylation of MLC and thus smooth 
muscle tone (152). A fourth RhoGEF is known to interact with Gα12/13, 
A-kinase anchor protein 13 (AKAP13), however this protein differs 
from the other three because it does not exhibit GAP activity to 
stimulate hydrolysis of GTP (153). In a rat model of asthma, 
repeated allergen exposure was shown to increase the abundance of 





1.5.3 Gαs and Gαi signalling 
 
Signalling of Gαs- and Gαi-linked GPCRs revolve around regulating the 
enzyme adenylyl cyclase (AC). Upon activation of a Gαs-coupled 
receptor, GDP is exchanged for GTP and the catalytically active Gα 
subunit dissociates from the Gβγ subunit, increasing AC activity. In 
contrast, Gαi antagonises this system by inhibiting AC activity. There 
are nine AC isoforms that are widely distributed across tissues of the 
body (155). It functions to catalyse the conversion of ATP into the 
secondary messenger cyclic adenosine monophosphate (cAMP). An 
increase in intracellular cAMP results in the activation of protein 
kinase A (PKA), which inhibits MLCK and therefore blocks smooth 
muscle contraction (156). In ASM cells PKA has been shown to 
promote bronchodilation, thus asthma management strategies have 
sought to exploit this pathway (157). 
The most common asthma management medications are inhaled β2-
adrenoceptor (β2-AR) agonists (158). They function by acting on the 




Gαs-linked β2-AR, which activates AC and increases intracellular 
cAMP, resulting in PKA activation and bronchodilation. They are 
primarily used to relieve acute exacerbation and to manage asthma 
in combination with inhaled corticosteroids, however, 10% of 
asthmatics do not respond to treatment (158). Crosstalk between 
Gαs and Gαi has been shown in cultured human ASM cells.  After 
prolonged treatment of ASM cells with a β2-AR agonist, PKA is able 
to activate Gαi-βγ signalling, which in turn activates the cAMP 
hydrolysing enzymes PDE4 (159). This mechanism has been 
attributed with β2-AR agonist insensitivity.  
In a rat model of airway hyper-responsiveness, induced by repeated 
allergen exposure, Gαi3 was found to have increased expression in 
bronchial smooth muscle cells (160). Moreover, transgenic mice 
overexpressing Gαi2 were found to have reduced contractile 
responses after methacholine challenge (161). However, the role of 





1.6 Transforming Growth Factor β 
TGFβ is a pleiotropic cytokine that is found in abundance within the 
ECM. It plays an essential role in homeostatic regulation of 
inflammation, tissue repair, and cell proliferation.  There is a large 
body of evidence that describes its role in fibrosis and airway 
remodelling within the airways. The features of airway remodelling, 
subepithelial fibrosis, epithelial damage, ASM hyperplasia and 
hypertrophy, goblet cell hyperplasia, and angiogenesis have been 
described in section 1.3. Although TGFβ is central to these processes, 
abolition of its signalling pathway is not a viable treatment option 
due to its pleiotropic nature. At lower concentrations TGFβ acts as a 
suppressor of inflammation, however in a fibrotic diseased state 
TGFβ activation increases to a pathologic levels and promotes airway 
fibrosis. The process of airway remodelling may act homeostatic 
response to protect against particular features of asthma such as 
airway hyper-responsiveness (AHR). A murine OVA model of asthma 
resulted in an increase in total TGFβ and fibrosis, which was reduced 
with an anti-TGFβ antibody but this also increased AHR (162). 
Moreover, overexpression of active TGFβ1 in rat airways results in 
an increase in fibrotic markers, including ECM deposition, fibronectin, 
and myofibroblasts (163).  
 
1.6.1 TGF-β Synthesis and Structure 
Transforming growth factor beta (TGFβ) is a pleiotropic cytokine that 
belongs to the transforming growth factor superfamily, which is 
composed of at last 30 signalling molecules including the activin and 
inhibins, bone morphogenetic proteins, and the TGFβ subfamily; 
TGFβ1, TGFβ2, and TGFβ3. The three TGFβ isoforms share 64-85% 
sequence homology and are expressed in most cell types in humans, 




TGFβ is synthesised as a pro-hormone composed of a short C-
terminal sequence that forms the active TGFβ molecule, a long N-
terminal that forms the latency-associated peptide (LAP), and a 
signal sequence (165). The pro-hormone is cleaved in the Golgi 
complex by the endopeptidase furin, separating C-terminal TGFβ and 
N-terminal LAP domains (166). Individual LAP and TGFβ monomers 
form homodimers via disulphide bonds.  Both of these homodimers 
associate by another disulphide bond forming a complex referred to 
as the small latent complex (SLC). The LAP undergoes folding so that 
it envelops active TGFβ, preventing TGFβ from interacting with its 
receptors. Latent TGFβ binding protein (LTBP) binds to the SLC via 
disulphide bonds between cysteine residues on TGFβ and LTBP, 
forming a molecule known as the large latent complex (LLC) (166). 
TGFβ is secreted from most cells as the LLC. LTBP is a 120-240kDa 
protein glycoprotein that regulates the bioavailability of TGFβ by 
tethering it to the ECM where latent TGFβ is stored (167). Latent 
TGFβ can therefore be stored in abundance within the ECM.  
Liberation of the active TGFβ homodimer can be carried out by 
proteases such as plasmin, MMP-2 and MMP-9, reactive oxygen 
species, or integrins (133, 168, 169).   
 
1.6.2 TGFβ Activation 
TGFβ is secreted from cells and stored in the ECM. Its activation is 
the rate limiting step to its bioavailability (170). A number of 
methods of liberating the active TGFβ molecule from its LAP have 
been described including, acidification, alkalisation, high 
temperature, and reactive oxygen species (171, 172). However, very 
few mechanisms have been shown to have relevance in vivo. Some 
key mechanisms of TGFβ are described in more detail here, with 





1.6.2.1 Integrin mediated TGF-β Activation  
TGFβ activation occurs when the active molecule is liberated from 
the LAP, allowing it to bind to its receptor. One method of liberation, 
crucially relevant to this thesis, occurs upon binding of an integrin. 
Integrins are mechanosensitive cell surface proteins composed of α 
and β subunits that bind to components of the ECM including 
fibronectin, collagen, and laminin, and also interact with other cells. 
There are five integrins that can activate TGFβ; αvβ1, αvβ3, αvβ5, 
αvβ6, and αvβ8 (133, 173-176).  
Integrins undergo conformational change upon sensing force. When 
inactive they remain in a ‘closed’ conformation that sterically 
prevents the head domain from interacting with its target RGD 
sequence. Upon feeling force the integrin lengthens into an ‘open’ 
conformation allowing the binding head to interact with various 
targets.  The force that activates integrins can be from both external 
or internal signals, so called ‘outside-in’ and ‘inside-out’ signalling. 
Internal force leading to integrin activation can be generated by 
reorganisation of the actin cytoskeleton. This occurs during cellular 
contraction induced by binding of agonists such as LPA and 
methacholine. Integrins are predominantly found at focal adhesion 
sites where the cytoskeleton is linked to the ECM via multiple 
structural proteins including talin and vinculin (177). The large 
mechanosensitive protein talin binds to the cytoskeletal tail of 
integrin, which is linked to the actin cytoskeleton via the crosslinking 
protein vinculin (178). Mature TGFβ is enveloped by the LAP that 
renders it inactive. The LAP of TGFβ1 and TGFβ3, but not TGFβ2, 
contains an RGD sequence that is a target of integrin. Therefore, 




conformational change and liberate mature TGFβ, allowing it to 
interact with cell surface receptors. 
Processes such as cellular contraction in response to GPCR agonists 
via the Ca2+-dependent and Ca2+-independent pathways described 
in section 1.4.1 result in cytoskeletal reorganisation. This induces the 
formation of focal adhesion complexes, leading to talin binding to the 
cytoplasmic tail of integrin and its subsequent activation. In severe 
asthma, this mechanism of TGFβ activation is prominent because 
patients suffer from frequent and uncontrolled exacerbation 
therefore exerting force throughout the airways. 
ASM cells from asthmatics activate more TGFβ than those from non-
asthmatics in response to methacholine and LPA (133). Cultured ASM 
cells treated with anti-β5 antibody inhibited methacholine and LPA-
induced TGFβ, demonstrating that the αvβ5 integrin is responsible 
for TGFβ activation in ASM cells (133). Moreover, mutations in the 
talin binding portion of the cytoplasmic tail of β5 abolished TGFβ 
activation, confirming that talin is essential for integrin mediated 
TGFβ activation (133). The actin assembly inhibitor, cytochalasin D, 
also prevents contraction-induced TGFβ activation because integrin 
cannot be activated without being linked to the cytoskeleton. Airway 
remodelling observed in the OVA model of asthma is completely 
abolished in vivo upon application of an RGDS peptide that blocks 
the binding site of integrins, thus preventing integrin mediated TGFβ 
activation (179). Moreover, transgenic mice with a mutation in the 
RGD sequence to RGE in the LAP shared characteristics of TGFβ null 
mice despite normal levels of TGFβ synthesis (180). ECM matrix 
stiffness has also been implicated in TGFβ activation. In 
myofibroblasts, αvβ5-mediated TGFβ activation was found to 




In contrast to ASM cells, epithelial cells activate TGFβ via the αvβ6 
integrin (181). Initially the GPCR agonist thrombin has been shown 
to activate αvβ6 and TGFβ by binding to the PAR1 receptor (175). 
Agonist-induced TGFβ activation in epithelial cells was shown to 
induce cytoskeletal reorganisation via RhoA and ROCKI/II (128). 
Moreover, LPA-induced TGFβ activation was inhibited by siRNA 
knockdown of Gαq/11 but not Gα12/13 or Gαi (128). Interestingly, total 
TGFβ within the murine lung is increased after high-pressure forced 
ventilation, but this effect is abrogated upon epithelial knockout of 
Gαq/11 (127). These studies suggest that GPCR agonist induced TGFβ 
activation occurs via a Gαq/11 RhoA-integrin pathway in epithelial 
cells. 
TGFβ activation can also occur via mechanical signalling without 
addition of an agonist. The mechanosensitive nature of integrin and 
talin allows TGFβ activation in response to force, such as matrix 
stiffness and mechanical stretch (182-184). There is evidence that 
TGFβ gene expression is increased in response to 12% cyclical 
stretch in ASM cells, which required RhoA and ROCKI/II (183). It is 
not clear however, whether stretch directly results in TGFβ 
activation. A study of cyclical stretch on vascular smooth muscle cells 
showed secretion of TGFβ was inhibited by the angiotensin receptor 
inhibitor, saralasin (185). This implies that stretch induces the 
release of autocrine factors that act on cell surface receptors in 
induce TGFβ release. Release and activation of TGFβ in response to 
stretch causes the release of ECM components including fibronectin 
and collagen (182, 185). The implication in asthma is that 
uncontrolled exacerbation increases mechanical force within the 






1.6.2.2 Proteolytic TGFβ Activation 
Proteolytic activation of TGFβ has been described to occur through 
the serine protease and metalloproteases plasmin and MMP-2 and 
MMP-9 (168, 186). They play a role in ECM degradation, and TGFβ 
plays a key role in maintaining and stimulating ECM production, thus, 
this method of TGFβ activation may play a key role in ECM turnover 
(187). Proteases can cleave the LAP, thus liberating the active TGFβ 
molecule from the ECM, allowing it to bind to its receptor (188). 
However, thus far this mechanism has only been demonstrated to 
activate TGFβ in vitro. 
1.6.2.3 Thrombospondin-1 (TSP1) Activation of TGFβ 
The homotrimer thrombospondin-1 is part of the thrombospondin 
family of large glycoproteins. It plays a variety of roles in processes 
including, cell adhesion, angiogenesis, platelet aggregation, and cell 
proliferation (189). TSP1 is expressed in tissues of the kidneys, 
aorta, skeletal muscle fibres, and the lung (190). Its expression has 
been shown to increase in response to injury and has been implicated 
in wound healing (191). TGFβ can secreted from activated platelets 
in an inactive LLC. However, TGFβ can be secreted in its active form 
and has been shown to do so in complex with TSP1, thus suggesting 
that TSP1 can activate TGFβ (192). Moreover, TSP1 has also been 
shown to activate TGFβ secreted by endothelial cells (193).  
The mechanism by which TSP1 is able to activate TGFβ does not 
involve liberation of the active TGFβ molecule from the LAP. Rather, 
TSP1 interacts with the LAP, inducing conformational change that 
exposes the active TGFβ molecule and allows it to interact with its 
receptor whilst still attached to the LAP (194).  TSP1-null mice show 
a slight overlap with TGFβ-null mice with increased inflammation, 
thus suggesting that this mechanism of TGFβ activation is relevant 




activation as there was still residual staining of active TGFβ in TSP1-
null mice, and TSP1 does not activate all latent TGFβ in vitro (193, 
195).  
 
1.6.3 TGF-β Receptors and Signalling Pathway 
The TGFβ superfamily signal through heterotrimeric complexes of 
serine/threonine kinase cell surface receptors, known as type I and 
type II receptors. There are five type I receptors and seven type II 
receptors that associate in different combinations to specifically bind 
to each ligand of the TGFβ superfamily (196). The three TGFβ 
isoforms of TGFβ bind to the type I receptors, ALK1, ALK5, and 
TGFβRI and to the type II receptor TGFβRII. There is also a type III 
receptor, TGFβRIII, which binds to TGFβ but is thought to present 
TGFβ to TGFβRII as opposed to direct involvement in signalling. Both 
TGFβ1 and TGFβ3 bind to TGFβRII with high affinity, whereas TGFβ2 
binds with low affinity and required the assistance of TGFβRIII for 
signalling (197).  
Activation of these receptors by TGFβ requires binding of the dimeric 
ligand to two type I and two type II receptors. Initially, TGFβ binds 
to the constitutively active type II receptor kinase, TGFβRII, which 
phosphorylates the GS domain of the type I receptor kinase, 
resulting in activation of type I receptor kinase activity (196). The 
phosphorylation targets of TGFβRI are members of the Smad 
signalling family. Smads directly transduce signals from the TGFβ 
superfamily into the nucleus to regulate transcriptional activity. 
There are five receptor regulated Smads that are phosphorylated by 
type I receptors; Smad1, Smad2, Smad3, Smad5, and Smad8. 
Scaffolding proteins such as Smad anchor for receptor activation 
(SARA) link Smads to the receptor complex, enabling efficient 




phosphorylation of Smad2 and Smad3, which oligomerise to form a 
Smad2/3 complex. The Smad2/3 complex bind to the co-Smad, 
Smad4, forming a heterotrimer. Smad4 undergoes constitutive 
nuclear import and is actively exported. Upon forming a complex with 
Smad2/3 the whole complex localises to the nucleus and nuclear 
export is inhibited, resulting in accumulation of the Smad2/3/4 
complex within the nucleus (199). Both Smad3 and Smad4 are able 
to bind to Smad-binding elements (SBEs) and promoter regions of 
target genes to regulate transcription (200).  
TGFβ signalling is terminated through signalling of inhibitory Smads. 
Smad7 acts as a negative regulator by sterically inhibiting the kinase 
domain of TGFβRI, thus preventing phosphorylation of Smad2 and 
Smad3 (201). Moreover, Smad7 recruits phosphatases to 
desphosphorylate TGFβRI and ubiquitin ligases to signal for receptor 
degredation (202, 203). Smad2/3 are also dephosphorylated by 
phosphatases within the nucleus that halt transcriptional regulation 
and promote nuclear export (204). 
1.6.4 Biological functions of TGFβ 
TGFβ is found in most cell types and plays a number of diverse roles 
within the body. These vary from prenatal organ development to 
inflammatory regulation. As such, knockout of any TGFβ isoforms 
results in increased embryonic lethality. Interestingly, there is little 
phenotypic overlap between mice null of each TGFβ isoform, 
suggesting that there is no redundancy in their respective signalling 
pathways. 
There is significant embryonic lethality associated with TGFβ1 
knockout because transgenic mice with this mutation give birth to 
half the expected offspring (205). This is due to defective 
haematopoiesis and endothelial differentiation within the embryo 




display a progressive wasting syndrome 2 weeks after birth, 
weighing half that of their healthy littermates at time of death at 
around 3 to 5 weeks old (205). These mice were found to have an 
influx of inflammatory cells, including lymphocytes and 
macrophages, in the lungs and heart, which ultimately resulted in 
organ failure and death (207).  
Two-thirds of TGFβ2 knockout mice die shortly before or during birth 
and the rest suffer from developmental defects and only survive for 
a few minutes (208). Developmental defects are seen in the heart, 
skull, eye, inner ear, skeletal malformations and cleft palate (208). 
Lung development was not affected, however the structure of the 
large airways was compromised.  
A crucial role for TGFβ3 in development of the lung has been 
demonstrated. TGFβ3 null mice typically die within 20 hours of birth 
due to defective lung development. This was particularly evident in 
the terminal airspaces where alveoli failed to develop properly and 
there was observable intrapulmonary haemorrhage in addition to an 
increased number of mesenchymal cells (209). These mice also had 
a cleft palate due to failure of the epithelium to bind to the 
mesenchyme, suggesting that TGFβ3 plays a vital role in interaction 
of these cell types (209, 210). 
These studies in transgenic mice highlight the differing roles of the 
three TGFβ isoforms. TGFβ1 is a vital regulator of immune response 
as well as heart development and vasculogenesis. TGFβ2 is essential 
for development of an array of organs and skeletal structure. TGFβ3 






1.6.5 TGFβ in asthma 
 
TGFβ plays a central role in asthma pathogenesis, in particular 
promoting airway remodelling (see overview in figure 4.1). An 
increase in TGFβ1 and TGFβ2 is observed in the bronchoalveolar 
lavage (BAL) fluid of asthmatics (74). Allergen challenge of asthmatic 
patients resulted in an increase in TGFβ1 24 hours post-challenge as 
part of the late asthmatic response (211). The amount of TGFβ1 
within the submucosa was both higher in asthmatics than healthy 
individuals and associated with asthma severity (212, 213). 
Furthermore, an increase in phospho-Smad2 has been observed in 
bronchial biopsies from asthmatic patients, indicating that there is 
more TGFβ is being activated (214). A study in mice that underwent 
the OVA model of asthma have increased ECM deposition, ASM cell 
proliferation, and mucus production, all of which were reduced by 
treatment with an anti-TGFβ antibody (118). These studies 
demonstrate that TGFβ is increased in the airways of asthmatic 
Figure 1.4. Summary of the effects of TGFβ within the airways that 





patients and that it is activating its signalling pathway via phosho-
Smad2. It is also clear that TGFβ1 is the primary TGFβ isoform of 
interest in asthma because it activated genes involved in airway 
remodelling, including PAI1, collagen, VEGF, and fibronectin (215). 
Evidence for the role of TGFβ2 in asthma is more limited, however it 
has been demonstrated to increase the expression of mucin in 
epithelial cells from asthmatic patients, which a major component of 
mucous (117). There is little evidence for the role of TGFβ3 in 
asthma, which plays a key role in lung development. 
TGFβ1 is expressed in nearly all cell types within the lungs including 
the epithelium, fibroblasts, ASM cells, vascular smooth muscle cells 
(216-219). The primary source of TGFβ within the lung of asthmatic 
patients has been shown to be eosinophils, which are recruited to the 
airways by the milieu of proinflammatory chemokines (212). IL-5 
promotes eosinophil survival and is elevated in the asthmatic airway. 
Treating asthmatic patients with the anti-IL-5 antibody, 
mepolizumab, reduced lung eosinophilia, TGFβ1 expression and 
concentration in the BAL fluid, and reduced deposition of some ECM 
components (220). Moreover, IL-5 null mice subjected to OVA 
challenge for 3 months had reduced TGFβ and total lung collagen 
compared to wildtype controls (221). Despite the reduction of 
eosinophils and ECM synthesis seen when administering 
mepolizumab, there was no reduction in airway hyper-
responsiveness in response to allergens. Consequently, severe 
asthmatics who have frequent and uncontrolled exacerbations are 
still able to activate TGFβ through many other cell types within the 
lung. 
One of the most obvious features of airway remodelling in asthma is 
subepithelial fibrosis, to which TGFβ contributes greatly. The 




fibronectin, tenascin, and proteoglycan. In asthma it becomes 
thickened and stiffer due to an increase in deposition of ECM, 
including collagen and fibronectin (69). The main source of ECM 
deposition is mesenchymal cells, in particular myofibroblasts. As 
highlighted in section 1.3, TGFβ promotes fibroblast to 
myofibroblasts transition and proliferation (79). Moreover, TGFβ can 
induce MMP and TIMP expression, which play an essential role in ECM 
turnover (83, 222). Mice administered with TGFβ1 had increased 
collagen I and III mRNA, and a significant increase in total lung 
collagen (223). Moreover, TGFβ is able to induce fibronectin 
synthesis in ASM via the integrin αvβ5 (224). Subjecting vascular 
smooth muscle cells to mechanical stretch induces collagen and 
fibronectin synthesis as well as MMP2 activity (182). A similar stretch 
protocol on ASM cells yielded an increase in TGFβ expression (183). 
It is likely that the force generated within the lung during 
exacerbation contributes to TGFβ activation, and therefore airway 
remodelling, due to the mechanosensitive nature of TGFβ-activating 
integrins. 
When observing airway remodelling in the asthmatic lung there is a 
clear increase in the amount of ASM cells. This results in thick bands 
of ASM that are able to contract with a greater force. Coupled to the 
other features of airway remodelling, this increases the risk of an 
exacerbation completely occluding the airways. ASM cells have been 
shown to activate TGFβ by the integrin αvβ5. Treating mice subjected 
to the OVA model of asthma with an anti-αvβ5 antibody prevented 
thickening of the ASM layer seen in isotype control mice (133). 
Moreover, αvβ5 knockout mice subjected to the A. fumigatus model 
of asthma had reduced thickening of the ASM layer (133). Despite 




inflammatory cells observed in the BAL fluid, highlighting the 
pleiotropic role of TGFβ (133).  
In culture, activation of mitogen-activated protein kinases (MAPKs) 
by TGFβ has been shown to induce ASM cell proliferation(225). TGFβ 
has also been shown to promote ASM cells to synthesise ECM 
proteins. Cultured ASM cells are able to secrete and activate TGFβ, 
which binds to its receptor on the ASM cell surface to activate 
synthesis of collagen I (226). Connective tissue growth factor (CTGF) 
induces synthesis of collagen I and fibronectin in fibroblasts (227). 
TGFβ is able to induce synthesis and release of CTGF from ASM cells, 
an effect which is greater in cells taken from asthmatics in 
comparison to healthy controls (228, 229). CTGF is also able to act 
on ASM to promote synthesis of the ECM proteins collagen I and 
fibronectin (230). Overall the structure of the ASM layer in the 
airways of asthmatic patients is clinically different to healthy patients 
and contributes to airway remodelling.  
Vascular remodelling is a feature of airway remodelling. There are 
more blood vessels in bronchial mucosa of asthmatics and these 
vessels are more permeable (107). VEGF is a strong inducer of 
endothelial cell growth and vascular permeability (106). In the 
asthmatic airways there is a correlation between the number of VEGF 
positive cells and vascular area (107). TGFβ is able to augment VEGF 
synthesis in human ASM cells and fibroblasts via the Smad signalling 
cascade (231, 232).  
There is an increase in the amount of mucous in the airways of 
asthmatic patients that is particularly prominent in fatal asthma 
(233). This is due to an increase in the number of goblet cells and 
size of mucous glands. TGFβ2 has been shown to induce synthesis of 
mucins, a major component of mucous, in airway epithelial cells 




an anti-TGFβ antibody reduced mucous production in the airway 
(118). In a severely remodelled airway where the lumen diameter is 
already reduced, mucous overproduction can plug the airway and 
increase the likelihood of a fatal asthma attack.  
The epithelial layer is damaged in asthmatic patients due to a process 
known as epithelial shedding (234). This leaves underlying cells 
exposed to inhaled particles and allergens that can induce an 
exacerbation. Analysis of bronchial biopsies has demonstrated a 
correlation between epithelial damage and airway hyper-
responsiveness (60). TGFβ is able to have both an apoptotic and 
antiapoptotic effect on cells depending on the cellular context and 
phase of the cell cycle (64). A pro-apoptotic effect of TGFβ is seen in 
cultured human epithelial cells when it signals through a non-Smad 
pathway mediated by MAPK (64). Another mechanism of epithelial 
wall degradation is through EMT. TGFβ induces EMT in epithelial cells 
through its canonical Smad signalling pathway, an effect which is 
greater in cells from asthmatic patients (65). This implies that 
epithelial cells in asthmatics are primed for EMT. Overall, the 
combination of TGFβ promoting apoptosis and EMT results in 






Asthma is an inflammatory disease with high prevalence. An 
estimated 10% of asthmatics suffer from a severe form of the 
disease, which is characterised by frequent and uncontrolled 
exacerbations. These patients present clinical features including 
subepithelial fibrosis, ASM hypertrophy and hyperplasia, 
angiogenesis, epithelial damage, and goblet cell hyperplasia, 
collectively known as airway remodelling.  
The pleiotropic cytokine TGFβ is central to airway remodelling and is 
found activated more in the airways of asthmatic patients than 
healthy patients. It is therefore important to determine the signalling 
pathway that results in TGFβ activation to identify new therapeutic 
targets that prevent airway remodelling. Within the inflammatory 
milieu of the asthmatic lung there are many agonists of 
heterotrimeric G-protein coupled receptors (GPCR), which are key to 
inducing exacerbation and airway hyper-responsiveness. In murine 
embryonic fibroblasts and epithelial cells, the heterotrimeric G-
protein family Gαq/11 and small G-protein RhoA is required for TGFβ 
activation. In ASM cells the integrin αVβ5 is required for LPA- and 
methacholine-induced TGFβ activation. However, the precise 
signalling pathway that leads to TGFβ activation in ASM cells, the 
primary contractile cells of the airway, is not known. This thesis, 
therefore, attempts to delineate the signalling pathway that induces 
TGFβ activation in response to cyclical mechanical stretch and the 





1.8 Hypothesis and Aims 
The overall aim of this thesis was to test the hypothesis that the 
heterotrimeric G-protein family Gαq/11 are required for TGFβ 
activation in ASM cells in vitro. This was broken down into three 
aims: 
1. Develop a new cell-based model to study G-protein signalling 
in ASM cells.  
2. Determine whether Gαq/11 are required for LPA-induced TGFβ 
activation.  
3. Determine whether Gαq/11 are required for cyclical mechanical 
stretch-induced TGFβ activation. 
 
To answer this broad hypothesis, it was broken down into smaller 
stages. At each step, a stimulus was applied to human ASM cells in 
the form of the GPCR agonist LPA, or cyclical mechanical stretch. The 
primary endpoint measured to determine TGFβ activation throughout 
this thesis was phosphorylation of Smad2 (pSmad2).  
Figure 1.5 Hypothesised pathway leading to TGFβ activation in ASM 
cells. Red circles represent molecules in the pathway that were inhibited. 




The pathway that leads to TGFβ activation was interrogated at 
various points. To determine whether there was a role for GPCRs in 
TGFβ activation, the heterotrimeric Gɑq/11 were targeted through a 
combination of genetic and molecular approaches. This part of the 
pathway has not been defined in ASM cells. There is a small body of 
evidence that demonstrated the role of RhoA and its effector 
ROCKI/II are involved in TGFβ activation in other cell types. It was 
important, therefore, to assess the possible role of these signalling 
proteins. ROCKI/II was targeted directly using a small molecule 
inhibitor. RhoA activation was targeted indirectly by inhibition of 
heterotrimeric G-proteins.  
As this thesis progressed it became clear that RhoA was regulated 
by another family of heterotrimeric G-proteins, Gɑ12/13. The possible 
role of Gɑ12/13 in TGFβ activation was explored in the final chapter of 









2 Chapter 2: Materials and Methods 
2.1 Cell Culture 
2.1.1 Human Airway Smooth Muscle Cells 
Primary human airway smooth muscle (HASM) cells were supplied 
by Professor Simon Johnson, Nottingham respiratory research unit, 
University of Nottingham, UK, or, Professor Dominic Shaw, NIHR 
Biomedical Research Centre, University of Nottingham, UK. Staining 
for α-smooth muscle actin was carried out by the biomedical research 
unit to confirm that cells were mesenchymal. They were cultured at 
passage 5 or 6 in Dulbecco’s modified Eagles medium (DMEM) 
(Sigma-Aldrich) supplemented with 10% foetal calf serum (FCS) 
(Harlan UK) and 4mM L-glutamine at 37°C, 5% CO2 in a humidified 
incubator. The medium was changed every 2-3 days until cells were 
100% confluent for experiments. Cells were growth arrested for 24 
hours prior to experiments in serum free DMEM, 4mM L-glutamine. 
ASM cells were collected by Simon Johnson with approval from the 
Nottingham Research Ethics Committee (12/EM/0199). Cells were 
grown from bronchial biopsies that were dissected to separate ASM 
bundles before being expanded in primary culture. Asthmatic 
patients were asked to cease taking inhaled medication, including 
short/long acting β2-agonists and inhalers for 48 hours prior to the 
first visit. Patients were defined as mild/moderate asthmatics 
through the following criteria (235): 
Inclusion criteria for patients with asthma 
• 18-65 years of age 
• Physician diagnosed asthma 
• Post bronchodilator FEV1>80% predicted 
• Asthma phenotype fitting criteria for methacholine challenge 
• Able to give informed consent 
 
Exclusion criteria for patients with asthma 
• Participation in a clinical drug trial within 3 months 




• Any other chronic respiratory condition 
• Smoker within the last year or previous smoking history of >10 
pack years 
• History of life threatening exacerbation of asthma 
• Use of >1000mcg inhaled corticosteroid / day 
• Exacerbation of asthma within the last 6 weeks 
• Use of oral steroids, theophylline or leukotriene antagonists with 
the last 6 weeks 
• Any severe systemic illness (malignancy, diabetes, tuberculosis) 
• Inability to give informed consent 
• Known Cerebral or Aortic Aneurysm 
• Recent myocardial infarction 
• Recent eye surgery 
 
Inclusion criteria for healthy subjects 
• 18-65 years of age 
• Non-smoker or less than 10 pack year smoking history 
• Post bronchodilator FEV1>80% predicted normal value 
• No known respiratory illness 
• Able to give informed consent 
 
Exclusion criteria for healthy subjects 
• Diagnosis of asthma or any other respiratory disease 
• Smoker within the last year or previous smoking history of >10 
pack years 
• Respiratory infection within the last 6 weeks (e.g. pneumonia, 
bronchitis) 
• Use of oral steroids, theophylline, or leukotriene antagonists within 
the last 6 weeks 
• Any severe systemic illness (e.g. malignancy, diabetes, 
tuberculosis) 
• Inability to give informed consent 
• Pregnant or breast feeding 
• Known Cerebral or Aortic Aneurysm 
• Recent myocardial infarction 
• Recent eye surgery  
 
Cells collected by Professor Dominick Shaw were under ethical 
approval (11/EM/0062). Cells were grown from bronchial biopsies 
that were dissected to separate ASM bundles before being expanded 
in primary culture. Patients were defined as having moderate to 
severe asthma by the following criteria (236): 
Inclusion Criteria 
• Male or female aged between 18 and 80 years old 




• Symptomatic despite receiving treatment at step 4 of the BTS 
asthma guidelines: evidence of poor asthma control in terms of 
regular night‐time awakening (>2/week) or more than four puffs of 
relief medication/day (>twice/week) requiring repeated (two or 
more per year) courses of oral corticosteroids despite treatment 
with high‐dose inhaled corticosteroids (≥1000μg beclomethasone 
or equivalent) and treatment with, or a previous unsuccessful trial 
of, a long‐acting beta‐agonist or leukotriene antagonist 
 
 
Exclusion Criteria  
• Pregnant females 
• Inadequate contraception or lactation 
• Antibiotic course within the last 6 weeks 
• Smoking history in excess of 20 pack years 
• Clinical diagnosis of allergic bronchopulmonary aspergillosis 
• Bronchiectasis 
• Abnormal liver function tests 
• History of liver disease 
• Medication known to interact with azithromycin (e.g., ciclosporin, 




2.1.2 Transformed Mink Lung Epithelial Cells 
Transformed Mink Lung Epithelial Cells (TMLC) express the TGFβ 
responsive portion of the PAI1 promoter that drives a luciferase gene 
and a neomycin resistance gene (237). They were a kind gift from 
Professor Dan Rifkin, NYC. TMLC were grown in DMEM, 10% FCS, 
4mM L-glutamine, and 25μg/ml G418. 
2.1.3 Murine Tracheal Smooth Muscle Cells 
Gqfl/flG11-/- mice were a kind gift from Professor Stefan Offermanns, 
Max-Planck-Institute for Heart and Lung Research, Germany (238). 
Mice were bred under project and personal licence authorised under 
the Animals in Scientific Procedures Act 1986. Tissue collection was 
ethically approved by the Animal Welfare Ethical Review Board 
(ethics number 000078).  
Mice were a mix of male and female aged between 6 and 8 weeks 




Animal (Scientific Procedures) Act 1986. Animals were sacrificed by 
overdose of sodium pentobarbital that was given by intraperitoneal 
injection. Lungs were dissected from the mice by first cutting through 
the rib cage to expose the lungs before the trachea was cut as high 
as possible and lungs removed. Lungs were transferred to Dulbecco’s 
modified Eagles medium (DMEM) (Sigma-Aldrich) supplemented with 
10% FCS (Harlan UK) and 4mM L-glutamine, 200µg/ml 
streptomycin, 5µg/ml amphotericin B.  
To isolate tracheal smooth muscle cells, a 6-well plate was scratched 
using a scalpel to help the trachea to stick to the plate. The trachea 
was then removed from the lungs and cut into quarters using a 
scalpel. Sections of trachea were stuck onto the tissue culture plate 
ensuring the lumen side of the airway was facing down and the 
ringed cartilage facing up. The trachea was incubated in the same 
media described above at 37˚C, 5% CO2. Media was changed every 
3 days until colonies of cells appeared in the wells. Once the well was 
50% confluent, cells were trypsinised and transferred to a T25 cell 
culture flask. These cells were deemed passage 1. Cells were stored 
in liquid nitrogen in 90% FCS plus 10% dimethyl sulfoxide (DMSO) 
at 5x105cell/ml for future use.  
2.2 Co-Culture Assay 
2.2.1 Principle 
The co-culture assay was designed so that TGFβ activated by HASM 
cells could be quantified. When TGFβ is activated it will bind to the 
TGFβ receptor on the surface of the TMLC. The PAI1 promoter then 
drives luciferase transcription and translation. The bioluminescence 
from luciferase can be measured in relative light forming units 
(RLFU). To ensure that the quantity of luciferase is proportional to 
active TGFβ a standard curve was produced by treating TMLCs alone 




only used if RLFU was within the linear range of the standard curve. 
This is a specific method of measuring active TGFβ, however it is 
indirect. It is possible to calculate the amount of TGFβ within a 
sample using the standard curve, but there is a high level of 
variability and noise within the system due to the steep gradient of 
the standard curve, therefore relative increase in TGFβ was 
calculated to normalise noise between experiments. The advantage 
of this method is that only active TGFβ is measured and it is relatively 
fast and simple in comparison to measuring phospho-Smad2, 
another common measure of TGFβ activation.  
2.2.2 Method 
HASM cells were seeded in a 96-well tissue culture plate, at 
2x105cells/ml in a volume of 50µl and allowed to bind to the plate 
overnight. Cells were growth arrested for 24 hours prior to 
experiments. Immediately before the experiment, 50μl TMLCs were 
added to the wells at 1x106cell/ml, final well volume 200μl. The 
conditions were carried out in triplicate, on both HASM cells plus 
TMLC and TMLC alone. A standard curve was generated by 
stimulating TMLCs alone with recombinant TGFβ1(R&D Systems) at 
0, 250, 500, 1000pg/ml. Eighteen hours post stimulation cells were 
washed with PBS and lysed with 50μl luciferase lysis buffer 
(Promega). The plate was frozen at -20°C for at least 1 hour to aid 
cell lysis. Lysate was transferred to a white opaque 96 well plate and 
luminescence was measured by an Omega FLUOstar® plate reader 
that was set to inject 50μl luciferase assay reagent from the Promega 
luciferase assay system kit. Luminescence was measure in relative 
light forming units (RLFU) and values were determined to be within 
the linear portion of the TGFβ standard curve. RLFU values generated 




value to remove TGFβ independent luminescence. Data was 
normalised to relative change by using the following formular: 
Relative inhibition = (Sample RLFU - Positive Control RLFU) / Positive 
control RLFU 
If there is inhibition this gives a negative value i.e. if there is 50% 
inhibition, relative fold change will be -0.5. To graphically represent 
this value the following formula was applied: 
Inhibition = 1 – Relative inhibition 
Therefore the positive control sample will always equal 1, and if there 
is 50% inhibition a sample value will equal 0.5. 
 
2.3 Western Blotting 
2.3.1 Principle 
Western blotting is a technique that is used to separate proteins by 
molecular weight. Cells are lysed in ice cold lysis buffer and kept at 
a maximum of 4˚C throughout preparation to minimise protein 
degradation. Cell lysates are run through a sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel by applying an 
electric current that repels negatively charged proteins to the 
positive end of the gel by electrostatic repulsion. Smaller proteins 
migrate further through the gel, whereas larger proteins do not travel 
as far, thus, proteins are separated based on size. The protein is 
transferred to a polyvinylidene fluoride (PVDF) membrane via an 
electric current. Proteins can then be detected by addition of an 
antibody that targets a protein-specific antigen. The molecular 
weight can be determined by comparing how far the protein ran 




gel and has coloured bands that stop at different points based on 
their molecular weight. 
2.3.2 Cell Lysis 
Cell medium was removed and cells washed with ice-cold PBS. Cells 
were lysed in 100μl cell lysis buffer and the plate was scraped before 
being put in the freezer at -80°C for at least 1 hour to aid lysis. 
Lysate was transferred to a pre-chilled eppendorf tube and 
centrifuged at 16,000xg for 10 minutes to remove cell debris. Protein 
concentration was determined by BCA assay.  
2.3.3 BCA Assay and Sample Preparation 
The BCA assay (Thermofisher) uses set protein concentrations 
ranging from 100µg/ml to 2000µg/ml to generate a standard curve. 
Protein lysate samples were loaded in a 96-well plate with the 
standard curve. Protein detection reagent was then added to the 
wells and the plate incubated at 37°C for 20 minutes. Protein 
concentration determined by measuring absorbance at 562nm. The 
standard curve was used to determine the protein concentration in 
each sample to ensure that an equal concentration of protein could 
be loaded into the western blot gel. Each sample was mixed with 4x 
Laemmli buffer at a ratio of 3:1, and boiled for 5 minutes. 
2.3.4 Running the Western Blot 
Gel casting apparatus were set up according to manufacturer’s 
protocol (BioRad). A 10% resolving gel was prepared in the 
laboratory by adding 6.66ml 30% Bis/acrylamide, 5.2ml buffer 1, 
7.92 distilled water. The stacking gel was prepared by adding 1.3ml 
30% Bis/acrylamide, 2.5ml buffer 2, and 6.1ml distilled water. The 
gel was added to the apparatus and allowed to set before the 
resolving gel was applied on top with a comb insert. Once set, the 
gel was put into the tank and comb removed. The compartment and 




protein marker (Sigma-Aldrich) was added to the first lane followed 
by samples. The gel was run at 150V until the lowest molecular 
weight band had reached the bottom of the gel (approximately 1 
hour). 
Protein transfer was carried out by first soaking a PVDF membrane 
in methanol for 30 seconds and washing with tap water. Sponge, 
filter paper, and the PVDF membrane were left in transfer buffer to 
soak. The SDS-PAGE gel was removed from the apparatus and placed 
in transfer buffer (see appendix). In a transfer cassette a sponge was 
laid on the red side followed by filter paper, membrane, gel, filter 
paper and another sponge. A roller was used to ensure that no air 
bubbles were left between the membrane and gel. The cassette was 
placed in a transfer tank with the gel closest to the negative 
electrode. Voltage was applied at 100mV for 50 minutes with the 
tank standing in ice, to transfer the protein from the gel and into the 
PVDF membrane. Following transfer, the membrane was stained with 
Ponceau’s stain (BioRad) to ensure protein transfer and washed with 
Tris-Buffered Saline, 0.1% Tween® (TBST) 2 x 5 minute (see 
appendix).  
2.3.5 Protein Detection 
To reduce non-specific binding of antibodies the membrane was 
blocked in 5% non-fat milk (BioRad) for 1 hour at room temperature. 
Primary antibody (described for each experiment within the figure 
legends, see appendix for code and concentration) was diluted in 5% 
bovine serum albumin (BSA) TBST and left on the membrane 
overnight at 4°C. The membrane was washed in TBST 2 x 5 minutes. 
Secondary antibody goat anti-rabbit (Agilent, E0432) was diluted in 
5% non-fat milk and incubated with the membrane for 2 hours at 
room temperature. To remove any non-specific secondary antibody 




protein detection, the membrane was blotted dry and placed on cling 
film, equal parts of Clarity™ ECL solution (BioRad) was applied to the 
membrane for 30 seconds. A second piece of cling film sandwiched 
the membrane and was placed into a cassette along with Hyperfilm 
ECL, in the dark room. Developed bands were compared to the 
Rainbow™ marker to determine molecular weight. GAPDH or 
Smad2/3 were as a loading control. Note that western blots towards 
the end of this thesis were developed using a LI-COR C-DiGit® Blot 
Scanner. 
 
2.4 siRNA Transfection  
2.4.1 Principle 
Transfection is the process of introducing nucleic acids into a cell. 
The method described here uses a lipid reagent that merges with the 
cell membrane, releasing its contents into the cell. A lipid vector was 
used to carry siRNA, which is a short strand of nucleic acids that have 
a complimentary sequence to the mRNA of a gene that is to be 
silenced. The siRNA strand binds to free mRNA within the cell, 
preventing mRNA translation and therefore synthesis of the target 
protein. This method of gene silencing is only temporary, but is a 
simple and effective way to transiently knock down proteins of 
interest. The effectiveness of transfection can be measured at the 
RNA level by quantitative polymerase chain reaction (QPCR) and at 
the protein level by western blot. At the RNA level, knockdown of a 
genes expression can typically be seen between 24 and 72 hours 
post-transfection. Whereas knockdown at the protein level can be far 
more variable depending how rapid protein turnover is, for example 
the expression of very stable proteins that are turned over slowly will 






Cells were plated at a density of 1.2x105cells/ml in a volume of 1ml 
in a 6 well plate to ensure 40% confluency at the time of transfection. 
In separate tubes, 8μl lipofectamine 2000 (Sigma-Aldrich) (1µl per 
100µl final volume of Opti-MEM)was added to 400μl Opti-MEM media 
(Thermofisher), and 60nM of siRNA was added to 400μl of Opti-MEM. 
For each experiment, a non-targeting control siRNA was used as a 
negative control to ensure that siRNA delivery was not effecting our 
target gene. A transfection reagent control labelled ‘mock 
transfected’ was also carried out for each experiment, containing 
only lipofectamine, to ensure that the vehicle was not having any 
obscure effect. The siRNA and lipofectamine were then combined to 
allow the lipofectamine to engulf siRNA strands within a lipid vesicle, 
and incubated at room temperature for 20 minutes. Growth media 
was removed from the cells and the transfection mixture was 
overlaid on cells for 4 hours. The mixture was then removed, cells 
washed with PBS, and growth media added to cells allowing 
expansion prior to experiments. Both, QPCR and protein expression, 
were measured to determine whether the target gene had been 
knocked down.   
Note: when multiple siRNA sequences were used, they were pooled 
together following exactly the same protocol i.e. 60nM Gαq + 60nM 
Gα11 in 400µl Opti-MEM, mixed with 8µl of lipofectamine 2000 in 
400µl of Opti-MEM.  
 
2.5 Quantitative Polymerase Chain Reaction QPCR 
2.5.1 Principles 
Quantitative polymerase chain reaction (QPCR) is used to quantify 




transcription polymerase chain reaction (RT-PCR). QPCR is the 
process of amplifying DNA within a sample using a thermocycler, 
where a fluorescent dye, such as SYBR Green, intercalates with 
double stranded DNA (dsDNA) product and the fluorescence intensity 
is measured after each amplification cycle. As the dye intercalates 
with dsDNA, fluorescence is directly proportional to the amount of 
DNA product. A single gene can be targeted by designing specific 
primer sequences that bind to the 3’ and 5’ end of a gene product. A 
stable and ubiquitously expressed endogenous control gene 
(housekeeping gene), such as β-2-microglobulin, is also amplified 
within the same sample to minimise variability. Gene expression is 
then calculated versus the housekeeping gene. 
To ensure that a single DNA sequence has been amplified the PCR 
dissociation curve is analysed. The dissociation curve is a graph that 
shows fluorescence intensity on the Y-axis and melting temperature 
on the X-axis. A single peak is present if there has been amplification 
of a single DNA sequence. A non-targeting control (NTC) well of 
water is also run alongside samples. The dissociation curve of the 
NTC should be a flat line, indicating that there has been no amplified 
gene product or show a very small double peak that indicates primer 
dimer formation that can occur when there is no DNA sample present 
in a well. Once satisfied that a single gene product has been amplified 
the expression versus the housekeeper can be calculated (239).   
 
2.5.2 Cell Lysis and RNA Isolation 
RNA isolation was carried out using a NucleoSpin RNA II kit 
(Macherey Nagel). Cells were washed with PBS and lysed using 350μl 
RAI lysis buffer supplemented with β-mercaptoethanol (10μl/ml). 
Lysate was transferred to the homogenisation column and 




350μl 70% ethanol was mixed with the flow-through. This was added 
to the NucleoSpin filter column and centrifuged at 11,000xg for 30 
seconds to bind RNA to the column. Flow-through was discarded and 
350μl membrane desalting buffer was added to the column to 
remove unwanted salts, and centrifuged at 11,000xg for 30 seconds. 
DNase mixture was prepared by adding 90μl DNase I reaction buffer 
to 10μl DNase I per sample. 95μl of this mixture was applied to the 
column for 15 minutes at room temperature to remove any DNA. The 
membrane was washed with 200μl RA2 buffer and centrifuged at 
11,000xg for 30 seconds. A final 2 washes were completed using 
600μl RA3 buffer and centrifuging at 11,000xg for 30 seconds and 
then 2 minutes to completely dry the membrane. The RNA was eluted 
from the column by adding 40μl nuclease-free water to the column 
and incubating for 10 minutes at room temperature before 
centrifuging at 11,000xg for 2 minutes. RNA was stored at -80°C. 
RNA concentration and purity was measured using 
spectrophotometry using a nanodrop to ensure that isolated RNA was 
at sufficient purity and concentration to be reverse transcribed.  
Concentration:  
RNA (μg/μl) = OD260nm x RNA extinction coefficient x dilution factor 
Purity: 
A ratio of OD 260nm:280nm between 1.8 - 2 was used for PCR 
reaction.  
 
2.5.3 Reverse Transcription and Polymerase Chain Reaction 
To anneal the primer to template RNA a mixture containing 0.5µg 
Oligo d(T)20, 1μl dNTP mixture (10mM each), 6μl nuclease free water 
was added to 5μl isolated RNA. The mixture was heated to 65°C for 




minute. A reverse transcription reaction mixture was prepared 
containing 4μl 5x SuperScript IV buffer, 1μl 100mM DTT, 25 units of 
RNasin™, and 1μl SuperScript IV, per sample. 7μl of this mixture was 
added to each well and incubated at 55°C for 10 minutes. Once the 
reaction was completed cDNA was stored at -20°C. 
2.5.4 QPCR Method 
Takara SYBR Premix Ex Taq mastermix containing SYBR green was 
combined with 2µl of cDNA and specific primers (see appendix for 
primer sequences), making a total volume of 20µl. A no template 
control containing no cDNA was carried out. All conditions were 
measured in duplicates. QPCR was carried out in the thermocycler 
Mx3000P® by Stratagene under the following conditions: 95˚C for 2 
minutes, then 35 cycles of 95˚C for 1 minute, 60˚C for 1 minute, 
72˚C for 1 minute, and 72˚C for 5 minutes. The point at which PCR 
product is detected is determined by the fluorescent dye breaching 
a determined threshold. The cycle number at which this occurs is 
called cycle threshold (Ct). A Ct value is given to both the gene of 
interest and housekeeping gene, β2-microglobulin (β2-M). Data was 
normalised by subtracting the Ct of β2-M from the target gene. 
Control samples were then subtracted from all data points giving 
ΔΔCt. Relative gene expression was then determined by the following 
calculation: 
Relative expression (fold increase)  = 2 – ΔΔCt 
2.6 Lentivirus Production and Transduction 
2.6.1 Principles 
Lentivirus’ are derived from human immunodeficiency virus (HIV-1) 
and can be used as a gene delivery vector that has the ability to 
infect both dividing and non-dividing cells. The lentivirus traverses 




import apparatus to enter the nucleus. Lentiviruses integrate genetic 
material into the host genome for stable and long-term expression. 
The components to produce lentivirus are split across 3 plasmids and 
are replication incompetent for safe use in the laboratory. These 
plasmids consist of a lentiviral transfer plasmid, packaging plasmid, 
and envelope plasmid. The lentiviral transfer plasmid contains the 
gene of interest surrounded by long terminal repeat sequences, 
which allow the plasmid sequence to be incorporated into the host 
genome. The packaging and envelope plasmids encode components 
of the viral capsid. To produce an active lentivirus, all three plasmids 
are combined in ‘packaging cells’, usually HEK T293 cells. Active virus 
is then released into the media, where is can be harvested and 
applied to target cells. Lentiviruses interact with the host cell 
membrane and release viral RNA. Often, lentiviruses also carry the 
proteins reverse transcriptase and integrase. Once the genetic 
material is in the cell the RNA is reverse transcribed into cDNA and 
then integrated into the host genome by integrase. The gene will 
then be stably expressed in the host cell. 
2.6.2 Plasmid Amplification 
The three lentiviral plasmids were a kind gift from Professor Maddy 
Parsons, Kings College London, UK. The plasmids arrived in blotting 
paper, and therefore required amplification. They were eluted in dH20 
and the concentration was determined by measuring the A260 and 
A320 on the nanodrop. The following formula determines the DNA 
concentration: 
Concentration (µg/ml) = (A260 - A320) x dilution factor x 50µg/ml 
DNA yield (µg) =  DNA concentration x sample volume 
Each plasmid contained an ampicillin resistance gene to allow 




Stbl3™ Chemically Competent E. coli (Thermofisher) were thawed on 
ice before addition and gentle mixing of 100pg of plasmid. The vial 
of E. coli and plasmid DNA was incubated on ice for 30 minutes before 
undergoing heat shock for 45 seconds in a 42˚C water bath. The vial 
was immediately placed on ice for 2 minutes, after heat shock. Next, 
250µL of pre-warmed super optimal broth with catabolite repression 
(S.O.C) media (Thermofisher) was added to the vial. Vials were 
placed in a horizontal shaker at 225rpm at 37˚C for 1 hour. Both 
25µL and 100µL of transformed E. coli were spread on agar plates 
containing 100µg/ml Ampicillin to positively select transformed 
bacterial colonies. Plates were incubated overnight at 37˚C, 5% CO2. 
Individual colonies were scraped from the agar plate and added to 
25ml of warm nutrient broth (Sigma-aldrich) containing 100µg/ml 
ampicillin. The mixture was placed in a 37˚C shaker at 220rpm for 8 
hours. This mixture was then added to 100ml of nutrient broth and 
incubated in a 37˚C shaker at 220rpm overnight.  
2.6.3 Plasmid Midiprep 
The midiprep was conducted using the Qiagen® Kit (cat. 12143). The 
bacterial culture was centrifuged at 6000xg for 15 minutes at 4˚C to 
form a large pellet and discard excess broth. The pellet was 
resuspended in 4ml of buffer P1. Next, 4ml of buffer P2 was gently 
added to the mixture and inverted 5-6 times, then incubated for 5 
minutes at room temperature to lyse the E. coli. Next, 4ml of P3 
buffer was added and mixed vigorously before being incubated on 
ice for 15 minutes to precipitate DNA, proteins, and cell debris. After 
incubation, the micture was centrifuged at 20000xg for 15 minutes 
at 4˚C. The supernatant, containing plasmid, was removed and the 
pellet discarded. The QIAGEN-tip 100 was equilibrated by applying 
4ml of QBT buffer until all of the buffer had run through the tip by 




the plasmid within the resin. Once the supernatant had passed 
through the tip, a wash step was carried out to remove any 
contaminants by applying 2x10ml of QC buffer. DNA was then eluted 
from the resin in 5ml of QF buffer, and collected in a 15ml tube. 
Precipitation of DNA was achieved by adding 10ml of 100% ethanol 
and mixing. The solution was then aliquoted into eppendorfs and 
placed in a 4˚C centrifuge at 10000xg for 10 minutes. The ethanol 
was then tipped off and left upside down to dry, leaving only a pellet 
of DNA. Next, 1ml of 70% ethanol was added to wash away any salts 
remaining in the DNA pellet. The sample was then centrifuged at 
room temperature, 10000xg for 3 minutes. The ethanol was then 
pipetted off and the remaining ethanol was left to evaporate 
overnight. Finally, the pellets were resuspended in 30µl dH2O and 
combined before measuring DNA purity and concentration on the 
nanodrop (described above). 
To ensure that the plasmids had been copied without base-pair 
errors, they were sent for Sanger sequencing. Due to the large size 
of the plasmids, 9kbp, only the active portion of the plasmid was 
sequenced. Sanger sequencing requires a primer, DNA polymerase, 
normal deoxynucleotidetriphosphates (dNTP) and di- 
deoxynucleotidetriphosphates (ddNTP) that are modified to have a 
specific fluorescent dye attached based on the dNTP present. This 
allows the precise sequence of the plasmid to be determined by 
measuring the colour of the fluorescent dye.  
2.6.4 Lentivirus Production - FuGENE® HD 
Human embryonic kidney (HEK) cells were used to package the 
lentiviral plasmids. They were grown in a T25 flask until 70% 
confluent. In an eppendorf, 2.85µg transfer plasmid, 0.7µg 
packaging plasmid, and 2.15µg envelope plasmid were mixed in 




separate eppendorf, 17.1µl FuGENE® HD, a nonliposomal 
transfection reagent, was mixed with 600µl Opti-MEM. The contents 
of these eppendorfs were then mixed and left at room temperature 
for 15 minutes to allow of the DNA and transfection reagent to 
combine. Next, media was aspirated from HEK cells and washed with 
PBS. The plasmid transfection mixture was incubated overnight. The 
transfection mix was then aspirated and replaced with antibiotic free 
growth medium for 48 hours. After 48 hours the media, containing 
lentivirus, was harvested and centrifuged at 1000xg for 3 minutes to 
pellet cell debris. 
2.6.5 Lentivirus production – Polyethylenimine (PEI) 
Another method of lentivirus production used in this thesis involved 
the use of PEI (Sigma-Aldrich) as a transfection reagent, instead of 
FuGENE® HD. PEI was prepared by dissolving in dH2O to achieve a 
final concentration of 1mg/ml and adjusting to pH 7 using HCL. It 
was then filtered by a 0.22µm filter to remove insoluble material. 
HEK cells were grown to 70% confluency. A total of 20µg of plasmid 
DNA was added to 150µl Opti-MEM reduced serum media 
(Thermofisher) (10µg transfer plasmid, 3.3µg packaging plasmid, 
and 6.7µg envelope plasmid). The volume of PEI added to the tube 
varied between a ratio of 1:1, 2:1, or 3:1 PEI to DNA. The mixture 
was incubated at room temperature to allow negatively charged DNA 
to associate with positively charged PEI. Next, half of the growth 
media was removed from HEK cells and this Opti-MEM, DNA, and PEI 
mixture was added to the HEK cells for 48 hours. After 48 hours the 
media, containing lentivirus, was harvested and centrifuged at 
1000xg for 3 minutes to pellet cell debris. 
2.6.6 Lentivirus detection 
Lenti-X GoStix (Takarabio) are a rapid qualitative tool determine 




lentiviral capsid protein p24, but do not show whether the lentivirus 
is active, only that it has been successfully packaged.  
20µl of supernatant was added to the Lenti-X GoStix well. Next, 3 
drops of Chase Buffer were added to the well and bands were left to 
develop for 10 minutes. There is an internal control band always 
develops and a sample band that develops if p24 is detected in the 
sample. If the sample band and control band are of similar intensity, 
it indicates your sample has more than 5x105 IFU/ml (infectious units 
per ml).   
 
2.6.7 Lentivirus Transduction  
Target cells were seeded at a density of 1.5x105cells/ml to achieve 
70% confluency. Lentiviral media was added to the target cells so 
that is comprised either 25%, 50%, 75%, or 100% of the total 
volume of growth media depending on the lentiviral titer. 
Lentiviruses have a negatively charged membrane, thus they are 
repelled from the surface of target cells. To overcome this, the 
cationic polymer, polybrene (Sigma-Aldrich) 8µg/ml, was added to 
the growth media to neutralise the negatively charged cell 
membrane. This allows the lentivirus to interact with the cell 
membrane and insert its RNA into the host cell. The target gene is 
then reverse transcribed by reverse transcriptase before being 
integrated into the host genome by integrase. Cells were incubated 
with the lentiviral media for 3 days.  




2.6.8 Positive Selection of Cells Transfected with Lentivirus 
The target genes in this thesis included a puromycin resistance gene 
to allow positive selection of transduced cells. First, a kill curve was 
produced by treating target cells with an ascending concentration of 
puromycin up to 8000ng/ml. Each concentration of puromycin was 
carried out in triplicate wells. Cells were incubated with puromycin 
for 3 days until cell viability was assessed via 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) assay. 
Cells were incubated at 37˚C, 5% CO2 for 30 minutes with 0.5mg/ml. 
Next, media was aspirated and cells washed with PBS before the 
addition of 50µl DMSO. Absorbance at 550nm was measured on an 
Omega FLUOstar® plate reader.  
Once cells had been incubated with lentivirus, transduced cells were 
positively selected. The lowest concentration of puromycin (Sigma-
Aldrich) that killed all cells after 3 days, as determined by the kill 
curve, was used. Cells were incubated with this concentration of 
puromycin in growth media for 3 days.  
2.6.9 Counting GFP positive cells  
Cells transduced with lentivirus containing a GFP gene were counted 
to determine transduction efficiency. Four random areas of the 6-
well plate were selected and marked with a dot. A light microscope 
was aligned with the dot at X100 magnification. Both, the total 
number of cells, and GFP positive cells, within the field of view were 
manually counted. Cells were deemed GFP positive if they were 
green. The total number of cells and GFP positive cells in each area 
were added together and the following formula was used to 
determine transfection efficiency: 





2.7 Cyclical Mechanical Cell Stretching 
2.7.1 Principle 
This process has been designed to replicate breathing where 
constant contraction and cell elongation occurs and uses the 
Flexcell® FX-5000™ Tension System. Contrary to active contraction, 
cell stretching is a process whereby cells elongate passively. Cells 
were cultured on a flexible membrane that can be placed on a fixed 
post. A vacuum pump is used to pull the flexible membrane over the 
post which results in equibiaxial cell stretching. Both the frequency 
and amplitude of stretching can be changed so that it can replicate 
breathing in difference species. Tidal breathing in mice occurs at a 
frequency of 1Hz, whereas humans do so at 0.3Hz. The percentage 
of elongation can also be changed by the user from 5% to 25% 
elongation, allowing replication of tidal breathing or of deep 
inhalation.  
2.7.2 Methods 
Cells were plated at 2x105cells/ml to achieve 100% confluency on 
collagen I coated BioFlex® six-well plates and serum starved 24 hours 
prior to stretching. Collagen I coated plates were used because 
previous work from a member of our laboratory found that cells don’t 
adhere to uncoated plates after a long stretching regimen.  All cells 
were plated on duplicate collagen I coated BioFlex® plates so that 
one could be stretched and another left unstretched to use as a 
control. Lubricant was applied to the fixed post of the Flexcell® to 
allow the membrane to stretch freely. The plates were placed on the 
Flexcell® posts and put in a cell culture incubator. A piece of Perspex 
was placed on top of the plates to ensure that they did not moved 
while undergoing a stretching regimen. Unstretched plates were 




specified frequency and percentage of elongation over a period of 
time ranging between 4 and 48 hours.  
 
2.8 RhoA G-LISA Activation Assay 
2.8.1 Principles 
The RhoA G-LISA® (Cytoskeleton) is an enzyme-linked 
immunoabsorbent assay (ELISA) designed to detect activated RhoA 
(RhoA<GTP>). The kit contains a RhoA<GTP>-binding protein linked 
to the 96 well plate, which binds RhoA<GTP> while RhoA<GDP> is 
removed during wash steps. A positive control containing 
concentrated RhoA is included in the assay to ensure that the assay 
is detecting the protein. A negative control with only lysis buffer is 
used as a blank, and samples that had not been stimulated with LPA 
were used to show baseline RhoA activation in ASM cells. In each 
sample, RhoA activation is determined by comparing activated 
versus non-activated lysates. It is essential to keep all samples ice-
cold until they are added to the ELISA plate to prevent hydrolysis of 
GTP to GDP. This assay does not determine the concentration of 
activated RhoA, but shows whether RhoA is activated, or not, and 
allows relative activation to be compared between sample conditions.   
 
2.8.2 Method 
Cells in 6-well plates were stimulated with LPA (Sigma-Aldrich) for 3 
minutes. At 3 minutes, cells were washed with ice-cold PBS and 80μl 
lysis buffer added to wells. Lysate was transferred to pre-chilled 
eppendorf tubes and centrifuged at 10,000xg for 1 minute. 2 x 5μl 
lysate was transferred to a 96-well plate for protein quantification, 




To determine protein concentration 295μl Precision Red was added 
to 5μl sample lysate and incubated at room temperature for 3 
minutes. Absorbance was measured at 600nm. The value was 
multiplied by 7.5 to give protein concentration. All samples were 
equalised to a concentration between 0.4-2mg/ml. 
RhoA G-LISA strips were activated by adding 100μl ice-cold dH2O. A 
positive control was prepared by adding 12μl reconstituted RhoA 
protein to 48μl lysis buffer and 60μl binding buffer. A blank was made 
up of 60μl lysis buffer and 60μl binding buffer. Samples were 
equalised immediately before the ELISA by adding ice cold lysis 
buffer. Samples were then prepared by adding 60μl ice-cold binding 
buffer and 60µl sample lysate to a chilled eppendorf and vortexed for 
5s. A volume of 50μl was added to the ELISA plate in duplicate and 
placed on a cold orbital shaker set to 400rpm at 4°C for 30 minutes. 
The ELISA plate was then washed twice before adding 200μl of 
antigen presenting buffer for 2 minutes. The ELISA plate was washed 
3 times before 50μl anti-RhoA antibody, previously diluted 1/250, 
was added and left to incubate for 45 minutes on an orbital shaker 
set at 400rpm at room temperature. The plate was then washed 3 
times before a secondary HRP labelled antibody, previously diluted 
1/62.5, and incubated on an orbital shaker at 400rpm for 45 minutes 
at room temperature. Detection reagent was prepared by mixing 
equal volumes of solution A and B. The ELISA plate was then washed 
3 times and 50μl detection reagent was added per well and incubated 
at 37°C for 12 minutes. To stop the reaction 50μl stop solution was 
added and the results were collected by reading the absorbance of 
each well at 490nm.  
2.9 Statistics 
Data is expressed as median ±interquartile range (IQR) unless 




Whitney U test because this is a non-parametric test and the number 
of replicates in most experiments were low. With low replicate 
numbers it is not possible to determine if data is parametric. The 
Mann-Whitney U test ranks data points into groups for comparison 
and does not take into account the size of the change, only whether 
there is a change or not. A limitation is that there cannot be a p value 
0.05 with three replicates, no matter how large the effect size is.  
For multiple comparison tests a one-way Kruskal-Wallis ANOVA was 
used. This test compares the means of three or more groups and 
determines whether there is a difference between two or more group 
means. It does not, however, determine which groups have a 
difference. This requires a follow up test. In this thesis a Dunnetts 
test was used because it compares all of the group means with a 
control mean. 
A one-sample t-test was used once during this thesis because the 
data had been processed so that the control was equal to 1 and all 
groups were relative to the control. The test compares the mean of 
all groups with a single sample. This test requires approximately 
normal distribution and no significant outliers. 
An unpaired t-test has been used in this thesis to compare a groups 
containing six cell lines. This test assumes normal distribution and 
compares the means of two groups to determine whether there is a 
significant difference. Unlike the Mann-Whitney U test, the t-test 




3 Chapter 3 Optimisation of lentivirus production and 
transduction 
3.1 Rationale 
Asthma is a chronic inflammatory disease of the airways. Asthma 
pathology is characterised by airway hyper-responsiveness, 
bronchoconstriction, and airway remodelling. 5.4 million people in 
the UK suffer from asthma with 1.1 million children and 4.3 million 
adults (Asthma UK). 10% of asthma patients suffer from severe 
asthma and do not respond to available treatments. This results in 
frequent and uncontrolled asthma attacks that trigger structural 
changes within the airway, known as airway remodelling.  
Airway remodelling is a term that describes the structural changes 
seen in the asthmatic lung, including subepithelial fibrosis, ASM 
hypertrophy and hyperplasia, loss of epithelial integrity, 
angiogenesis, and goblet cell hyperplasia (240). These structural 
changes increase airway resistance and therefore reduce lung 
function (241). TGFβ is a pleiotropic cytokine that is central to airway 
remodelling in asthma (223, 242). TGFβ is able to induce epithelial 
apoptosis and epithelial-mesenchymal transition (65, 243). 
Subepithelial fibrosis describes thickening and fibrosis of the airways 
caused by deposition of excess ECM such as collagens, fibronectin, 
and proteoglycans (73, 223, 244). Differentiation of fibroblasts to 
myofibroblasts, the primary source of excess ECM deposition in the 
asthmatic airway, is induced by TGFβ (78, 79). Increased ASM mass 
is a key feature of airway remodelling in severe asthma, resulting in 
stronger contractions of the airways during exacerbation. TGFβ 
induces ASM cell proliferation and migration, resulting in increased 
ASM mass (242). Both goblet cell hyperplasia and angiogenesis have 





Determining the precise activation pathway of TGFβ is therefore 
important to identify potential treatment strategies to prevent airway 
remodelling. In mice, knockout of Gαq/11 in the alveolar epithelium 
prevented a force-induced increase in TGFβ activation (127). In 
human epithelial cells, Gαq is required for LPA-induced TGFβ (128). 
This has led to the hypothesis that the heterotrimeric G-proteins 
Gαq/11 are required for TGFβ activation in ASM cells. 
One of the methods of testing this was to genetically knockdown 
Gαq/11 and there are multiple methods available to achieve genetic 
knockdown. This could be done by using transient gene knockdown 
of mRNA by using targeted siRNA. This has the advantage of being a 
relatively quick method genetic manipulation and can functionally 
reduce the mRNA and protein target. However, it is difficult to 
achieve complete protein knockout within the cell, the effect is 
transient, and siRNA is most effective in dividing cells (245). 
Clustered regularly interspaced short palindromic repeats (CRISPR) 
is a genome editing technique adapted from the defence mechanism 
of bacteria against bacteriophage (246). When bacteria are infected 
with bacteriophage they capture DNA fragments from the 
bacteriophage and create CRISPR arrays. Upon infection of the same, 
or similar virus, the bacteria use the CRISPR array to transcribe RNA 
that is complementary to the bacteriophage DNA, which it binds to 
and signals DNase enzymes to cut the DNA thus disabling the virus 
(247). CRISPR is frequently used to knockdown gene expression and 
is described as a cheap and easy method to employ. An RNA guide 
sequence is designed that binds to the target DNA and endonuclease. 
The enzyme then cuts the DNA at the target and the DNA is repaired, 
deleting the target gene. There are challenges achieving complete 
knockout with CRISPR, for example it can have off-target effects due 




5 base pair mismatches, resulting in mutations in unwanted genes 
(248). The guide RNA sequence can greatly affect the cleavage 
capability of the target gene. Guide RNA that forms strong secondary 
structures have a reduced ability to cleave the target gene, thus, a 
panel of guide RNA should be tested in a cleavage assay to determine 
efficacy before being introduced into the target cell (249). 
Lentivirus are derived from human immunodeficiency virus (HIV-1) 
and can be used as a gene delivery vector that has the ability to 
infect both dividing and non-dividing cells (250). This is possible 
because the virus traverses the plasma membrane by endocytosis 
and can interact with nuclear import apparatus to enter the nucleus 
(251).  An advantage of using lentivirus as a gene delivery vector is 
that they can integrate genetic material into the host genome for 
stable and long-term expression (252, 253). The components to 
produce lentivirus are split across 3 plasmids and are replication 
incompetent to increase safety. These plasmids consist of a lentiviral 
transfer plasmid, packaging plasmid, and envelope plasmid (254). 
The lentiviral transfer plasmid contains the gene of interest 
surrounded by long terminal repeat sequences, which allow the 
plasmid sequence to be incorporated into the host genome. The 
packaging and envelope plasmids encode components of the viral 
capsid. To produce an active lentivirus, all three plasmids are 
combined in ‘packaging cells’, usually HEK T293 cells (255). 
Lentivirus is then produced and released into the media, which can 
be used to transfect target cells. 
Our laboratory had acquired Gqfl/flG11-/- mice from Professor Stefan 
Offermanns, Max-Planck-Institute for Heart and Lung Research, 
Germany. These mice had a ‘floxed’ Gαq gene and Gα11 knocked out. 
The term floxing refers to a gene that has been sandwiched between 




tyrosine recombinase enzyme from bacteriophage. The result of Cre 
recombination of Lox P sites is deletion of the sandwiched gene, thus 
creating a stable genetic knockdown of the target gene, in this case 
Gαq. ASM cells from the Gqfl/flG11-/- mice were isolated from the 
tracheae. This was done by sacrificing the mice in order to remove 
the tracheae, dissecting it into quadrants, and sticking them down to 
a tissue culture plate. The cells were then expanded to create stocks 
for lentiviral transfection. The principle of this chapter was to 
transfect the Gqfl/flG11-/- ASM cells with lentivirus containing a Cre-




Generate lentivirus containing a plasmid encoding Cre-recombinase. 
Transfect murine Gqfl/flG11-/- ASM cells with lentivirus to generate a 







3.3.1 Amplifying plasmid stocks and generating puromycin resistant 
lentivirus 
The lentiviral transfer, packaging, and envelope plasmids were a gift 
from Professor Maddy Parsons, Kings College London. The transfer 
plasmid encoded Cre, which would induce removal of Gαq, and a 
puromycin resistance gene to allow positive selection of transduced 
cells. A small quantity was delivered and therefore needed to be 
amplified to create a stock. Competent E. coli were transformed with 
each plasmid individually and left to grow overnight. Transformed E. 
coli were harvested the following day and a Qiagen midiprep kit was 
used to isolate the amplified plasmid stocks (figure 3.1A). Next, 
murine Gqfl/flG11-/- ASM cells were cultured and exposed to an 
increasing concentration of puromycin for 3 days. An MTT assay was 
conducted to assess cell viability and generate a kill curve (figure 
3.1B). There was a linear reduction in cell death from no puromycin 
to 1000ng/ml where maximum cell death was reached. There was a 
plateau from 1000ng/ml to 8000ng/ml. Therefore 1000ng/ml 
puromycin was the optimum concentration to use for positive 








Figure 3.1. The transfer plasmid pLKO Cre, envelope plasmid p8.91, 
packaging plasmid pMDG were amplified to generate a stock, A. Murine 
Gqfl/flG11-/- ASM cells were treated with an increasing concentration of 
puromycin for 3 days and cell viability was determined by an MTT assay, 




Next, I sought to produce active lentivirus that could be used to 
transduce the murine Gqfl/flG11-/- ASM cells. This would incorporate 
Cre recombinase into the host genome and generate a double 
knockout of Gαq and Gα11. First, 2.85µg transfer plasmid, 0.7µg 
packaging plasmid, and 2.15µg envelope plasmid were combined in 
with FuGENE® HD transfection reagent in a flask containing the 
packaging cells HEK T293 for transfection. The virus was produced 
and released into the media which was collected after 48 hours 
(figure 3.2A). To confirm that lentivirus had been produced, the 
supernatant was applied to Lenti-X GoStix, which confirmed the 
presence of the structural virus capsid protein p24 (data not shown). 
Supernatant was aliquoted and stored at -80˚C for further use. 
Transduction was initially attempted in wild-type murine embryonic 
fibroblasts (WT MEFs) because they are easier to transfect than 
primary cells and therefore represented a good cell type to validate 
whether the lentivirus was viable. The DNA to be delivered into the 
host cells included Cre recombinase and a puromycin resistance 
gene. Lentiviral media from frozen stock was mixed with normal 
growth media to make up 25%, 50%, or 75% of the total media. 
Media was then applied to WT MEFs, grown to 100% confluence, in 
a 6-well tissue culture plate and incubated for 3 days to allow 
transduction to take place. After 3 days, lentiviral media was 
replaced with normal growth media containing 1000ng/ml of 
puromycin, as determined by the kill curve (figure 3.1B), and 
incubated for 3 days for positive selection to take place. However, no 
cells survived positive selection indicating that transduction did not 
take place (no data shown). This could have been due to low yield of 
lentivirus in the packaging step, or due to lentivirus losing viability. 
Next, lentiviral transduction was repeated in WT MEFs. Cre 




transduction was successful and the lentivirus was viable. Fresh 
lentiviral media was used directly from packaging cells instead of 
using frozen lentiviral media as described above. Lentivirus-
containing supernatant was diluted in normal media to make up 
25%, 50%, or 75% of the total media volume and applied to WT 
MEFs for 6, 8 or 52 hours (figure 3.2B). Cre was measured by QPCR 
in WT MEFs to determine whether the lentivirus had successfully 
incorporated into the host genome. The positive control was a sample 
of whole lung protein collected from mice that had Cre expression 
restricted to epithelial cells. Cre expression was observed in all 
samples that were exposed to lentivirus regardless of the percentage 
of lentiviral supernatant applied or the exposure time (figure 3.2C). 
Cre expression in the WT MEFs that were exposed to 75% lentiviral 
supernatant for 52 hours was highest with expression 40-fold higher 
than the control. Cre expression in samples that were exposed to 
lentivirus for 6 hours show a percentage-dependent increase, with 
25% and 50% lentiviral media having 6-fold and 10-fold Cre 







Figure 3.2. The process of producing lentivirus using packaging cells, A. 
The process of transducing target cells with lentivirus, B. WT MEFs were 
treated with different percentages of lentiviral supernatant for 6, 8, or 









































































Due to successful transduction of Cre in WT MEFs using fresh media, 
transduction of WT MEFs and positive selection was carried out. Fresh 
lentiviral media comprising 25%, 50%, 75%, or 100% of the total 
growth media was applied to WT MEFs, grown to 100% confluence, 
in a 6-well plate. WT MEFs were incubated with lentiviral media for 3 
days. Lentiviral media was then replaced with fresh growth media 
containing 1000ng/ml puromycin for positive selection of transduced 
cells. After 3 days there were 3 small colonies of cells in the well 
containing 100% lentiviral media, however they did not expand (data 





3.3.2 Transduction of cells using a transfer plasmid containing GFP  
Lentiviral transduction of WT MEFs with Cre was successful. Next, I 
wanted to transduce Gqfl/flG11-/- ASM cells with Cre and puromycin 
resistance, and positively select transduced cells to generate a 
double knockout of Gαq and Gα11. The experimental methods 
discussed in the previous section were repeated on Gqfl/flG11-/- ASM 
cells, however all of the cells died upon addition of puromycin 
because transduction did not occur (no data not shown).  
At this point 2 things were changed to improve transduction and 
efficiency and analysis: 
1. A lentiviral plasmid encoding GFP instead of a puromycin 
resistance was used to allow visual identification of 
transduction and, 
2. The transfection reagent FuGENE® HD was swapped with 
polyethylenimine (PEI) to improve transfection of packaging 
cells and lentivirus yield. 
Lentivirus was produced in packaging cells that had been transfected 
using a PEI to DNA ratio of either 3:1, 2:1, or 1:1. GFP positive 
packaging cells were observed when harvesting supernatant, 
indicating that lentiviral production had been successful. Supernatant 
from the three conditions was transferred to the target HEK T293 
cells for 48 hours. Four random areas of the tissue culture plate were 
selected for counting of GFP positive cells and percentage 
transfection calculated (figure 3.3A). There was a small PEI to DNA 
ratio-dependent increase in GFP positive cells. The highest 
transduction percentage was 42% at a 3:1 PEI to DNA ratio with the 
lowest at 24% from 1:1 PEI to DNA.   
Next, I repeated the experiment targeting Gqfl/fl G11-/- murine ASM 




increase in GFP positive cells, however the transduction percentage 
was very small. A PEI to DNA ratio of 3:1 elicited the highest 
transfection percentage of 6%, compared to 1% in cells that were 
treated with supernatant from 1:1 DNA to PEI. Proportionally the 
ratio-dependent increase in transduction was similar between WT 
MEFS and Gqfl/flG11-/- murine ASM cells however the total efficiency 
was approximately 90% lower. Due to the low transfection efficiency 
in the primary Gqfl/flG11-/- murine ASM cells the lentivirus experiments 































































































Figure 3.3. Lentiviral supernatant from packaging cells transduced with 
a PEI:DNA ratio of 1:1, 2:1, and 3:1 was used to transduce HEKS and 
Gqfl/flG11-/- murine ASM cells with lentivirus, A+B. GFP positive cells were 
counted from 4 random areas using a fluorescent microscope. HEK T293 
cells had a ratio-dependent increase in transduction, maximal at 42% 
(n=1 experiment), A. Gqfl/flG11-/- murine ASM cells also showed a ratio-






TGFβ plays a key role in fibrotic disease and has been identified as 
central to airway remodelling in asthma. Previous work has 
highlighted that Gαq and RhoA are required for LPA-induced TGFβ 
activation in mouse embryonic fibroblasts (128). Knockout of 
epithelial Gαq and Gα11 in mice inhibited force-induced increase in total 
lung TGFβ (127). These studies suggest that Gαq and Gα11 might be 
important for TGFβ activation in asthma. The aim of this thesis was 
to determine whether Gαq and Gα11 were required for LPA and stretch 
induced TGFβ activation in ASM cells.  
Transgenic mice with a double knockout of Gαq and Gα11 die at 
embryonic day 11, and mice with only one allele of either Gαq or Gα11 
die shortly after birth with cardiac malformation and craniofacial 
defects (256). This chapter set out to produce a primary ASM cell 
line with stable genetic knockdown of Gαq and Gα11. Using a stable 
genetic knockdown has significant advantages in comparison to 
transient genetic knockdown; there is complete knockout of the gene 
and protein, experimental time courses are not limited by transient 
knockdown, and the cell line could be kept as a tool for future use.  
Lentiviruses are a subtype of retroviruses and can have long 
incubation periods. Perhaps the most well-known lentivirus is Human 
Immunodeficiency Virus (HIV). Lentiviral vectors are efficient gene 
delivery tools that induce long-term gene expression. They are able 
to traverse the plasma membrane due to the envelope protein VSV-
G and enter the host cell nucleus by interacting with nuclear import 
complexes (251). An advantage using lentivirus as a gene delivery 
tool is that it can transduce both dividing and non-dividing cells 
(252). They are designed to be replication deficient so once they 




To acquire the ASM cells Gqfl/flG11-/- mice were sacrificed and ASM cells 
from the tracheae were harvested. These mice were Gαq floxed and 
Gα11 null. Floxing is a mechanism whereby LoxP promotor sites are 
introduced to flank a target gene. These sites are recognised by Cre 
recombinase, a tyrosine recombinase enzyme, and recombined thus 
removing the target gene. My aim was to generate a lentivirus 
containing Cre and a puromycin resistance gene that could transfect 
the Gqfl/flG11-/- ASM cells to knockout Gαq and Gα11. Transfected cells 
would undergo positive selection by incubation with puromycin.  
First, I amplified the plasmid stocks that had been received as a gift 
from Professor Maddy Parsons, Kings College London. To achieve 
this, E. coli were transformed with the transfer, envelope, and 
packaging plasmids. Plasmid concentrations were measured by using 
a nanodrop, which showed that there was a sufficient concentration 
to store them as a stock for lentivirus generation (figure 3.1).  
To produce active lentivirus, the transfer, packaging, and envelope 
plasmids had to be combined in a packaging cell. Typically HEK T293 
cells are used for lentiviral packaging because they are easy to 
transfect and grow rapidly (255). Commercially available FuGENE® 
was the transfection reagent used in experiments that were 
producing lentivirus containing Cre and puromycin resistance. To 
confirm that lentivirus had been produced, the supernatant was 
applied to Lenti-X GoStix, which confirmed the presence of the 
structural virus capsid protein p24 (data not shown). This indicated 
that lentiviral production had been successful. However, directly 
measuring p24 often overestimates the quantity of active lentivirus 
because it measures total p24 within a sample regardless of whether 
it is in an active viral capsid (257). Another method for measuring 
lentivirus is to measure viral RNA using qPCR targeting specific viral 




(257). Lentivirus can be measured using functional assays that 
measure effects of the virus in target cells. Examples include, using 
antibiotic resistance and measuring the number of cell colonies that 
survive, or measuring the target gene by qPCR in target cells (257).  
Initially, I transduced WT MEFs because they are fast growing and 
easy to transduce (254). Lentiviral media taken from frozen stocks, 
produced as described above, were diluted in media so that lentiviral 
media constituted 25%, 50%, or 75% of the total volume. After three 
days of incubation with lentivirus, media was replaced with fresh 
media containing 1000ng/ml of puromycin for positive selection of 
transduced cells. However, no cells survived, suggesting that there 
was no transduction. It is important to note that this experiment used 
frozen lentiviral media, which was intended to standardise 
experiments and allow consistent replication. Lentivirus, however, is 
difficult to store and rapidly degrades. A single freeze-thaw cycle has 
been shown to reduce infection efficiency by 33% (258). Moreover, 
lentivirus infection efficiency reduces exponentially every 1.4 days 
when stored at 4˚C (258). Thus, it was decided that all further 
experiments would be carried out using fresh lentiviral media that 
did not require storing.  
Next, fresh lentivirus media was diluted in normal media to make up 
25%, 50%, or 75% of the total volume. I measured Cre expression 
by qPCR in WT MEFs that had been incubated with lentivirus to 
confirm that viable lentivirus was able to integrate into the cell 
genome. Cre was expressed in all cells that were exposed to lentiviral 
media. The percentage of lentiviral supernatant that WT MEFs were 
incubated with appeared to affect the Cre expression (figure 3.2C). 
WT MEFs treated for 4 hours with media composed of 50% lentiviral 
supernatant had a 4-fold increase in Cre expression compared 25% 




cells with higher concentrations of lentivirus increases transduction 
(259). WT MEFs treated with 75% lentiviral supernatant for 52 hours 
had a 30-fold increase in Cre expression. Previous studies have 
shown that increased incubation time of lentivirus with target cells 
results in increased transduction efficiency (259). However, it is not 
possible to say whether more cells had been transfected with Cre 
because the lentivirus may have incorporated Cre multiple times into 
a single cell. The positive control used in this experiment used whole 
lung lysate from mice that expressed Cre in epithelial cells. This may 
explain why Cre in the samples were comparably high when 
compared to the positive control because the epithelial cells will have 
made up a small proportion of the whole lung lysate. These results 
confirmed that viable lentivirus was produced and able to transduce 
into the target gene into cells.  
Expression of Cre had been observed in all WT MEFs incubated with 
fresh lentiviral media. This indicated that transduction was taking 
place. Next, I wanted to determine whether I could positively select 
WT MEFs that had been transduced. Again, cells were treated with 
fresh lentiviral media constituting 20%, 50%, 75%, or 100% of the 
total volume of media. There were a few small colonies of WT MEFs 
that survived three days of positive selection, however they did not 
expand. It is possible that the sheer amount of cell death that 
occurred due to low transduction efficiency resulted in the release of 
large quantities of anti-proliferative molecules, such as IL-1 and 
nitric oxide, thus preventing expansion of positively selected cells 
(260). This result was in contrast a previous experiment where no 
WT MEFs survived positive selection after incubation with frozen 
lentiviral media. However, it is important to note that there was a 




To generate a stable cell line with Gαq and Gα11 knocked out I 
replicated transduction described above in Gqfl/flG11-/- murine ASM 
cells. Incubation was left for 3 days before adding 1000ng/ml 
puromycin for positive selection. No cells survived puromycin insult 
indicating that transfection was unsuccessful (no data available). To 
overcome the lack of transduction in primary cells and optimise 
transduction I changed 2 things: 
1. I acquired a transfer plasmid containing a GFP sequence to 
allow visualisation and rapid identification of transfected cells 
using a fluorescent microscope. 
2. I changed my transfection reagent from FuGENE® HD to 
polyethylenimine (PEI) in order maximise transfection of 
packaging cells and therefore lentiviral concentration. 
During the packaging and production of lentivirus I used PEI to 
plasmid DNA ratios of 1:1, 2:1, and 3:1. PEI is a highly branched 
polymer that condenses DNA to form positively charged particles 
(261). These are able to bind to the negatively charged cell surface 
and be endocytosed into the cell (262). HEK T293 cells were used for 
optimisation because they are easy to transduce, and incubated with 
100% lentiviral supernatant. Random areas of the plate were 
selected to count GFP positive cells by microscopy to calculate 
transduction efficiency. There was a ratio-dependent increase in GFP 
positive cells. The highest transduction efficiency was 42% in cells 
with lentiviral supernatant produced with a 3:1 ratio of PEI to DNA. 
This was 2-fold higher than cells transduced with lentiviral 
supernatant from a PEI to DNA ratio of 1:1, which had a transfection 
efficiency of 24%. However, when this was replicated in Gqfl/flG11-/- 
murine ASM cells transduction efficiency was far lower. Lentiviral 
supernatant produced with a PEI to DNA ratio of 3:1 elicited 6% 




Proportionally, the increase of transduction efficiency seen when 
changing the PEI to DNA ratio was similar in Gqfl/flG11-/- murine ASM 
cells and HEK T293 cells, however the transduction efficiency was 
around 90% lower. The low transduction efficiency seen in Gqfl/flG11-
/- murine ASM cells transduced with GFP provides an explanation to 
the unsuccessful antibiotic selection. It suggests that either there 
was no transduction of the target gene or, transduction efficiency 
was far too low for a colony of cells to survive.  
Retroviruses have a short half-life and the distance they can travel 
is limited to a few hundred microns by Brownian motion (263). In 
the past, methods such as flow-through transduction have been used 
to enhance transduction and overcome this physical restraint (264). 
More recently it was noted that both the cell surface and virus are 
negatively charged, creating electrostatic repulsion (265). The 
cationic polymer, polybrene, increases viral absorption into the cell 
by neutralising charge repulsion between the negatively charged cell 
surface and virus (265, 266). Polybrene was used in all of the 
experiments in this thesis to enhance lentiviral transduction, 
however transduction efficiency remained low. Transduction of any 
cell type can be challenging, however this is particularly true when 
transducing primary cells. This is evidenced in this thesis with the 
difference between HEK T293 cells and Gqfl/flG11-/- murine ASM cells.  
The low efficiency of transduction is likely to be the result of low 
lentivirus yield, thus reducing the likelihood of interaction and 
absorption of lentivirus into the ASM cells. Lentivirus can be 
concentrated by using ultracentrifugation at a relative centrifugal 
force (RCF) of 90,000xg for 1 hour (267). A more accessible method 
of concentrating lentivirus has been demonstrated using an RCF of 
10,000xg for 4 hours with a 20% glucose gradient, and resulted in a 




lentivirus (258). This particular method was not attempted, however 
if I were to try to carry out lentivirus transduction in the future I 
would. It would increase the concentration of lentiviral particles in 
supernatant and a smaller volume could be used thus allowing more 
particles to reach the cell surface before becoming inactive.  
Another modern approach to gene editing is CRISPR-cas9. This 
process requires the design of RNA with a guide sequence that binds 
to the target gene and Cas9 enzyme. The enzyme then cuts the DNA 
at the target and the DNA is repaired, deleting the target gene. This 
method of gene editing is often described as easy and cheap. 
However, complete knockout isn’t always achievable with CRISPR 
and it can have off-target effects due to mutations within the DNA 
(248). Analysis of knockout at the protein level using 4 guide RNAs 
per gene showed that CRISPR can be highly variable depending on 
the guide RNA sequence (268). A recent publication has used CRISPR 
to knockout Gαq and Gα11 in HEK T923 cells highlighting that this 
method can be successfully employed to analyse the role of GPCRs 
(269). Ultimately, lentivirus was the gene delivery tool that was used 
due to the availability of Gqfl/flG11-/- mice where there was an 
opportunity to generate a cell line that had permanent and stable 
knockout of Gαq and Gα11. 
In this chapter a series of steps have been carried out from 
amplifying individual lentivirus plasmids to transducing primary cells. 
Lentivirus production and lentiviral transduction have been improved 
throughout this chapter using PEI. Transduction of lentivirus into WT 
MEFs to induce Cre expression was successful, however there were 
challenges translating this into murine ASM cells. It was a similar 
story with transduction of GFP which was achieved in HEK T293 cells, 




4 Chapter 4: Investigating the role of Gαq/11 and RhoA in 
LPA-induced TGFβ activation in airway smooth muscle 
cells 
4.1 Rationale 
LPA is a water-soluble phospholipid present in all tissues of the body. 
LPA acts on five G-protein coupled receptors, LPA1-LPA5, and can 
regulate multiple cellular functions including proliferation, survival, 
growth, migration, and angiogenesis [see review (270)]. LPA1 and 
LPA2 couple to Gαi/0, Gαq/11, and Gα12/13, LPA3 couples to Gαi/0, Gαq/11, 
not Gα12/13, and LPA4 and LPA5 couple to Gαq/11, Gα12/13, and Gαs (271). 
There have been studies in humans with allergic asthma showing LPA 
in the BAL increased in response to allergen challenge (272). 
Moreover, allergen challenge increases the concentration of 
autotaxin, an enzyme that synthesises LPA, in BAL of human 
asthmatic patients (273). Although the specific role of LPA in asthma 
is unknown, there have been suggestions that it could be involved in 
epithelial-barrier repair (272). Intranasal inhalation of LPA in healthy 
mice resulted in an increase in the murine homologue of IL-8, via 
PKC/NF-kappaB signalling, suggesting a role in airway inflammation 
(274). Moreover, inhibition of the LPA2 receptor in a HDM model of 
asthma reduced airway inflammation and IL-4 and IL-5 
concentration within the lung (275, 276). These studies suggest that 
LPA is a positive regulator of inflammation in vivo. LPA is present 
within many tissues, and is typically found at concentrations of 0.1μM 
in the blood plasma and 10μM in the serum (277).  
In addition to its effect on airway inflammation, LPA enhances 
contraction and inhibits the relaxation of isolated tracheal rings 
(278), suggesting a potential role in asthmatic bronchoconstriction. 




effect was prevented by a C3 exoenzyme that inhibits RhoA 
activation, and by a double siRNA knockdown of Gαq and Gαi-2 (279). 
LPA is known to activate TGFβ by altering actin dynamics via the 
small GTPase RhoA (280, 281). RhoA regulates Rho-kinase I/II 
(ROCKI/II), a serine/threonine kinase (282). The kinase activity of 
ROCKI/II is rendered inactive due to autoinhibitory intramolecular 
folding. Activation of RhoA occurs when a RhoGEF promotes 
exchange of GDP for GTP allowing it to bind to the Rho binding 
domain of ROCKI/II, which disrupts its autoinhibitory folding and 
thus activating its serine/threonine kinase activity (283). Both stress 
fibre formation and cell contractility are regulated by ROCKI/II. 
Stress fibres form when ROCKI/II phosphorylates LIM kinase, which 
in turn phosphorylates and therefore inhibits cofilin, an actin 
depolymerisation protein (figure 4.1) (284). Stress fibres cause 
integrins to cluster at the cell surface, forming large protein 
structures that connect the cell cytoskeleton to the ECM, called focal 
adhesions. Talin and integrin are mechanosensitive proteins found 
within focal adhesion complexes. Talin binds to the cytoplasmic 
portion of integrin in response to force, causing integrin to form an 
‘open’ active structure. When active, integrin exposes its binding 
domain, which recognises an RGD motif found in the latent 
associated peptide that keeps TGFβ biologically inactive (285). LPA-
induced TGFβ activation occurs via a RhoA-integrin αvβ6 pathway in 
bronchial epithelial cells (281). In contrast, the integrin αvβ5 is 
required for LPA and methacholine-induced TGFβ activation in airway 
smooth muscle cells (133).  
As discussed in section 1.5.5 TGFβ plays a central role in the 
structural changes within the asthmatic airway, collectively known as 
airway remodelling. TGFβ has been shown induce epithelial apoptosis 




fibrosis (73, 223, 244), differentiation of fibroblasts to myofibroblasts 
(78, 79), increased ASM mass ASM cell proliferation and migration, 
resulting in increased ASM mass and strong airway contraction upon 
exacerbation (242). Furthermore, both goblet cell hyperplasia and 
angiogenesis have been linked to the effects of TGFβ in the asthmatic 
airways (117, 231).  
Smooth muscle cell contraction occurs through two mechanisms. 
One mechanism occurs via phospholipase C (PLC), a membrane 
associated enzyme that catalyses the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to diacyl glycerol (DAG) 
and inositol 1,4,5-trisphosphate (IP3). IP3 binds to calcium channels 
in the sarcoplasmic reticulum, causing an efflux of calcium into the 
cytosol. Calcium binds to calmodulin, which then binds to and 
activates myosin light-chain kinase (MLCK). Phosphorylated MLC 
induces cross-bridge cycling and contraction. Myosin light chain 
phosphatase (MLCP) acts as a ‘brake’ to contraction by 
dephosphorylating MLC. ROCKI/II is able to phosphorylate and 
inhibit MLCP via the RhoA/ROCK pathway, thus resulting in sustained 





G-protein coupled receptors (GPCRs) are seven transmembrane 
receptors that couple with heterotrimeric G-proteins. GPCRs undergo 
conformational change upon ligand binding, allowing them to act as 
a GEF and bind an associated G-protein. GDP is exchanged for GTP 
in the Gα subunit causing dissociation of Gα from Gβγ and allowing 
them to modulate intracellular signalling. There are four G-protein 
sub-classes, Gαs, Gαi/o, Gαq/11, Gα12/13, distinguished by sequence 
homology. While GCPRs tend to bind a particular class of G-proteins, 
they are capable of activating multiple classes. Moreover, ligand 
binding to a GPCR may activate multiple G-proteins, allowing for 
diverse array of downstream signalling events.  
Traditionally, Gαq/11 have been associated with initiating calcium-
contraction signalling via PLCβ in smooth muscle cells, described 
above. On the other hand, Gα12/13 activate RhoA and therefore induce 
stress fibre formation. However, Gαq has been shown to activate TGFβ 
via a RhoA-integrin αvβ6 pathway in bronchial epithelial cells (128, 
286). Moreover, mice with epithelial Gαq/11 knockout had reduced 
Figure 4.1. Diagram of the calcium-dependent and calcium-independent 




total TGFβ concentration in lung homogenate and were protected 
against TGFβ activation in response to high stretch ventilation (287). 
This suggests that downstream signalling pathways of G-proteins is 
cell type specific. The sub-class of G-protein that is required for TGFβ 
activation in ASM cells in currently unknown. 
 
4.2 Aims 
The G-protein class required for integrin-mediated TGFβ activation in 
ASM cells is not established. This chapter investigates whether Gαq/11 
and RhoA are required for LPA-induced TGFβ activation in ASM cells.  
  






4.3.1 LPA activates RhoA and the TGFβ pathway in ASM cells 
Before beginning to determine the role of the G-proteins Gαq/11 on the 
TGFβ activation pathway in ASM cells, LPA concentration responses 
were carried out to confirm that the cells would activate the TGFβ in 
response to LPA. First, a coculture experiment where TMLC cells 
containing a plasmid encoding the TGFβ responsive portion of the 
PAI1 promotor driving luciferase synthesis, were added to cultured 
ASM cells (133). This provided an indirect readout of TGFβ activation, 
proportional to bioluminescence. Raw bioluminescence was 
normalised to the no LPA control so data is shown as fold change 
versus control. Both asthmatic and non-asthmatic ASM cells 
responded in a concentration-dependent manner to LPA (figure 4.3). 
Asthmatic, but not non-asthmatic cells, had significantly increased 
TGFβ activation at 100µM LPA.  The median magnitude of change 
was similar between non-asthmatic and asthmatic cells, however 
there was more variability in asthmatic cells and the fold-change was 







Figure 4.3. Human ASM cells were cultured in 96 well plates and TMLC 
cells were added to each well immediately prior to the experiment. 
Human ASM cells (n=4 cell lines) and TMLC co-culture were stimulated 
with a concentration range of LPA and incubated for 18 hours. Cells were 
lysed and bioluminescence measured by spectrophotometry. 
Bioluminescence, and therefore TGFβ activity, increased in a 
concentration-dependent fashion in response to LPA in both non-
asthmatic and asthmatic ASM cells, A+B. Data expressed as the median 
fold change versus 0μM LPA control ± IQR. Statistical test is a Kruskal-




As the coculture assay measured TGFβ activation indirectly via a 
luciferase readout a direct measurement of TGFβ activation was used 
to validate the coculture data. Phosphorylation of Smad2/3 complex 
is the first signalling event that occurs downstream of TGFβ receptor 
(see section 1.5 in the introduction), thus pSmad2 can be measured 
by western blot and Smad2/3 can be used as the loading control. 
Increasing concentrations of LPA were added to cultured ASM cells 
and incubated for 4 hours whereupon the cells were lysed and 
pSmad2 measured by western blot. The pSmad2 signal, measured 
by densitometry, increased in a concentration-dependent fashion in 
response to LPA addition which was maximal and significant at 
100μM (figure 4.4). The lowest concentration of LPA to elicit a 
consistent response across four separate cell lines was 25uM, 
however the pSmad2 signal was variable. Taken together both of 
these experiments show that LPA activated TGFβ in ASM cells. Due 
to the consistent and strong pSmad2 signal using 100µM LPA, this 








Figure 4.4. Human ASM cells were stimulated with a concentration 
range of LPA for 4 hours. Cells lysates were harvested and a western 
blot performed to detect pSmad2, A. LPA increased pSmad2 in a 
concentration-dependent fashion, maximal at 100μM. Densitometry 
of repeat experiments in different asthmatic donor cell lines is shown 
as median pSmad2 over Smad2/3 ± IQR (n=4 cell lines), B. 




Previously this group has shown that LPA-induced TGFβ activation 
required activation of RhoA in epithelial cells (281). RhoA is a small 
GTPase that is primarily involved in cytoskeletal reorganisation and 
acts upon its effector ROCKI and II, a serine threonine kinase that 
phosphorylates myosin light chain kinase, inducing stress fibre and 
focal adhesion formation. Here I measured active RhoA by ELISA in 
ASM cells treated with LPA to determine whether RhoA was activated 
in response to LPA in ASM cells.  
First, to determine the optimum time point that RhoA becomes 
activated in response to LPA, a time course of active RhoA was 
carried out. ASM cells were treated with 100μM LPA between 0 and 
30 minutes with intervals that were recommended by the 
manufacturers’ protocol. The reaction kinetics of GDP to GTP 
exchange and subsequent GTP hydrolysis occur rapidly with an 
immediate increase in active RhoA at minute 1, peaking at minute 3 
and decreasing to baseline at minute 30 (figure 4.5a). After 
determining the optimum time point to measure RhoA activation, 
experiments were performed to assess RhoA activation in response 
to 10 and 100uM LPA (figure 4.5b). This was carried out to ensure 
that LPA directly increased RhoA activation. LPA at 10μM induced an 
increase in active RhoA that was 2-fold higher than basally active 
RhoA. Absorbance increased from 0.4 to 0.5 when comparing 10μM 
and 100μM LPA stimulation indicating an increase in RhoA activation 
of approximately 20%. This demonstrates concentration-dependent 
activation of RhoA in response to LPA; 100µM was used for future 





Figure 4.5. Human asthmatic ASM cells were stimulated with 100μM 
LPA and active RhoA was measured by ELISA between 1 and 30 
minutes (n=1 experiment), A. RhoA activation occurred rapidly, 
peaking at minute 3 and decreasing over time until minute 30. 
Human asthmatic ASM cells were then stimulated with either 10 or 
100μM LPA and active RhoA measured at minute 3 by ELISA (n=2 
experiments, same cell line), B. Data is expressed as median 




In summary, this section has shown that RhoA and TGFβ is activated 
in an LPA concentration-dependent fashion in ASM cells. TGFβ 
activation has been shown both indirectly by luciferase synthesis in 
coculture with TMLC cells and directly by measuring pSmad2 by 
western blot. Lastly, RhoA activation occurred in response to LPA in 





4.3.2 Small molecule inhibition of the Gαq/11/14 does not inhibit TGFβ 
or RhoA activation in ASM cells 
To determine whether Gαq/11 were required for LPA-dependent TGFβ 
activation, a small molecule inhibitor of Gαq/11/14 was used, YM-
254890 (Wako Chemicals). YM-254890 is a cyclic dipsipeptide 
isolated from Chromobacterium sp. QS3666 that is membrane 
permeable and prevents the Gα subunit from exchanging GDP for 
GTP, thereby rendering the G-protein in its inactive state. It as a 
reported IC50 of 0.1-0.2µM (288).  ASM cells were cultured and TMLC 
were added immediately prior to the experiment. Cells were pre-
incubated with a concentration range of YM-254890 for 45 minutes 
prior to 100µM LPA addition. Bioluminescence was measured as an 
indirect readout of TGFβ activation after 18 hours (Figure 4.6a). The 
LPA positive control was norlised to 1 so data is plotted as relative 
change versus 1, which is represented as a dotted line. As with 
previous experiments LPA increased TGFβ versus media alone. YM-
254890 reduced LPA-induced TGFβ concentration-dependently with 
maximal inhibition achieved at 10nM with a p value of 0.056. The 
difference in effect size between 10nM and 100nM YM-254890 was 
negligible despite non-significant and significant respectively. TGFβ 
activation remained 1.5-fold higher in cells treated with 10nM YM-
254890 when compared to cells treated with media alone. To ensure 
that the inhibitor did not affect the TMLC cells, the concentration 
range of YM-254890 was also applied to TMLC cells alone (figure 
4.6b). There was a significant reduction in LPA-induced luciferase in 
TMLC treated with YM-254890, however it was not concentration-
dependent. This indicates that there is a non-specific inhibitory effect 
of YM-254890 on TMLC, therefore validation in ASM cells in 





Figure 4.6. Human asthmatic ASM cells were cultured in 96 well plates 
and TMLC cells were added to each well immediately prior to the 
experiment. Cells were pre-treated with YM-254890 45 minutes prior 
to 100μM LPA addition. Cells were lysed and bioluminescence 
measured by spectrophotometry. The LPA positive control has been 
normalised to 1 (dotted line) and plotted values are the relative 
difference versus 1. There was a YM-254890 concentration-dependent 
decrease in LPA-induced bioluminescence in ASM cells co-cultured 
with TMLC (n=4 cell lines), A. There was a significant but not dose-
dependent effect of YM-254890 on TMLC alone (n=4 experiments), B. 
Data expressed as the mean fold change versus 0μM LPA control ± 





To validate inhibition of TGFβ activation demonstrated in the ASM-
TMLC coculture a second readout of TGFβ activity was used, PAI1 
expression. TGFβ can induce transcription of PAI1 and therefore be 
used as an indirect measure of TGFβ activation. ASM cells were pre-
treated with 10nM of the Gαq/11/14 inhibitor YM-254890 because this 
was the lowest concentration that reduced TGFβ activation in the 
ASM-TMLC coculture (figure 4.7). LPA treatment significantly 
increased PAI1 expression by 4-fold versus the no LPA control. The 
inhibitor did not reduce LPA-induced PAI1 (figure 4.6). PAI1 is a quick 
endpoint that can indicate TGFβ activation, however, it is an indirect 







Figure 4.7. Human ASM cells were pre-treated with YM-254890 prior 
to 100μM LPA addition. PAI1 mRNA expression was measured 4 hours 
after LPA treatment, (n=4). LPA significantly increased PAI1 
expression, however this was not inhibited by YM-254890. Data 
expressed as the median fold change versus β-2M ± IQR. Statistical 

































PAI1 Expression is not Inhibited by a Gq/11/14





















Next, a pSmad2 western blot was carried out to validate the 
coculture assay and PAI1 QPCR because it is a direct and specific 
measure of TGFβ pathway activation. A monoculture of human ASM 
cells were pre-incubated with a concentration range of YM-254890 
45 minutes prior to 100µM LPA addition (figure 4.8a+b). 
Densitometry of pSmad2 over the Smad2/3 loading control was used 
to quantify repeat western blots. There was a significant increase in 
pSmad2 in response to LPA, with a similar effect size seen in the 
ASM-TMLC coculture and PAI1 QPCR assay. However, in contrast to 
the coculture there was no reduction in pSmad2 at any concentration 
of YM-254890. This result was similar to the PAI1 QPCR carried out 
in a monoculture of ASM cells where there was no inhibition of LPA-





Figure 4.8. Human asthmatic ASM cells, pre-treated with YM-254890 
were stimulated with 100μM LPA for 4 hours. Cells lysates were 
harvested and a western blot was run to detect pSmad2, A. 
Densitometry of repeat experiments is shown as mean pSmad2 over 
Smad2/3 ± SEM (n=3 cell lines), B. There was no reduction in LPA-
induced pSmad2 at any concentration of YM-254890. Statistical test 




RhoA has previously been shown to be essential for TGFβ activation 
in epithelial cells and is activated after 3 minutes of LPA treatment 
in ASM cells (figure 4.5). Next, I wanted to determine whether 
inhibiting Gαq/11 would inhibit LPA-induced RhoA activation. ASM cells 
were pre-treated with a concentration range of the Gαq/11/14 inhibitor 
YM-254890 for 45 minutes before the addition of 100µM LPA. Active 
RhoA was measured after 3 minutes by ELISA and presented as 
percentage absorbance versus the +LPA control (figure 4.9). There 
was a significant increase in active RhoA in response to LPA that was 
3-fold higher than the no LPA control, however there was no effect 
of YM-254890 on RhoA activation at any concentration suggesting 
that Gαq/11/14 do not play a role in LPA-induced RhoA activation.  
In summary, this section aimed to determine whether the 
heterotrimeric G-proteins Gαq/11 were required for LPA-induced TGFβ 
activation in ASM cells. This was tested using the small molecule 
inhibitor of Gαq/11/14, YM-254890. These data show that when ASM 
cells were cultured alone, pSmad2, PAI1 expression, and RhoA 
activation was not inhibited by YM-254890, suggesting that Gαq/11 are 
not required for TGFβ activation. This was in contrast to when ASM 
cells were cocultured with TMLC, which showed that TGFβ activation 
reduced at 10nM YM-254890. It was therefore important to use 
another method of inhibiting Gαq/11 to validate these data, which was 







Figure 4.9. Human asthmatic ASM cells, pre-treated with YM-254890 
were stimulated with 100μM LPA for 3 minutes. Cells lysates were 
harvested and active RhoA measured by ELISA (n=3, same cell line). 
Data shown as mean percentage absorbance versus +LPA ± SEM. 























































































4.3.3 Knockdown of Gαq/11 by siRNA does not inhibit RhoA or TGFβ 
activation in ASM cells 
To further investigate a role for Gq/11 in LPA-induced TGFb 
activation and validate the Gαq/11/14 inhibitor data transient siRNA 
knockdown of the Gαq and Gα11 subunits in ASM cells was carried out. 
Initially ASM cells were transfected with a negative control siRNA, 
Gαq and Gα11 siRNA, or mock transfected with lipofectamine 
transfection reagent. Gαq and Gα11 mRNA was measured 24, 48, and 
72 hours post transfection to ensure that the siRNA knocked down 
its target. Gene expression is normalised to the housekeeping gene 
β-2M and data is shown as fold change versus control siRNA. Both 
Gαq and Gα11 mRNA was significantly reduced by approximately 95% 
down at all time points compared to both mock transfected and 
control siRNA transfected cells (figure 4.10). This demonstrated that 










Figure 4.10. Human ASM cells were either, mock transfected, 
transfected with control siRNA, or siRNA targeting Gαq and Gα11. Cell 
lysates were harvested and mRNA expression measured by QPCR 
(n=3). Normalisation of QPCR data was done against the housekeeping 





Next, protein knockdown was determined to ensure that siRNA 
knockdown of Gαq and Gα11 mRNA resulted in a reduction at the 
protein level. Protein knockdown of Gαq was measured by western 
blot and showed greatest reduction at 72 hours post-transfection 
(appendix 1). To determine whether Gαq and Gα11 knockdown had an 
effect on LPA-induced TGFβ activation, ASM cells were treated with 
100µM LPA for 4 hours, 72 hours post-transfection. For each 
experiment Gαq and Gα11 protein was measured by western blot and 
quantified by densitometry to ensure that there was sufficient protein 
knockdown. Both Gαq and Gα11 were significantly, but not completely, 
knocked down by siRNA at the protein level in each experiment 
(figure 4.11 A & B). There was approximately 80% knockdown of Gαq 












Figure 4.11. Human asthmatic ASM cells mock transfected, 
transfected with control siRNA, or transfected with Gαq and Gα11 siRNA 
for 72 hours (n=3 cell lines). Representative western blot showing Gαq 
and Gα11 protein in lysates from siRNA transfection experiments, A. 
There was significant knockdown of both Gαq and Gα11 in all 
experiments (n=3 cell lines) shown by densitometry, B. Data is 
presented as median ± IQR. Statistical test used was a Mann-Whitney 





Once protein knockdown of Gαq and Gα11 was determined, the ratio of 
pSmad2 to Smad2/3 was measured using densitometry of western 
blots to assess activation of the TGFβ pathway. LPA induced an 
increase in pSmad2 in all conditions when compared to each no LPA 
control (figure 4.12 A & B). In cells mock transfected with 
lipofectamine and control siRNA there was no detectible basal 
pSmad2. Knockdown of Gαq and Gα11 did not reduce LPA-induced 
pSmad2 and actually increased pSmad2 in cells that were either 
untreated or treated with 100µM LPA. This increase was not 
significant, however there was a large effect size that was 2-fold 
higher than LPA-induced pSmad2 in mock transfected and control 
siRNA transfected cells. Basal pSmad2 was detectible in ASM cells 
treated with Gαq and Gα11 siRNA, however this was approximately 
80% lower than pSmad2 in control cells treated with LPA. 
These data validate the data shown in the previous section which 
showed a Gαq/11/14 inhibitor did not reduce LPA-induced pSmad2, 
PAI1 expression, or RhoA activation. Taken as whole the data that 
has been presented so far shows that Gαq/11 are not required for LPA-





Figure 4.12. Human asthmatic ASM cells mock transfected, 
transfected with control siRNA, or transfected with Gαq and Gα11 siRNA 
for 72 hours (n=3 cell lines). Cells were treated with 100μM LPA for 4 
hours after transfection. Representative western blot showing 
pSmad2 and Smad2/3, A. Densitometry shows that there was an LPA-
induced increase in pSmad2 and this was not reduced in ASM cells 
treated with Gαq and Gα11 siRNA, B. Data is expressed as median ± 





Next, I wanted to validate previous data in this chapter showing a 
Gαq/11/14 inhibitor did not inhibit LPA-induced RhoA activation. ASM 
cells were treated with control, or Gαq and Gα11 siRNA, and RhoA 
activation was measured by ELISA (figure 4.13). Active RhoA was 
increased in both controls at 3 minutes after treatment with LPA. 
Treating ASM with Gαq and Gα11 siRNA resulted in a small non-
significant reduction in RhoA activation from an absorbance of 0.18 
to 0.13. However, the confidence interval was large and overlapped 
with the siRNA control group. This suggests that Gαq/11 may play a 








Figure 4.13. Human asthmatic ASM cells mock transfected, 
transfected with control siRNA, or Gαq and Gα11 siRNA, siRNA for 72 
hours (n=3 cell lines). Cells were treated with 100μM LPA for 3 
minutes after siRNA transfection and active RhoA measured by ELISA. 


































LPA-induced RhoA activation at 3 minutes in ASM cells


























4.3.4 ROCKI/II inhibition blocks LPA-induced TGFβ activation 
RhoA is required for TGFβ activation in epithelial cells through 
induction of cytoskeletal reorganisation. In ASM cells, cytoskeletal 
reorganisation activates TGFβ by integrin αVβ5 however a role for 
the RhoA pathway in ASM has not previously been demonstrated. To 
ensure the RhoA pathway was involved in LPA-induced TGFβ 
activation, its effectors ROCKI/II serine-threonine kinases were 
inhibited using the small molecule inhibitor Y27623 (Tocris). Previous 
studies have used 5µM or 10µM concentrations of this inhibitor, 
however, the reported IC50 to inhibit contraction of rabbit aortic strips 
was reported between 0.3-1µM (289, 290). Human ASM cells were 
pre-treated with 5μM or 10μM of a ROCKI/II inhibitor for 30 minutes 
before addition of 100µM LPA for 4 hours. LPA-induced pSmad2 was 
measured by densitometry of western blots. There was inhibition of 
pSmad2 by the ROCKI/II inhibitor Y27623 at 10µM, although this 
was not significant the effect size was large with a reduction in 
pSmad2 that was 4-fold lower than ASM cells treated with LPA alone 
(figure 4.14). The reduction in pSmad2 was concentration-
dependent between 5µM and 10µM of the ROCKI/II inhibitor. These 
data suggest that the RhoA-ROCKI/II pathway is required for TGFβ 







Figure 4.14. Human asthmatic ASM cells were pre-treated with the 
ROCKI/II inhibitor Y27623 for 30 minutes before addition of 100μM 
LPA for 4 hours. pSmad2 measured by western blot and quantified by 
densitometry (n=4 cell lines). LPA-induced pSmad2 was inhibited at 
10μM Y27623. Data is expressed as median ± IQR. Statistical analysis 






In the lung of patients suffering with severe asthma there are 
extensive structural changes within the airways. These structural 
changes are termed as airway remodelling and include subepithelial 
fibrosis, ASM hyperplasia and hypertrophy, epithelial damage, goblet 
cell hyperplasia, and angiogenesis (1). The pleiotropic cytokine TGFβ 
plays central role in airway remodelling. It is therefore important to 
understand the precise signalling pathway that activates TGFβ in 
ASM cells.  
The aim of this chapter was to test the hypothesis that the 
heterotrimeric G-proteins Gαq/11 are required for LPA-induced TGFβ 
activation in ASM cells. In the murine lung, high pressure forced 
ventilation was shown to increase total TGFβ in the lung and was 
abrogated by epithelial knockout of Gαq and Gα11 (127). Further, LPA-
induced TGFβ activation in murine embryonic fibroblasts is 
dependent on integrin β6, RhoA, and Gαq (128). In ASM cells, the 
integrin αvβ5 is required for TGFβ activation and a polymorphism in 
the cytoplasmic domain of β5 abrogates LPA-induced TGFβ activation 
(133). However, the role of GPCRs in ASM cell TGFβ activation has 
not been explored. LPA was used as an agonist because its receptors 
are upstream of Gαq/11, Gα12/13, Gαs, and Gαi/o (271). Moreover, LPA is 
increased in the BAL of asthmatic patients after allergen challenge 
and has been used to elicit a pSmad2 signal in murine embryonic 
fibroblasts (128, 272).  
All of the experiments described in this chapter, except the 
comparison of non-asthmatic and asthmatic cells, were carried out 
in asthmatic ASM cells. There were two reasons for this; first, in order 
to show inhibition of TGFβ I wanted the maximum TGFβ signal, and 
asthmatic ASM cells have been shown to activate more TGFβ than 




analysis of the TGFβ signalling pathway was relevant in cells taken 
from asthmatic patients because asthmatic cells behave differently 
to non-asthmatic cells. A comparison between asthmatic patients 
and allergic rhinitis patients given inhaled bronchoconstrictors 
showed that only asthmatics suffered exaggerated airway narrowing 
(291). 
Initially, this chapter set out to show that LPA could activate 
elements of TGFβ signalling including, TGFβ activation, TGFβ 
signalling by pSmad2, and RhoA activation. Consistent with previous 
work both active TGFβ, shown by TMLC coculture, and pSmad2 were 
increased in ASM cells in a concentration-dependent manner in 
response to LPA treatment (128, 133). Asthmatic cells showed a 
slightly higher fold-increase of luciferase, indicating active TGFβ, 
when treated with LPA in coculture compared to non-asthmatic cells. 
Previous work has shown that asthmatic ASM cells activate more 
TGFβ than non-asthmatic cells in response to both LPA and 
methacholine (133). Throughout the rest of this chapter 100µM of 
LPA was because it gave a strong and consistent pSmad2 signal. 
Although this is higher than the physiological range, 0.1-10µM, the 
limited sensitivity of the assay required a higher concentration of LPA 
to amplify the system to allow efficient interrogation of the signalling 
pathway (277). 
In epithelial cells, RhoA and integrin αvβ6 are central to TGFβ 
activation (128, 175). RhoA and its effector ROCKI/II play an 
important role in actin polymerisation and contraction in response to 
agonists in smooth muscle cells (292, 293). Data in this chapter 
shows that RhoA activation occurs rapidly, peaking at 3 minutes, in 
response to LPA in ASM cells. Taken collectively these data show that 
LPA activates the TGFβ pathway and RhoA in ASM cells. LPA has been 




it is not known whether RhoA is required for TGFβ activation in ASM 
cells (293, 294).  
After demonstrating that LPA induced TGFβ activation I sought to 
inhibit TGFβ activation by inhibiting Gαq/11. This family of 
heterotrimeric G-proteins have been shown to be involved in LPA-
induced TGFβ activation in murine embryonic fibroblasts (128). The 
Gαq/11/14 inhibitor, YM-254890, significantly blocked LPA-induced 
TGFβ activation in a coculture of ASM cells and TMLC with an effect 
size of approximately 50%. A small significant reduction in luciferase 
activity was seen in TMLC cells treated with LPA and Gαq/11/14 
inhibitor, suggesting that the inhibitor was effecting the TMLC, 
however the reduction was not concentration-dependent. This 
suggested that inhibiting Gαq/11/14 abrogates LPA-induced TGFβ 
activation. Next, I measured LPA-induced PAI1 expression in a 
monoculture of ASM cells. PAI1 mRNA can be used as an indirect 
measure of TGFβ activation because it is regulated, although not 
exclusively, by the TGFβ signalling (133). A concentration of 10nM 
of the Gαq/11/14 inhibitor was selected because this concentration 
significantly inhibited TGFβ activation in an ASM-TMLC coculture. 
However, the Gαq/11/14 inhibitor had no effect on LPA-induced PAI1 
expression. Both of these experiments used indirect measures of 
TGFβ activation. The coculture assay used the TMLC reporter cell line, 
measuring PAI1 driven luciferase activity. Whereas PAI1 mRNA 
expression was measured in a monoculture of ASM cells. Moreover, 
PAI1 is regulated by TGFβ and Wnt/β-catenin signalling, and is 
therefore not a specific or direct measure of TGFβ activation (295). 
Thus, it was important to use a specific and direct measure of TGFβ 





Measuring pSmad2 is the most specific indicator of TGFβ activation 
because phosphorylation of Smad2 is the first signalling event after 
activation of the TGFβ receptor. Therefore, pSmad2 was measured 
by western blot to validate either the ASM-TMLC coculture or PAI1 
expression data. Interestingly, LPA-induced pSmad2 was not 
inhibited at any concentration of the Gαq/11/14 inhibitor. This result was 
the same as when measuring LPA-induced PAI1 expression. 
However, it was in contrast to the ASM-TMLC coculture, which 
showed that luciferase, and therefore TGFβ activation, was inhibited 
by the Gαq/11/14 inhibitor. The reason for the difference between the 
ASM-TMLC coculture data and the PAI1 mRNA and pSmad2 data is 
difficult to pinpoint. To date there have been no studies that have 
measured TGFβ activation using both a TMLC coculture assay and 
pSmad2 western blot. The coculture provides an indirect measure of 
active TGFβ via luciferase. In contrast, phosphorylation of Smad2 is 
the first signalling event after TGFβ receptor binding. Measuring 
pSmad2 is therefore a more specific indicator of TGFβ activation than 
the coculture assay. Additionally, both pSmad2 and PAI1 expression 
were measured in a monoculture of ASM cells, thus removing any 
effects of interaction between the ASM cells and TMLC. Additionally, 
there was a small inhibitory effect of the Gαq/11/14 inhibitor on TMLC 
alone, although the effect size was small it is likely that this 
contributed to the inhibitory effect seen.  
Due to the discrepancy between these experiments, siRNA 
knockdown of Gαq and Gα11 was carried out to validate either the ASM-
TMLC coculture assay or pSmad2 western blot. Knockdown of Gαq 
and Gα11 protein was achieved at 72 hours and ASM cells were treated 
with 100μM LPA. Knockdown of Gαq and Gα11 did not reduce LPA-
induced pSmad2 in ASM cells, in fact pSmad2 was increased in 




pSmad2 was 2-fold compared to ASM cells transfected with control 
siRNA. Genetic knockdown can have indirect effects on other G-
protein family members. In HeLa cells, both Gαi1 and Gα12 expression 
was increased in cells that had undergone siRNA knockdown of Gαq/11 
(296). Thus, the increase in pSmad2 after Gαq/11 knockdown may be 
due to an increase in expression of other heterotrimeric G-proteins. 
These data show that pSmad2 is not inhibited by the Gαq/11/14 inhibitor 
nor Gαq/11 siRNA transfection and suggest that Gαq/11 are not required 
for LPA-induced TGFβ activation. This is in contrast to epithelial cells 
and murine embryonic fibroblasts where Gαq/11 have been shown to 
be involved stretch and LPA mediated in TGFβ activation respectively 
(127, 128).  
In epithelial cells, it is accepted that there is a Gq-RhoA-integrin β6 
pathway required for LPA-induced TGFβ activation (127, 128). The 
GTPase RhoA and its effector ROCKI/II, a serine/threonine kinase 
responsible for cytoskeletal organisation, are central to integrin-β6 
mediated TGFβ activation in epithelial cells (175). ROCKI/II increases 
smooth muscle cell contractility and stress fibre formation by 
inhibiting myosin light chain phosphatase, therefore maintaining 
myosin light chain phosphorylation and activation (130). ROCKI also 
activates a range of proteins involved in cytoskeletal regulation, 
including LIM kinase which stabilises actin filaments (283). In ASM 
cells, LPA-induced TGFβ activation has been shown to occur via 
integrin αvβ5, however the pathway leading to integrin activation has 
not been described. For the first time ROCKI/II  has been shown to 
be required, although not exclusively, for LPA-induced pSmad2 
activation in ASM cells. This might suggest that RhoA is also likely to 
be involved in this TGFβ pathway in ASM cells because ROCKI/II is 
the primary effector of RhoA (282, 297). However, RhoA does not 




pathways have been described. Arachidonic acid is able to activate 
ROCKI/II by binding to its auto-inhibitory PH domain and induce 
contraction of smooth muscle fibres (298). Moreover, ROCKI 
activation can also be induced by phosphoinositide-dependent 
kinase-1 (PDK1) binding in competition with its negative regulator 
RhoE (299). 
So far this chapter has shown that the RhoA effectors ROCKI/II, but 
not Gαq/11, are required for LPA-induced TGFβ activation in ASM cells. 
This suggested that RhoA activation was unlikely to be regulated by 
Gαq/11, however it was important to rule this out. A study in HEK T293 
cells has shown that Gαq is able to activate RhoA, however the 
majority of studies show that Gα12/13 are primarily responsible for 
RhoA activation (300-302). In this thesis, active RhoA was measured 
by ELISA after 3 minutes of incubation with LPA. No reduction in 
active RhoA was observed at any concentration of the Gαq/11/14. There 
was a small non-significant reduction in LPA-induced RhoA after 
treatment with siRNA targeting Gαq/11. However, there was large 
confidence interval that overlapped with the control siRNA group, 
therefore suggesting that Gαq/11 were not the primary heterotrimeric 
G-proteins that regulated RhoA in ASM cells. This finding is in 
contrast to work in murine embryonic fibroblasts, which showed that 
LPA-induced TGFβ activation required RhoA and Gαq (128). 
A family of guanine nucleotide exchange factors (RhoGEFs) are 
required to catalyse GDP to GTP exchange in RhoA. They transduce 
the signals from active heterotrimeric G-proteins to RhoA (303). The 
RhoGEF family is diverse and many have a single GTPase target 
making them essential signal transducers between GPCRs. Moreover, 
regulation of RhoGEFs has been suggested to occur via 
spatiotemporal mechanisms and subcellular localisation (304). At 




protein signalling to RhoA activation; p115-RhoGEF, PDZ-RhoGEF, 
LARG, p63-RhoGEF, and AKAP13 (148, 149, 301).  
Traditionally, the primary effector of Gαq/11 in smooth muscle cells is 
PLCβ which catalyses PIP2 to IP3 and DAG, leading to increased 
cytosolic calcium, which in turn results in phosphorylation of the 
myosin light chain and cell contraction (305). More recently however, 
p63RhoGEF was identified as a specific link between the Gαq/11 
angiotensin 1 receptor and RhoA in vascular smooth muscle cells 
isolated from rat aorta (306). Moreover, sphingosine-1-phosphate 
has been shown to activate RhoA through a combination of Gαq and 
Gα12/13 in vascular smooth muscle cells isolated from rat aorta (307). 
However, classical research has shown p115-RhoGEF, PDZ-RhoGEF, 
and leukaemia-associated RhoGEF (LARG) to specifically associate 
with Gα12/13 and activate RhoA (148, 303, 308). Analysing expression 
of RhoGEFs in ASM cells was not within the scope of this thesis, 
however it could indicate which heterotrimeric G-proteins are 
coupled to RhoA. 
In conclusion, this chapter has demonstrated that Gαq/11 are not 
required for LPA-induced TGFβ or RhoA activation in ASM cells. 
Moreover, for the first time, this chapter has shown ROCKI/II are 
required for LPA-induced TGFβ activation. These data disprove the 
hypothesis that Gαq/11 are required for LPA-induced TGFβ activation 
in ASM cells. Moreover, it suggests that RhoA is likely to be required 
for LPA-induced TGFβ activation. The question remains, which 
heterotrimeric G-proteins are upstream of RhoA and TGFβ activation. 
Research described above suggests that Gα12/13 are most frequently 
linked to RhoA activation through p115-RhoGEF, PDZ-RhoGEF, and 
LARG, therefore this hypothesis will be tested in chapter 6 (148, 303, 





5 Chapter 5: Investigating the role of G-proteins in 
cyclical mechanical stretch-induced TGFβ activation in 
ASM cells 
5.1 Rationale 
The lung is a dynamic organ that is constantly undergoing cycles of 
stretch and constriction due to the changes in air pressure that are 
experienced during breathing. This contributes to the unique, ever-
changing microenvironment within the lung. All cells within the lung 
are subjected to different forces throughout the breathing cycle. The 
asthmatic lung is exposed to more force due to the excessive 
contraction of a thickened ASM band (90). Moreover, the airways of 
asthmatic patients are stiffer because of the structural changes that 
occur during the process of airway remodelling (240). These 
structural changes increase airway resistance and therefore increase 
the amount of strain that individual cells are exposed to during 
normal breathing (241).  
It is well known that cells contain mechanosensitive proteins that 
initiate cellular signalling in response to force. These forces can be 
generated internally through reorganisation of the actin cytoskeleton 
during contraction. Alternatively, they can be generated through 
changes in the extracellular environment through remodelling of the 
ECM. These responses lead to a change of gene expression within 
the cell.   Cyclical stretch of cardiac fibroblasts results in an increase 
in total protein synthesis, including TGFβ, in comparison to 
unstretched cells (309). Hepatic stellate cells also increase both 
mRNA and TGFβ release in response to stretch, an effect that is 
abrogated when RhoA is inhibited (310). ASM and vascular smooth 
muscle cells have been shown to increase TGFβ1 expression in 
response to cyclical mechanical stretch (183, 311). Moreover, an 




(311). These studies demonstrate that TGFβ and ECM components 
mRNA expression can be upregulated in response to cyclical 
mechanical stretch. Not only is total TGFβ expression and protein 
upregulated in response to stretch, TGFβ activation is also increased. 
Fibrotic lung strips taken from a rat and subjected to tensile force 
showed an increase in active TGFβ1 liberated from extracellular 
stores and an increase in phospho-Smad2, a specific measure of 
TGFβ signalling (312). 
As discussed in section 1.5.5 TGFβ plays a central role in the 
structural changes within the asthmatic airway, collectively known as 
airway remodelling. TGFβ has been shown induce epithelial apoptosis 
and epithelial-mesenchymal transition (65, 243), subepithelial 
fibrosis (73, 223, 244), differentiation of fibroblasts to myofibroblasts 
(78, 79), increased ASM mass ASM cell proliferation and migration, 
resulting in increased ASM mass and strong airway contraction upon 
exacerbation (242). Furthermore, both goblet cell hyperplasia and 
angiogenesis have been linked to the effects of TGFβ in the asthmatic 
airways (117, 231). 
The mechanism of stretch-induced TGFβ activation is not entirely 
clear. Tensile force-induced TGFβ activation in a fibrotic lung strip 
was attenuated by an integrin αv subunit inhibitor and a ROCKI/II 
inhibitor (312). Similarly, cyclical stretch-induced TGFβ activation in 
hepatic stellate cells was blocked by a RhoA inhibitor (310). These 
studies suggests that RhoA/ROCKI/II are central to stretch-induced 
activation of TGFβ1. Further, a study on human ASM cells showed 
that cyclical mechanical stretch-induced TGFβ1 expression and 
secretion was abrogated by inhibitors of RhoA, ROCKI/II, PI3K, PTK, 
and MEKI/II (183). It went on to highlight that the transcription 
factor AP-1 was involved in cyclical mechanical stretch-induced 




mechanical stretch itself is not responsible for TGFβ1 expression, but 
stretch induces the release of factors that bind to receptors on the 
cell surface to induce TGFβ expression. A study on vascular smooth 
muscle cells showed that cyclical mechanical stretch-induced TGFβ1 
expression and secretion was inhibited by the angiotensin II receptor 
inhibitor, saralasin (185). This study suggested that angiotensin II 
was acting in a paracrine manner to induce TGFβ1 activation and 
release. TGFβ1 itself acts as a paracrine factor, being expressed and 
released from cells, binding to its tyrosine kinase receptor and 
induces gene expression changes such as collagen III synthesis (185, 
313).  
If cyclical mechanical stretch induces the release of paracrine factors 
that stimulate TGFβ activation then it may act via GPCRs. At present, 
it is not known whether a specific class of heterotrimeric G-protein is 
involved in stretch-induced TGFβ activation. If angiotensin is acting 
in a paracrine factor to stimulate TGFβ release in vascular smooth 
muscle cells then it is highly likely that a heterotrimeric G-protein is 
involved because the angiotensin receptors couple to Gαq/11, Gα12/13, 
and Gαi/o (314). In cardiac myocytes subjected to pressure overload 
found that the Gα12/13-coupled receptor P2Y6 was required for TGFβ-
induced fibrosis in the heart (315). A study in mice showed that 
forced high pressure ventilation resulted in an increase in total lung 
TGFβ1, an affect that was abrogated in transgenic mice with 
epithelial knockout of Gαq/11 (127). These data suggest that there 
could be a role for Gαq/11 or Gα12/13 in stretch-induced TGFβ activation 
in various cell types. The specific class of heterotrimeric G-proteins 








This chapter investigates whether Gαq/11 are required for cyclical 
mechanical stretch-induced TGFβ activation in ASM cells.  
  






5.3.1 Cyclical mechanical stretch activates TGFβ in both non-
asthmatic and asthmatic ASM cells 
First, a cyclical mechanical stretch time course was carried out to 
determine the optimum time point to measure pSmad2. ASM cells 
isolated from asthmatic patients were stretched at a frequency of 
0.3Hz, to replicate normal human breathing, and at an equibiaxial 
stretch of 15%. Cells were stretched for 4, 8, 24, and 48 hours and 
pSmad2 measured by western blot. Quantification of western blots 
was done by measuring the densitometry of pSmad2 over Smad2/3. 
There was an increase in pSmad2 at all time points except at 48 
hours in one experiment (figure 5.2). Statistical testing of the 
unstretched group versus the stretched group at all time points 
pooled together shows that stretch induced a significant increase in 
pSmad2. The largest increase in pSmad2 was a 3-fold increase after 
4 hours of stretch. At 8 hours there was only a 1.5 fold increase in 
pSmad2, and at 24 and 48 hours the increase in pSmad2 because 
far more variable. For further, experiments 4 hours of stretch was 











Figure 5.2. Human ASM cells were cultured collagen I coated Flexwell 
tissue culture plates. Human ASM cells (n=3 cell lines) were stretched 
at a frequency of 0.3Hz and equibiaxial stretch of 15% for 4, 8, 24, and 
48 hours. Stretch induced a significant increase in pSmad2 versus 
unstretched cells (p=0.0286). Representative western blot of pSmad2, 
Smad2/3, and GAPDH measured at all time points, A. Densitometry of 
western blots expressed as median pSmad2/tSmad ± IQR. Statistical 




Next, a comparison of pSmad2 activation between ASM cells isolated 
from non-asthmatic and asthmatic patients was carried out by 
western blot. This was done to investigate whether more TGFβ 
activation might occur in the lung of asthmatic patients while 
breathing normally. Cells were stretched at a frequency of 0.3Hz and 
equibiaxial stretch of 15%. Quantification of western blots was done 
by measuring the densitometry of pSmad2 over Smad2/3. Stretch 
induced a significant increase in pSmad2 in both groups (figure 5.3). 
Non-asthmatic cells saw a 1.5-fold increase in pSmad2, whereas 
asthmatic cells exhibited a 2.5-fold increase. The increase in pSmad2 
in asthmatic cells was similar to the increase seen at 4 hours in the 
previous time course experiment (figure 5.2), however pSmad2 in 
non-asthmatic cells was 50% lower. Although there was not a 
significant difference between the two groups after stretch there is 
clearly a trend to more pSmad2 in asthmatic stretched cells. The 
mean pSmad2 increase in asthmatic ASM cells was 50% higher than 
the non-asthmatic group. It is likely that to see a statistical difference 
between the two stretched groups there would need to be a high 
sample size because of the large standard error of mean. However, 
this data does show that there is more stretch-induced pSmad2 in 
asthmatic versus non-asthmatic ASM cells despite the variability 





Figure 5.3. Human ASM cells were cultured collagen I coated Flexwell 
tissue culture plates. Human non-asthmatic ASM cells (n=6 cell lines) 
and asthmatic cells (n=6 cell lines) were stretched at a frequency of 
0.3Hz and equibiaxial stretch of 15% for 4 hours. Stretch induced a 
significant increase in pSmad2 in both groups. There was a small non-
significant difference in pSmad2 between both groups with asthmatic 
ASM cells inducing more pSmad2. Representative western blot of 
pSmad2, Smad2/3 and GAPDH A. Densitometry of western blots 




5.3.2 The role of Gαq/11 in stretch-induced pSmad2 in ASM cells 
To determine whether Gαq/11 were required for stretch-induced TGFβ 
siRNA knockdown of Gαq and Gα11 was carried out in the same manner 
as in chapter 4. Cells were treated with the transfection vehicle, 
negative control siRNA, or Gαq and Gα11 siRNA. Experiments were 
carried out 72 hours post-transfection. Knockdown of Gαq and Gα11 
was determined for each experiment by western blot and calculating 
the ratio of Gαq or Gα11 to GAPDH using densitometry (figure 5.4). 
There was significant knockdown of both Gαq and Gα11 protein when 
comparing the negative control transfected group against the Gαq and 
Gα11 transfected groups. Stretch had no effect on the efficiency of Gαq 
and Gα11 knockdown. The knockdown observed was similar to that 







Figure 5.4. Human ASM cells were cultured collagen I coated Flexwell 
tissue culture plates. Human asthmatic cells were treated with siRNA 
targeting Gαq and Gα11 (n=3 cell lines). Cells were stretched, 72 hours 
after transfection, at a frequency of 0.3Hz and equibiaxial stretch of 
115% for 4 hours. Representative western blot showing Gαq and Gα11 
protein in lysates from siRNA transfection experiments, A. There was 
significant knockdown of both Gαq and Gα11 in all experiments (n=3 cell 
lines) shown by densitometry, B. Data is presented as median ± IQR. 
Statistical test used was a Mann-Whitney U of control siRNA and Gαq + 




Once knockdown of Gαq and Gα11 was determined by western blot, 
activation of TGFβ was determined by measuring pSmad2. A western 
blot was carried out to determine whether pSmad2, the first 
signalling event after TGFβ receptor activation, was activated in 
response to cyclical mechanical stretch in ASM cells. Cells were 
stretched for 4 hours, 72 hours post siRNA transfection. Cyclical 
mechanical stretch induced an increase in pSmad2 in the transfection 
vehicle control, siRNA control and Gαq and Gα11 groups (figure 5.5). 
There was also a noticeable increase in basal pSmad2 in unstretched 
ASM cells treated with Gαq and Gα11 siRNA. Contrary to the hypothesis 
that knockdown of Gαq and Gα11 would inhibit cyclical mechanical 
stretch-induced pSmad2, there was actually a non-significant 2-fold 
increase in pSmad2 in the Gαq and Gα11 siRNA group versus the 
control siRNA group. Moreover, this result mirrors the effect of LPA-







Figure 5.5. Human ASM cells were cultured collagen I coated Flexwell 
tissue culture plates. Human asthmatic cells were treated with siRNA 
targeting Gαq and Gα11 (n=3 cell lines). Cells were stretched, 72 hours 
after transfection, at a frequency of 0.3Hz and equibiaxial stretch of 
15% for 4 hours. Representative western blot showing pSmad2 and 
Smad2/3 protein, A. There was no reduction of stretch-induced pSmad2 
in ASM cells treated with Gαq and Gα11 siRNA (n=3 cell lines) shown by 
densitometry of pSmad2 over Smad2/3, B. Data is presented as median 
± IQR. Statistical test used was a Mann-Whitney U of stretched control 




Next, the small molecule inhibitor of Gαq/11/14 was used to validate 
data showing cyclical mechanical stretch induced pSmad2 in ASM 
cells treated with Gαq and Gα11 siRNA. Asthmatic ASM cells were pre-
treated with 10nM of the Gαq/11/14 inhibitor, YM-254890, for 45 
minutes prior to stretch. This concentration was selected because it 
significantly inhibited LPA-induced TGFβ activation in a coculture of 
ASM cell and TMLC reporter cell experiment (figure 4.5a).  Moreover, 
this concentration of YM-254890 inhibited stretch-induced pSmad2 
in precision cut lung slices (Appendix figure 2). Cells were subjected 
to 15% stretch for 4 hours at a frequency of 0.3Hz to replicate normal 
breathing. Levels of pSmad2 were measured by western blot and 
quantified by densitometry. Cyclical mechanical stretch induced an 
increase in pSmad2 versus the unstretched controls in both the 
vehicle control and YM-254890 groups (figure 5.6). The stretch-
induced increase in pSmad2 was approximately 3-fold in the vehicle 
control group and 2-fold in the YM-254890 group compared to their 
respective unstretched controls. However, the magnitude of stretch-
induced pSmad2 in the YM-254890 treated group was around half 
that of the vehicle control group, suggesting that there was a trend 
towards inhibition of pSmad2. This is in contrast to experiments that 
used siRNA to knockdown Gαq and Gα11 where there was a clear 






Figure 5.6. Human ASM cells were cultured collagen I coated Flexwell 
tissue culture plates. Human asthmatic cells were pre-treated with a 
small molecule inhibitor of Gαq/11/14 YM-254890 45 minutes prior to 
stretch (n=3 cell lines). Cells were stretched at a frequency of 0.3Hz 
and equibiaxial stretch of 15% for 4 hours. Representative western blot 
showing pSmad2 and Smad2/3 protein, A. There was a reduction in the 
magnitude of stretch-induced pSmad2 in ASM cells treated with YM-
254890 compared to the vehicle control, however there was still a 
stretch induced increase in pSmad2 in both groups (n=3 cell lines) 
shown by densitometry of pSmad2 over Smad2/3, B. Data is presented 
as median ± IQR. Statistical test used was a Mann-Whitney U of the 




5.3.3 Small molecule inhibition of ROCKI/II inhibits cyclical 
mechanical stretch-induced pSmad2 
To determine whether there was a role for the serine/threonine 
kinase ROCKI/II in cyclical mechanical stretch-induced TGFβ 
signalling, a small molecule inhibitor was used. A concentration of 
10μM was used because this inhibited LPA-induced pSmad2 in 
asthmatic ASM cells in chapter 4 (figure 4.13). Human asthmatic 
ASM cells were pre-treated with an inhibitor of ROCKI/II, Y27623, 45 
minutes prior to stretch. Cells were subjected to 15% cyclical 
mechanical stretch for 4 hours at a frequency of 0.3Hz. Western blot 
was used to measure pSmad2 and densitometry pSmad2 over 
Smad2/3 determined the relative magnitude of pSmad2. There was 
a large stretch-induced increase in pSmad2 in the vehicle control 
group (figure 5.7). Stretch-induced pSmad2 was abrogated by the 
ROCKI/II inhibitor, Y27623. There was a 50% reduction in the 
magnitude of pSmad2 in the stretched Y27632 cells compared to the 
stretched vehicle control, however the confidence intervals were 
large and it was not significant. The level of pSmad2 was increased 
in the unstretched Y27623 group compared to the unstretched 
vehicle control, however it is clear that the stretch-induced pSmad2 





Figure 5.7. Human ASM cells were cultured collagen I coated Flexwell 
tissue culture plates. Human asthmatic cells were pre-treated with a 
small molecule inhibitor of ROCKI/II Y27623 45 minutes prior to stretch 
(n=3 cell lines). Cells were stretched at a frequency of 0.3Hz and 
equibiaxial stretch of 15% for 4 hours. Representative western blot 
showing pSmad2, Smad2/3 and GAPDH, A. Stretch-induced pSmad2 
was inhibited in the Y27623 group, however the amount of pSmad2 in 
unstretched cells was also higher in this group (n=3 cell lines) shown by 
densitometry of pSmad2 over Smad2/3, B. Data is presented as median 
± IQR. Statistical test used was a Mann-Whitney U of the stretched 





The pleiotropic cytokine TGFβ is known to play a central role in 
fibrotic diseases and can induce the expression of fibrotic genes that 
contribute to airway remodelling seen in the airway of severe 
asthmatic patients. Overexpression of TGFβ and pSmad2 in the 
asthmatic airways has been linked to subepithelial fibrosis, ASM cell 
hyperplasia and hypertrophy, epithelial damage, goblet cell 
hyperplasia, and angiogenesis (1, 211, 214). It is therefore 
important to fully understand the mechanism by which TGFβ 
becomes activated in the airways of severe asthmatics, who suffer 
from frequent exacerbation.  
All of the experiments described in this chapter, except the 
comparison of non-asthmatic and asthmatic cells, were carried out 
in asthmatic ASM cells. There were two reasons for this; first, in order 
to show inhibition of TGFβ I wanted the maximum TGFβ signal, and 
results in this chapter show, for the first time, that asthmatic ASM 
activate more TGFβ in response to stretch than non-asthmatic ASM 
cells. The second was to ensure that analysis of the TGFβ signalling 
pathway was relevant in cells taken from asthmatic patients because 
asthmatic cells can behave differently to non-asthmatic cells. A 
comparison between asthmatic patients and allergic rhinitis patients 
given inhaled bronchoconstrictors showed that only asthmatics 
suffered exaggerated airway narrowing (291). 
The primary statistical test used in this chapter was the Mann-
Whitney U. This was used because the majority of experiments used 
three replicates and therefore cannot be assumed to show normal 
(Gaussian) distribution. Gaussian distribution assumes that the 
results will fit in a standard bell-curve (316). A statistical limitation 
to the Mann-Whitney U test is that it does not measure the 




individual data point based on its value. It is therefore impossible to 
attain statistical ‘significance’ with three replicates no matter how 
large the effect size or small the confidence interval.  
The lung is a dynamic environment constantly subjected to 
mechanical forces during breathing. It has been hypothesised that 
mechanical stress is communicated between different cell types 
within the airways to induce structural changes (317). Integrins are 
mechanosensitive cell surface proteins that are able to liberate the 
active TGFβ molecule by binding to an RGD motif in the LAP of TGFβ. 
The integrin αvβ5 is responsible for TGFβ liberation in ASM cells, 
whereas αvβ6 is responsible in epithelial cells (128, 133). In mice 
subjected to low pressure and high pressure forced ventilation, there 
was a significant increase in total lung TGFβ1 after high pressure 
ventilation (127). This effect was abrogated by epithelial knockout of 
Gαq and Gα11, but not Gα11 alone (127). In cultured ASM cells, stretch 
has been shown to increase TGFβ1 gene expression via a 
RhoA/ROCKI/II signalling (183). However, it has not been 
determined whether a Gαq/11 play a role stretch-induced TGFβ 
activation in ASM cells. Nor has pSmad2, the first signalling event 
after TGFβ receptor activation, been measured in ASM that have 
undergone a stretching regimen. 
Previous work in human ASM cells has shown that TGFβ1 mRNA is 
increased after 3 hours of uniaxial cyclical mechanical stretch using 
a Flexcell™. Cells were subjected to 12% stretch at a frequency of 
0.3Hz (183). This frequency is experienced during human tidal 
breathing. Human ASM cells are stretched by 4-5% during tidal 
breathing and as much as 25%-30% during deep inspiration (318). 
For the experiments conducted in this thesis, 15% equibiaxial stretch 
was selected due to previous unpublished work in this laboratory and 




plausible that 15% stretch represents physiological levels in vivo that 
would be experienced during normal daily activity. 
It is known that levels of TGFβ are increased in the BAL fluid and 
submucosa of asthmatic versus non-asthmatic patients (74, 213). 
Further, human ASM cells from asthmatic patients treated with LPA 
induce more TGFβ activation than non-asthmatic ASM cells (133). 
However, a comparison of asthmatic versus non-asthmatic stretch-
induced TGFβ activation in human ASM cells has not been carried 
out. Measuring pSmad2 by western blot showed that there was more 
stretch-induced pSmad2, and therefore TGFβ activation, in asthmatic 
versus healthy ASM cells. The median increase in pSmad2 in 
asthmatic versus non-asthmatic ASM cells was clear but not 
significant due to large confidence intervals in both groups. However, 
a significant difference is likely to have been observed if the 
experiment carried greater power through more cells lines. More 
pSmad2 was expected in asthmatic ASM cells in response to stretch 
based on research that has shown TGFβ activation to be higher in 
asthmatic cells in response to other stimuli such as LPA and 
methacholine (133). This finding is important because it 
demonstrates that asthmatic ASM cells are primed to activate more 
TGFβ and are therefore induce airway structural changes in 
comparison to ASM cells from a non-asthmatic airway (133, 161).   
At present, it is not clear how mechanical stretch induces TGFβ 
activation. To date, most studies have linked cell surface receptors 
to stretch-induced TGFβ. Angiotensin II, a GPCR agonist, is required 
for cyclical mechanical stretch-induced TGFβ activation in vascular 
smooth muscle cells (185). Moreover, in mice total lung TGFβ is 
increased after high pressure forced ventilation and abrogated by 
epithelial knockout of Gαq/11 (127). These studies suggest that the 




released of a paracrine factor that can act back on the cell to trigger 
the TGFβ signalling pathway. There have been no in vitro studies to 
determine whether Gαq/11 are required for stretch induced TGFβ 
activation in ASM cells.  
In this thesis, siRNA was used to knockdown Gαq/11 prior to cyclical 
mechanical stretch. There was no reduction in stretch-induced 
pSmad2 in siRNA treated cells compared with the control groups. In 
fact, there was a 2-fold increase in pSmad2 in siRNA treated cells 
compared to the control group. This effect was also observed in 
chapter 4 when ASM cells were treated with Gαq/11 siRNA and 
stimulated with LPA. Conversely, treating ASM cells with small 
molecule Gαq/11/14 inhibitor before the stretch regimen reduced the 
magnitude of stretch-induced pSmad2, but did not abrogate stretch-
induced pSmad2. It is interesting that blocking Gαq/11 by siRNA 
caused pSmad2 to increase whereas using the small molecule 
inhibitor caused pSmad2 to decrease. Targeting Gαq/11 using siRNA 
knocks down the catalytically active Gα subunit, whereas the inhibitor 
keeps the heterotrimer locked in its inactive state by preventing the 
exchange of GDP for GTP (288). It is possible that knockdown of the 
Gα subunits by siRNA leaves excess free Gβγ subunits in the 
cytoplasm. Gβγ primarily function to trigger a negative feedback loop 
to stop GPCR signalling by activating G-protein coupled receptor 
kinases, thus it is unlikely that this caused the increase in pSmad2 
(319).  
The other obvious difference is that the inhibitor also blocks 
signalling of Gα14, the least studied subunit of the Gαq family. Gα14 has 
a more restricted expression pattern than the ubiquitously expressed 
Gαq/11, but is expressed in the lungs as determined by total organ 
RNA (320). However, expression of Gα14 was not measured in cells 




able to activate PLCβ through Gαq/11, some Gαi, and some Gαs coupled 
receptors (321). PLCβ catalyses the hydrolysis is PIP2 to IP3 and DAG, 
which are secondary messengers that can initiate intracellular 
calcium signalling and activate PKC. To date, there is no evidence 
that TGFβ activation is downstream of calcium signalling or PKC 
signalling, therefore it is unlikely that Gα14 is involved in TGFβ 
activation. However, it is interesting that pSmad2 increased by 50% 
in ASM treated with Gαq/11, whereas it decreased by 50% in cells 
treated with a Gαq/11/14 inhibitor. This reduction in pSmad2 in the 
presence of the Gαq/11/14 could be due to additional inhibition of Gα14. 
Alternatively, genetic manipulation of heterotrimeric G-proteins may 
have had off-target effects. There is evidence that genetic 
knockdown of a specific class of heterotrimeric G-protein can lead to 
an increase in expression of other G-proteins (296). It is therefore 
possible that knockdown of Gαq/11 is causing the expression of other 
G-proteins to increase. 
It clear is from both siRNA knockdown of Gαq/11 and small molecule 
inhibition of Gαq/11/14 that stretch continued to induce an increase in 
pSmad2, and therefore TGFβ activation. These results show that of 
Gαq/11 are not required for cyclical mechanical stretch-induced TGFβ 
activation in human asthmatic ASM cells. This finding is in contrast 
to data in airway epithelial cells. Increased total lung TGFβ in 
response to high pressure ventilation in mice was abrogated by the 
epithelial knockout of both Gαq/11 (127). These results indicate that 
either, paracrine factors released upon stretch are acting on 
receptors that are coupled to different G-protein families in airway 
epithelial and ASM cells, or mechanical stretch in ASM cells activates 
TGFβ independently of any GPCR.  
Angiotensin and endothelin are released from stretched aorta smooth 




GPCR agonists (185, 309). Mechanical strain on human ASM has 
been shown to induce secretion of the proteases MMP1 and MMP2, 
the latter of which has been identified as an activator of latent TGFβ 
(322). ATP is also released from multiple cell types, including human 
ASM cells, in response to mechanical strain and is associated with 
inflammation (323). Moreover, prostaglandin is released from ASM 
cells in response to stretch and its receptors are coupled to Gαs and 
Gαi heterotrimeric G-protein families (324). It would have been 
interesting to determine whether there was secretion of a specific 
mediator from stretched ASM that induced TGFβ activation. A media 
transfer experiment was considered, however, TGFβ is upregulated 
and secreted upon stretch so it would have directly induced pSmad2 
and thus not answered the question of whether a secreted mediator 
or stretch itself induces TGFβ signalling. Mass spectrometry of media 
from stretched ASM cells could also have been analysed, however, 
based on previous data described here there are likely to be many 
secreted factors from stretched ASM cells. This would be an 
interesting experiment to carry out in the future, particularly if there 
was data indicating a paracrine mechanism. 
In the majority of research analysing the pathway leading to TGFβ 
activation, the small G-protein RhoA and its effectors ROCKI/II are 
frequently described as central to its activation. Indeed, inhibition of 
RhoA or ROCKI/II abrogated uniaxial stretch-induced TGFβ1 
expression and secretion in ASM cells (183). Work in this thesis 
showed that inhibiting ROCKI/II using the small molecule inhibitor 
Y27623 prevented cyclical mechanical stretch-induced pSmad2, and 
therefore TGFβ activation. This result supports the current literature 
showing that Y27623 prevents stretch-induced TGFβ activation in 
fibrotic lung strips, and TGFβ expression in ASM cells (183, 312). 




in unstretched control ASM cells, a feature that does not happen in 
fibrotic lung strips treated with the same concentration of this 
inhibitor (312). Nor does TGFβ expression or secretion increase in 
unstretched ASM cells treated with the same concentration of Y27623 
(183). This is the first time that pSmad2 has been measured in ASM 
cells subjected to cyclical mechanical stretch treated with a ROCKI/II 
inhibitor. It indicates that ROCKI/II is central to the activation of 
TGFβ in stretched ASM cells, and fits with the current body of work 
that shows RhoA/ROCKI/II to be central to TGFβ activation from a 
range of stimuli. 
In conclusion, this chapter has highlighted for the first time in human 
ASM cells that cyclical mechanical stretch can induce TGFβ signalling 
through pSmad2. Moreover, the heterotrimeric G-protein family 
Gαq/11 is not involved in stretch-induced TGFβ activation in human 
ASM cells. It seems likely from this data and from others that the 






6 Chapter 6: Investigating the role of the Gα12/13 in LPA- 
and stretch-induced TGFβ activation in ASM cells 
6.1 Rationale 
Asthma is a chronic inflammatory disease of the airways 
characterised by airway hyper-responsiveness, inflammation, and 
bronchoconstriction. As a consequence the cells within the airways 
of asthmatics are subjected to a milieu of inflammatory cytokines 
and mechanical forces.  
Cells are subjected to a large contractile force during 
bronchoconstriction due to thickening of the ASM band in asthmatic 
patients (93). Moreover, lungs of asthmatic patients are described 
as having airway resistance, which describes resistance to air flow 
generated from friction and stiffening of the lungs (240). The result 
of these structural changes within the lung is that individual cells 
within the asthmatic lung are exposed to more strain during 
breathing (241). Moreover, data in chapter 5 of this thesis has shown 
that even when cells are subjected to equal strain, asthmatic cells 
activated more TGFβ than non-asthmatic cells. Thus, a combination 
of greater strain within the asthmatic airways and cells that are able 
to activate more TGFβ results in exaggerated TGFβ response ad 
contributes to airway remodelling (1).   
LPA is a water soluble phospholipid that is present in many tissues 
of the body and is typically found at concentrations of 0.1μM in the 
blood plasma and 10μM in the serum (277). LPA is increased in the 
BAL of human subjects after allergen challenge (272). Autotaxin, an 
enzyme responsible for LPA synthesis, is also increased in the BAL of 
human subjects after allergen challenge (273). Healthy mice dosed 
with LPA via intranasal inhalation developed an increase in the 




Moreover, inhibition of the LPA2 receptor in a HDM model of asthma 
reduced airway inflammation and IL-4 and IL-5 concentration within 
the lung (275, 276). These studies indicate that LPA plays a role in 
inflammation within the asthmatic airway. However, the role of LPA 
may not be limited to inflammation. LPA has been demonstrated to 
induce contraction and inhibit relaxation of isolated tracheal rings, 
and thus may be one of the many small molecules that induce 
bronchoconstriction within the asthmatic airway (278).  
As discussed in section 1.5.5 TGFβ plays a central role in the 
structural changes within the asthmatic airway, collectively known as 
airway remodelling. TGFβ has been shown induce epithelial apoptosis 
and epithelial-mesenchymal transition (65, 243), subepithelial 
fibrosis (73, 223, 244), differentiation of fibroblasts to myofibroblasts 
(78, 79), increased ASM mass ASM cell proliferation and migration, 
resulting in increased ASM mass and strong airway contraction upon 
exacerbation (242). Furthermore, both goblet cell hyperplasia and 
angiogenesis have been linked to the effects of TGFβ in the asthmatic 
airways (117, 231). 
LPA-induced TGFβ has been shown to require the small G-protein 
RhoA and its effector ROCKI/II in murine embryonic fibroblasts 
(128). The GPCR, protease activated receptor 1 (PAR1) has been 
shown to activate TGFβ in the murine lung and was suggested to 
occur via a RhoA and ROCK dependent mechanism, determined in 
murine embryonic fibroblasts (175). Fibrotic lung strips subjected to 
tensile force increase TGFβ activation and pSmad2, the first 
signalling event in the TGFβ pathway, an effect that was abrogated 
by an inhibitor of ROCKI/II (312). Further, cyclical mechanical 
stretch in human ASM cells is able to increase TGFβ1 expression, a 
process that is inhibited by an inhibitor of RhoA or ROCKI/II (183). 




release TGFβ in response to cyclical stretch which is inhibited by 
transfection with dominant negative RhoA (310). The sum of these 
studies clearly indicate that the RhoA/ROCKI/II axis is central to 
TGFβ activation and synthesis in response to both agonist and 
mechanical stretch stimuli. Indeed, this thesis has shown that 
inhibition of ROCKI/II abrogated TGFβ-induced pSmad2 in ASM cells 
stimulated with both LPA and cyclical mechanical stretch. 
RhoA is a small G-protein that exchanges GDP for GTP upon 
activation by a RhoGEF. Its effector ROCKI/II is a serine/threonine 
kinase that remains inactive due autoinhibitory intramolecular 
folding, which is disrupted upon binding of RhoA<GTP> (283).  
ROCKI/II is a regulator of cytoskeleton dynamics, cell contractility, 
and calcium sensitisation (325). ROCKI/II is able to promote cell 
contraction through phosphorylation and thus inhibition of myosin 
light chain phosphatase (MLCP), which prevents MLCP from 
dephosphorylating MLC (130, 326). Stress fibres are significant 
contractile structures that are regulated by ROCKI/II (327). Upon 
activation, ROCKI/II phosphorylates and activates LIM domain 
kinases, which in turn phosphorylate the actin depolymerising 
protein cofilin (283). This results in the formation stress fibres 
composed of actin bundles of 10-30 actin filaments, which are cross 
linked by several actin crosslinking proteins including α-actinin (328).  
Stress fibres are linked to large multiprotein complexes called focal 
adhesions, which serve to tether the actin cytoskeleton to the ECM. 
Integrins are mechanosensitive cell surface proteins that cluster at 
focal adhesion sites. Integrins are linked to the actin cytoskeleton 
through talin binding to the cytoplasmic portion of integrin, which is 
in turn cross linked to the actin cytoskeleton by vinculin (133). The 
extracellular portion of integrin binds to components of the ECM, thus 




activators of latent TGFβ that recognise the RGD motif in the latent 
associated peptide and thus liberate the active TGFβ molecule in 
response to mechanical force (284). In human ASM cells αvβ5 has 
been shown to activate TGFβ in response to LPA and methacholine, 
and inhibition of this integrin in a murine OVA model of asthma 
reduces airway remodelling (133). Moreover, RhoA has been shown 
to induce ASM contraction by catalysing the assembly of focal 
adhesions and regulating actin polymerisation (293). 
It is clear that the RhoA/ROCKI/II axis is central to TGFβ activation. 
The heterotrimeric G-protein class upstream of RhoA activation has 
not been fully established in ASM cells. Knockdown of Gαq in murine 
embryonic fibroblasts abrogated TGFβ activation, which was shown 
to require both RhoA and ROCKI/II (128). Moreover, knockout of 
epithelial Gαq/11 in the murine lung abrogated an increase in total 
TGFβ in response to forced high pressure ventilation (127). The link 
between Gαq/11 and RhoA is by no means clear in all cell types. Many 
agonists that activate RhoA are also able to activate Gαq, however 
Gαq/11 alone are rarely sufficient to activate RhoA (329). Platelets 
treated with thromboxane degranulate and undergo shape change 
that is dependent on RhoA and ROCKKI/II. Knockout of Gαq inhibited 
platelet degranulation, a calcium-dependent process, however shape 
change was shown to require Gα12/13 activation of RhoA and 
ROCKI/II, and MLC phosphorylation (330). Gα12/13, protein was found 
to be significantly upregulated in the bronchial smooth muscle of rats 
subjected to repeated antigen exposure (154). Moreover, in Gq/11 
deficient mice, LPA, serotonin, and bradykinin were able to induce 
stress fibre formation in fibroblasts through Gα13 (331). In contrast, 
stress fibre formation via the muscarinic M1 receptor required Gαq/11 




RhoA activation and RhoA-dependent responses, however it is also 
apparent that there is some crosstalk between Gαq/11 and Gα12/13. 
The point of crosstalk between Gαq/11 and Gα12/13 is not entirely clear, 
however both of these G-protein families have been shown to have 
the same targets. Classically, Gαq/11 were thought to exclusively 
target PLCβ and trigger calcium signalling and cell contraction. More 
recently, Gαq/11 have also been shown also bind p63-RhoGEF and 
LARG, both of which are able to activate RhoA (143, 144). Similarly, 
Gα12/13 are able to bind p63Rho-GEF, LARG, p115-RhoGEF, and PDZ-
RhoGEF (148, 149). This may act as a point of crosstalk between 
Gαq/11 and Gα12/13, however it has also been shown that Gαq/11 
activates these RhoGEF at a lower potency in comparison to Gα12/13, 
in murine embryonic fibroblasts (145). It is likely that the amount of 
crosstalk between these pathways varies between cell type. 
There is evidence of involvement of another family of heterotrimeric 
G-proteins, Gαi/o, in RhoA/ROCK signalling. Actin reorganisation in 
response to LPA and carbachol in ASM cells was abrogated by 
inhibition of RhoA (332). Targeting Gαi2 with siRNA inhibited 
carbachol-induced reorganisation, whereas both Gαi2 and Gαq siRNA 
were required to inhibit LPA-induced actin reorganisation (332). 
These data suggest that LPA can induce actin reorganisation via 
either Gαi2 or Gαq, with RhoA being central to this process. In contrast, 
overexpression of Gαi2 in murine ASM cells reduced cell contractility 
by downregulating PLCβ, the target of Gαq/11 (161). Moreover, 
inhibiting Gαi2 resulted in sensitisation of smooth muscle cells to Gαq 
mediated contraction by upregulating expression of PKCα (161). It 
was suggested that Gαi2 upregulation functioned as a protective 
mechanism to airway hyper-responsiveness.  
At present, there is evidence that Gαq/11 are involved in RhoA 




response to LPA (128). In this thesis, Gαq/11 have been definitively 
shown not to be required for LPA-induced RhoA or TGFβ activation, 
in human ASM cells. There many links between Gα12/13 and RhoA 
activation that have been highlighted, and RhoA is known to be 
involved in TGFβ activation, therefore this chapter assesses the 
whether Gα12/13 are involved in LPA- and stretch-induced TGFβ 
activation in ASM cells.  
6.2 Aims 
Assess whether the heterotrimeric G-proteins Gα12/13 are involved in 
LPA- and stretch-induced RhoA and TGFβ activation in ASM cells.  
  





6.3.1 Knockdown of G12 and G13 mRNA expression using siRNA 
Initially, validation of siRNA targeting Gα12 and Gα13 was carried out 
to determine that it was working and capable of reducing Gα12 and 
Gα13. ASM cells were treated with the transfection reagent alone 
(vehicle control), control siRNA, or Gα12 and Gα13 siRNA for 4 hours. 
QPCR was carried out on cell lysates taken at 24, 48, and 72 hours 
to quantify both Gα12 and Gα13 mRNA (figure 6.2). There significant 
knockdown of Gα12 and Gα13 mRNA at all time points that was around 
95% lower in comparison to the control siRNA group. These data 
indicated that the siRNA was working efficiently. The 72 hour time 
point was used in future experiments as this gave a good knockdown 
in expression and would allow consistency between these 









Figure 6.2. Human ASM cells were either, mock transfected, transfected 
with control siRNA, or siRNA targeting Gα12 and Gα13. Cell lysates were 
harvested and mRNA expression measured by QPCR (n=3 cell lines). 
Normalisation of QPCR data was done against the housekeeping gene 





6.3.2 Activation of RhoA is mediated through signalling from G12/13 in 
ASM cells 
To determine which heterotrimeric G-proteins were required for 
RhoA activation, asthmatic ASM were treated with siRNA targeting 
Gαq and Gα11 or, Gα12 and Gα13. The same protocol for siRNA 
transfection was carried out as previously described in chapter 4 of 
this thesis. Cells were treated with 100μM LPA, 72 hours post 
transfection, for 3 minutes and active RhoA was measured by ELISA 
(figure 6.3). LPA treatment increased active RhoA in the mock 
transfected, control siRNA, and Gαq and Gα11 transfected ASM cells, 
however this was abrogated in cells transfected Gα12 and Gα13 siRNA. 
The magnitude of absorbance in cells treated with LPA was around 
0.15 for all conditions except when ASM were treated with Gα12 and 
Gα13 siRNA, which reduced the absorbance to 0.03. The reduction in 
LPA-induced RhoA activation seen in ASM cells treated with Gα12 and 
Gα13 siRNA was not significant due to the statistical test used, 
however is likely to be significant if additional replicates were carried 
out, due to the large effect size and narrow confidence interval. It is 
notable that there is still a very small increase in LPA-induced RhoA 
activation in cells treated with Gα12 and Gα13 siRNA, however this 
could be due to incomplete protein knockdown or crosstalk from 
other G-protein families. Taken as a whole this experiment clearly 
shows that LPA-induced RhoA activation is primarily controlled by the 
















































LPA-induced RhoA activation at 3 minutes in ASM cells

























Figure 6.3. Note: this is the same graph as that shown in figure 4.13, 
however this graph additionally shows results from Gα12 and Gα13 
siRNA treated cells, which were cropped out in figure 4.13.   
Human asthmatic ASM cells were mock transfected, transfected with 
control siRNA, Gαq and Gα11 siRNA, or Gα12 and Gα13 siRNA for 72 hours 
(n=3 cell lines). Cells were treated with 100μM LPA for 3 minutes after 
siRNA transfection and active RhoA measured by ELISA. LPA-induced 
RhoA activation was blocked by treatment with Gα12 and Gα13 siRNA. 





6.3.3 LPA-induced pSmad2 is not reduced in ASM cells treated with 
Gα12 and Gα13 siRNA 
To determine whether Gα12 and Gα13 knockdown had an effect on LPA-
induced TGFβ activation, ASM cells were treated with 100µM LPA for 
4 hours, 72 hours post-transfection.  For each experiment Gα12 and 
Gα13 protein was measured by western blot and quantified by 
densitometry to ensure that there was sufficient protein knockdown. 
There was significant knockdown of both Gα12 and Gα13 protein that 
was approximately 60% lower than the control siRNA group (figure 
6.4). It is also notable that transfection with control siRNA appears 
to slightly increase Gα12 and Gα13 protein. These data combined with 
the functional effect of Gα12 and Gα13 knockdown on RhoA (figure 6.3) 
suggest that protein knockdown was sufficient to analyse the role of 






Figure 6.4. Human asthmatic ASM cells mock transfected, transfected 
with control siRNA, or Gα12 and Gα13 siRNA for 72 hours (n=3 cell lines).  
Representative western blots showing Gα12 protein and densitometry, 
A, and G13 protein and densitometry, B, from siRNA transfection 
experiments where ASM cells were treated with LPA. There was 
significant knockdown of both Gα12 and Gα13 in all experiments versus 
the control siRNA group (n=3 cell lines) shown by densitometry. Data 
is presented as median ± IQR. Statistical test used was a Mann-




Once knockdown had been determined, asthmatic ASM cells were 
treated with 100μM LPA for 4 hours, 72 hours post-transfection. The 
ratio of pSmad2 to Smad2/3 was measured by western blot to 
determine activation of the TGFβ signalling pathway. Densitometry 
was used to quantify western blots. LPA induced a strong pSmad2 
signal in all conditions that was not inhibited by treatment with Gα12 
and Gα13 siRNA (figure 6.5). The median ratio of pSmad2 to Smad2/3 
was around 25-50% lower in both siRNA treated groups versus the 
mock transfected group, however the siRNA groups have a much 
wider confidence interval. There was no difference between the 
control siRNA group and Gα12 and Gα13 group, which had wide 
overlapping confidence intervals. These data clearly indicate that 
siRNA knockdown of Gα12 and Gα13 does not inhibit LPA-induced 







Figure 6.5. Human asthmatic ASM cells mock transfected, transfected 
with control siRNA, or transfected with Gα12 and Gα13 siRNA for 72 
hours (n=3 cell lines). Cells were treated with 100μM LPA for 4 hours 
after transfection. Representative western blot showing pSmad2 and 
Smad2/3, A. Densitometry shows that LPA-induced pSmad2 was not 
reduced in ASM cells treated with Gα12 and Gα13 siRNA, B. Data is 




6.3.4 Cyclical mechanical stretch-induced pSmad2 is not reduced in 
ASM cells treated with Gα12 and Gα13 siRNA   
Next, the role of Gα12 and Gα13 in cyclical mechanical stretch-induced 
TGFβ activation was assessed using siRNA targeting using the same 
method described above. Human asthmatic ASM cells were subjected 
to 15% stretch at a frequency of 0.3Hz for 4 hours, 72 hours post-
transfection. To ensure that there was protein knockdown at the time 
of the experiment, both Gα12 and Gα13 protein was measured by 
western blot for each experiment and quantified by densitometry. 
There was approximately 90% knockdown of Gα12 in stretched ASM 
cells and around 70% knockdown in unstretched ASM cells (figure 
6.6A). A comparison of all conditions in the control siRNA group 
versus the Gα12 and Gα13 siRNA group showed that there was 
significant knockdown of Gα12. Analysis of Gα13, however, showed that 
there was no difference between the control siRNA group and Gα12 
and Gα13 group (figure 6.6B). This indicated that there was no 







Figure 6.6. Human asthmatic ASM cells mock transfected, transfected 
with control siRNA, or Gα12 and Gα13 siRNA for 72 hours (n=3 cell lines).  
Representative western blots showing Gα12 protein and densitometry, 
A, and G13 protein and densitometry, B, from siRNA transfection 
experiments where ASM cells were subjected to 15% stretch at 0.3Hz 
for 4 hours. There was significant knockdown of Gα12 but not Gα13 in 
all experiments versus the control siRNA group (n=3 cell lines) shown 
by densitometry. Data is presented as median ± IQR. Statistical test 





Next, pSmad2 and Smad2/3 were measured by western blot and 
quantified by densitometry to determine whether there had been 
activation of the TGFβ signalling pathway (figure 6.7). Stretch 
induced an increase in pSmad2 in the mock transfected group. 
Interestingly, siRNA transfection of either control siRNA or Gα12 and 
Gα13 siRNA increased basal pSmad2 in unstretched cells, which was 
also seen in transfected unstretched ASM cells in chapter 5 (figure 
5.5), but not in any experiments using LPA. There was no stretch-
induced pSmad2 increase in the control group, in part due to an 
increase in basal pSmad2 in unstretched cells. However, stretch did 
induce an increase in pSmad2 in the Gα12 and Gα13 siRNA group, with 
a median that was 3-fold higher than unstretched cells. This effect 
was comparable to stretch-induced pSmad2 in Gαq and Gα11 siRNA 
treated cells in chapter 5 (figure 5.5). Although the confidence 
interval is too wide to conclude that siRNA knockdown of Gα12 and 
Gα13 results in an increase in stretch-induced pSmad2, it is clear that 







Figure 6.7. Human asthmatic ASM cells mock transfected, transfected 
with control siRNA, or transfected with Gα12 and Gα13 siRNA for 72 
hours (n=3 cell lines). Cells were subjected to 15% stretch at a 
frequency of 0.3Hz for 4 hours. Representative western blot showing 
pSmad2 and Smad2/3, A. Densitometry shows that LPA-induced 
pSmad2 was not reduced in ASM cells treated with Gα12 and Gα13 




6.3.5 Quadruple knockdown of Gαq, Gα11, Gα12, and Gα13 by siRNA 
does not inhibit LPA-induced pSmad2 in ASM cells 
The question remained that if blocking Gαq and Gα11 or Gα12 and Gα13 
did not block stretch- or LPA-induced pSmad2 in ASM cells, what 
would happen if all of these G-proteins were knocked down. The 
same siRNA protocol was followed as described previously in this 
chapter, but instead used all 4 siRNA oligonucleotides. Human 
asthmatic ASM cells were treated with LPA for 4 hours, 72 hours after 
transfection. Initially, western blotting was used to determine 
efficient protein knockdown for each experiment. There was around 
90% knockdown of both Gαq and Gα11, which was statistically 
significant when comparing the control siRNA group with the Gαq, 






Figure 6.8. Human asthmatic ASM cells mock transfected, transfected 
with control siRNA or, Gαq, Gα11, Gα12 and Gα13 siRNA for 72 hours (n=2 
cell lines). Representative western blots showing Gαq and Gα11 protein, 
A, and densitometry, B. ASM cells were treated with 100µM LPA for 4 
hours, 72 hours after siRNA transfection. There was significant 
knockdown of both Gαq and Gα11 in all experiments versus the control 
siRNA group (n=3 cell lines) shown by densitometry. Data is 
presented as median ± IQR. Statistical test used was a Mann-Whitney 




Gα12 and Gα13 protein was also measured to determine knockdown 
efficiency (figure 6.9). There was efficient knockdown of Gα12 of 
around 90%, however this was not significant because of wider 
confidence intervals within the control siRNA group. On the other 
hand, there was no knockdown of Gα13 compared to the control siRNA 
group, similar to what was seen in experiments described above 
(figure 6.6). These data show that knockdown of Gαq and Gα11 or Gα12, 







Figure 6.9. Human asthmatic ASM cells mock transfected, transfected 
with control siRNA, or Gαq, Gα11, Gα12 and Gα13 siRNA for 72 hours (n=2 
cell lines). Representative western blots showing Gα12 protein and 
densitometry, A, and G13 protein and densitometry, B, from siRNA 
transfection experiments where ASM cells were treated with 100µM 
LPA for 4 hours. There was good but not significant knockdown of Gα12 
and no knockdown of Gα13 in all experiments versus the control siRNA 
group (n=2 cell lines) shown by densitometry. Data is presented as 
median ± IQR. Statistical test used was a Mann-Whitney U of control 




After determining the efficiency of siRNA knockdown, pSmad2 and 
Smad2/3 were measured by western blot and quantified by 
densitometry (figure 6.10). This was to determine TGFβ activation 
because pSmad2 is the first signalling event in the TGFβ signalling 
pathway. There was a large induction of pSmad2 in all groups treated 
with LPA. The median of both siRNA treated groups was around half 
the mock transfected group, although there were only 2 replicates 
and a wide confidence interval. There was no difference in LPA-
induced pSmad2 in the control siRNA group versus the Gαq, Gα11, Gα12, 
and Gα13 siRNA group. Data shown here has a similar trend as that 
seen in LPA-induced pSmad2 in ASM cells treated with Gα12 and Gα13 
siRNA (figure 6.5). These data suggest that neither Gαq and Gα11 or 
Gα12 are required for LPA-induced TGFβ activation, however there 
was no knockdown Gα13 therefore it is not possible to conclude 








Figure 6.10. Human asthmatic ASM cells mock transfected, 
transfected with control siRNA, or Gαq, Gα11, Gα12 and Gα13 siRNA for 72 
hours (n=2 cell lines). Cells were treated with 100μM LPA for 4 hours, 
72 hours after transfection. Representative western blot showing 
pSmad2 and Smad2/3, A. Densitometry shows that LPA-induced 
pSmad2 was not reduced in ASM cells treated with Gαq, Gα11, Gα12 and 





The pleiotropic cytokine TGFβ is known to play a central role in 
fibrotic diseases and can induce the expression of fibrotic genes that 
contribute to airway remodelling seen in the airway of severe 
asthmatic patients. Overexpression of TGFβ and pSmad2 in the 
asthmatic airways has been linked to subepithelial fibrosis, ASM cell 
hyperplasia and hypertrophy, epithelial damage, goblet cell 
hyperplasia, and angiogenesis (1, 211, 214). It is therefore 
important to fully understand the mechanism by which TGFβ 
becomes activated in the airways of severe asthmatics, who suffer 
from frequent exacerbation.  
In chapter 4 and 5 of this thesis it was clear that the heterotrimeric 
G-proteins Gαq/11 do not play a role in either LPA- or stretch-induced 
TGFβ activation in ASM cells. This is in contrast to findings in murine 
embryonic fibroblasts that showed Gαq to be the G-protein that led to 
LPA-induced TGFβ activation (128). Moreover, forced ventilation-
induced TGFβ secretion in mice was abrogated by epithelial 
knockdown of Gαq/11 (127). The heterotrimeric G-protein that 
transmits extracellular LPA and stretch signals to induction of TGFβ 
activation in ASM cells has not been analysed.  
Research across a range of cell types, looking at both TGFβ synthesis 
and activation, have identified RhoA and its effector ROCKI/II as 
central to this pathway (128, 175, 183). In murine embryonic 
fibroblasts both LPA- and PAR1-induced TGFβ activation was 
abrogated by an inhibitor of RhoA or ROCKI/II (128, 175). Further, 
mechanical stretch-induced TGFβ1 expression in ASM cells was 
abrogated by inhibiting RhoA or ROCKI/II (183). The heterotrimeric 
G-proteins Gα12/13 are found to be upregulated in the bronchial 
smooth muscle of rats subjected to repeated antigen exposure(154). 




RhoGEF, LARG, and p63-RhoGEF (148, 149). In Gαq/11 deficient mice, 
LPA was able to induce stress fibre formation, a process associated 
with RhoA activation, via Gα13 (331). These studies indicated that 
Gα12/13 were a good candidate for LPA- and stretch-induced TGFβ 
activation.  
There are currently no commercially available molecular inhibitors of 
Gα12/13, therefore genetic approaches were required to manipulate 
this pathway. Knockdown of Gα12/13 was done by using siRNA, which 
effectively abolished Gα12/13 mRNA at 24, 48, and 72 hours after 
transfection (figure 6.2). RhoA was the first endpoint to be measured 
after knockdown of Gα12/13. Knockdown of Gαq/11 was also carried to 
determine whether there was a dual role for these G-protein families 
in RhoA activation, or whether regulate distinct pathways. There was 
a clear drop in LPA-induced RhoA activation at 3 minutes in ASM cells 
treated with siRNA targeting Gα12/13, but not Gαq/11. The effect of 
Gα12/13 siRNA didn’t bring the median RhoA activation to the level of 
cells that were not treated with LPA. This may have been due to not 
achieving 100% protein knockdown, or due to Gαq/11 being able to 
activate RhoA albeit with far less potency. It isn’t possible to state 
which of these hypotheses are true because protein knockdown 
wasn’t measured during this experiment. It is clear however, that 
knockdown of Gα12/13 had a functional effect on RhoA activation. This 
is the first time that Gα12/13 have been shown to regulate LPA-induced 
RhoA activation in ASM cells. No previous studies have ascertained 
which family of heterotrimeric G-proteins regulates RhoA in ASM 
cells.  
Next, pSmad2 was measured to determine whether Gα12/13 was 
required for LPA-induced TGFβ activity in ASM cells. Previous studies 
have shown that Gαq was required for LPA-induced TGFβ activation 




that this is not the case in ASM cells (128). No reduction in LPA-
induced pSmad2 was observed in ASM cells treated with siRNA 
targeting Gα12/13. This result was surprising because knockdown of 
Gα12/13 blocked RhoA activation, therefore the hypothesis was that it 
would also block pSmad2 signalling. Indeed, inhibition of RhoA 
activation was measured 3 minutes after LPA treatment, whereas 
pSmad2 was measured after 4 hours of LPA treatment. However, it 
highly likely that RhoA activation was inhibited for the whole time 
course because siRNA knockdown is relatively stable and Gα12/13 
protein levels were significantly reduced. It is also notable that LPA-
induced pSmad2 activation was not increased in cells treated with 
Gα12/13 siRNA, which was the case in Gαq/11 siRNA treated cells in 
chapter 4. This suggests that knockdown of Gαq/11 amplifies TGFβ 
activation, whereas knockdown of Gα12/13 does not. 
Stretch-induced TGFβ synthesis has been shown to require RhoA and 
ROCKI/II in ASM cells (183). Indeed, inhibition of ROCKI/II 
abrogated stretch-induced pSmad2 in chapter 5 of this thesis. 
However, siRNA knockdown of Gα12/13 did not inhibit stretch-induced 
pSmad2, which in fact increased with a similar trend to that observed 
upon knockdown of Gαq/11 in chapter 5. It is clear that knockdown of 
Gα13 in cells undergoing a stretching regimen was not successful. The 
key difference between the conditions of stretched cells and LPA 
treated cells is the type of tissue culture plate. Cells undergoing 
stretch were on a flexible collagen I coated plate, whereas LPA 
treated cells were on a standard plastic plate. This may have effected 
knockdown efficiency, although this was not the case in knockdown 
of Gαq/11.  
Studies on stress fibre formation in fibroblasts have shown that LPA, 
bradykinin, and serotonin, act through Gα13 to induce this change 




and Gα13 in stress fibre formation in response to a variety of agonists 
(331). As there was no knockdown of Gα13 achieved in this 
experiment the question remains open as to whether it is involved in 
stretch-induced pSmad2. However, is also possible that RhoA 
activation in response to stretch does not occur in a paracrine or 
receptor mediated fashion. Indeed, a study that applied force directly 
to integrins on the surface of fibroblasts showed that the RhoGEFs 
LARG and GEF-H1 were activated in response to force (333). 
Moreover, both of these RhoGEFs were able to increase RhoA 
activation (333). This raises the possibility that stretch-induced TGFβ 
activation may be GPCR-independent and involve a feedback loop 
that starts with integrin activating RhoA, which in turn activates 
integrin and thus TGFβ activation. What is clear from this thesis is 
that ROCKI/II are essential for stretch-induced TGFβ activation, but 
Gαq/11 and Gα12 are not required. 
In this thesis, LPA-induced pSmad2 in ASM cells was not abrogated 
by either Gαq/11 inhibition with a small molecule inhibitor, Gαq/11 siRNA, 
or Gα12/13 siRNA. With genetic knockdown in particular, there can be 
indirect effects on other G-protein family members. In HeLa cells, 
both Gαi1 and Gα12 expression was increased in cells that had 
undergone siRNA knockdown of Gαq/11 (296). Further, Gαq/11 and 
Gα12/13 are both able to activate p63-RhoGEF and LARG, which in turn 
activate RhoA in some cell types (143, 144). Although this hasn’t 
been analysed in ASM cells it leaves open the possibility that there is 
crosstalk between these pathways. Moreover, LPA receptors have 
been shown to couple to Gαi/0, Gαq/11, Gα12/13, and Gαs (271). It was 
therefore important to rule out this possibility by knocking down both 
Gαq/11 and Gα12/13.  
Knockdown of Gαq, Gα11, and Gα12 was successful, however there was 




of a similar magnitude to knockdown Gα12/13 alone. These data 
suggest that LPA-induced pSmad2 may be acting via Gα13. 
Alternatively, it is possible that neither Gαq/11 nor Gα12/13 are required 
for LPA-induced TGFβ activation in ASM cells. Earlier in this chapter, 
knockdown of Gα12/13 was shown to inhibit RhoA activation. Although 
RhoA activation was not measured in this experiment, it would not 
be unreasonable to hypothesise that RhoA is being inhibited and 
therefore suggest that RhoA may not be required for LPA-induced 
TGFβ activation. Indeed, knockdown of Gαq/11 and Gα12/13, or Gα12/13 
alone did not inhibit LPA-induced pSmad2, however RhoA was 
inhibited by the latter. Moreover, inhibition of ROCKI/II in chapter 4 
did block LPA-induced pSmad2. These data would suggest that 
ROCKI/II but not RhoA are required for LPA-induced pSmad2. This 
hypothesis was in the process of being tested directly by using a C3-
exoenzyme that inhibits RhoA, however was cut short due to the 
COVID-19 pandemic. 
RhoA does not exclusively control ROCKI/II activation. Arachidonic 
acid is able to activate ROCKI/II by binding to its auto-inhibitory PH 
domain and induce contraction of smooth muscle fibres (298). 
Moreover, extracellular addition of arachidonic acid to rabbit artery 
strips has been shown to inhibit MLC phosphatase, a key effect of 
ROCKI/II activation (334). LPA has been shown to increase 
arachidonic acid in monocytes, but this has not been analysed in 
smooth muscle cells (335). ROCKI activation can also be induced by 
(phosphoinositide-dependent kinase-1) PDK1 binding in competition 
with its negative regulator RhoE (299). Moreover, LPA is able to 
induced PDK1 activation and stimulate cell growth via the AKT 
pathway in cancer cell lines (336).  
The final possibility is that there is a different heterotrimeric G-




receptors 1 to 5 are able to activate Gαi/0, Gαq/11, Gα12/13, and Gαs, 
however an analysis of which LPA receptors were expressed in ASM 
cells was not conducted in this thesis (271). LPA has been shown to 
induce cytoskeletal reorganisation in ASM cells via RhoA (279). 
Further, this effect was inhibited when both Gαq and Gαi2 were 
knocked down by siRNA, indicating that there is a level of crosstalk 
between these G-proteins (279). Gαi2 and Gαi3 expression has been 
shown to increase in the ASM of a murine and rat model of asthma 
respectively (160, 161). This raises the possibility of an involvement 
of the Gαi/0 family of G-proteins and perhaps a combination of families 
that contribute to TGFβ activation in ASM cells.  
In conclusion, this chapter has shown for the first time that Gα12/13, 
but not Gαq/11 are required for LPA-induced RhoA activation in ASM 
cells. Furthermore, Gα12/13 or Gαq/11 knockdown alone, nor Gαq/11 and 
Gα12 knockdown blocked LPA-induced pSmad2. Gα13 knockdown 
wasn’t sufficient to comment on its potential role. Knockdown of Gα12 
did not inhibit stretch-induced pSmad2. This chapter raises the 
possibility that there are other heterotrimeric G-protein families, or 
even a combination of G-proteins, regulate LPA-induced pSmad2 in 
ASM cells. Moreover, results in this thesis cannot conclude whether 
there is a role for heterotrimeric G-proteins in stretch-induced 
pSmad2, however it is clear that Gαq/11 or Gα12 alone are not 








7 Chapter 8: Conclusion and Future Direction 
7.1 Conclusions  
Asthma is a chronic inflammatory disease of the airways 
characterised by airway hyper-responsiveness, bronchoconstriction 
and inflammation, affecting 5.5 million people in the UK. 
Approximately 10% of asthmatics suffer from severe uncontrolled 
asthma, which induces structural changes in the lung. These changes 
are collectively termed airway remodelling and include, ASM 
hyperplasia and hypertrophy, subepithelial fibrosis, angiogenesis, 
epithelial shedding, and goblet cell hyperplasia (1). Airway 
remodelling is a progressive process that reduces lung function and 
restricts airflow. TGFβ is a pleiotropic cytokine that is central to 
airway remodelling and contributes to all of the structural changes 
outlined. It is therefore important to understand the precise 
mechanism by which TGFβ activation and therefore airway 
remodelling occur.  
This thesis is focussed on ASM cells, the primary contractile cells 
within the lung, and looked to define whether there is a role for 
heterotrimeric G-proteins in TGFβ activation. If one family of 
heterotrimeric G-proteins exclusively regulates TGFβ activation then 
it could be possible to develop inhibitors either targeting the G-
protein, or narrow down candidate GPCRs to target, thereby reducing 
airway remodelling in asthmatic patients. The overall hypothesis was 
that the heterotrimeric G-proteins Gαq/11 are responsible for initiating 
TGFβ activation in human ASM cells. The two methods for stimulating 
TGFβ activation were treating cells with LPA or subjecting them to a 
cyclical stretching regimen.  
The first aim of this thesis was to generate a Gαq/11 knockout ASM 
cells line. Tracheal ASM cells were isolated from Gqfl/flG11-/- mice with 




recombinase and an antibiotic resistance gene. This would have 
created a stable Gαq/11 knockout ASM cell line that could have been 
used as a tool to test the hypothesis is this thesis. Generation of cre-
producing lentivirus was successful because some murine embryonic 
fibroblasts were positively selected after incubation with lentivirus. 
However, it was not possible to replicate this in murine ASM cells. 
Further optimisation was carried out using a lentivirus encoding GFP 
to allow rapid visualisation of successful transduction. This resulted 
in some improvement in transduction efficiency in easy-to-transfect 
HEK T293 cells, again however, there was minimal transduction 
when this was replicated in murine ASM cells. 
Primary cells are more difficult to transduce than fast-growing 
commercially available cell lines. It is likely that the lentivirus yield 
was not high enough for transduction in primary ASM cells. One 
method that I would have liked to include in future studies is to 
maximise viral concentration and thus maximise the chance of 
transduction is centrifugation. In the past, concentrating virus 
required ultracentrifugation at 90,000xg for 1 hour, but this requires 
specialist equipment that isn’t always directly accessible (267). More 
recently, however, a method of centrifuging lentiviral media at an 
RCF of 10,000xg for 4 hours across a 20% glucose gradient has been 
shown to increase lentiviral transduction by 3-fold compared to un-
concentrated virus and 2-fold compared to ultracentrifugation (258). 
Despite optimisation of lentiviral transduction in murine ASM being 
unsuccessful, this method of concentrating lentivirus would be 
interesting to adopt in order to transduce primary ASM cells.  
LPA was used as a stimulus because it is able to induce a strong TGFβ 
signal and is increased in the airways of asthmatic patients (133). 
Moreover, it is able to activate heterotrimeric G-proteins from the 




analyse multiple signalling pathways. TGFβ1 mRNA expression has 
been shown to increase after uniaxial stretch in ASM cells, however 
TGFβ activation has not been shown in ASM cells subjected to a 
stretching regimen (183). Data from this thesis conclusively 
demonstrate, for the first time, that there is no role for the 
heterotrimeric G-protein family Gαq/11 in LPA- or stretch-induced 
TGFβ activation. This finding is in contrast to evidence in murine 
embryonic fibroblasts, which showed LPA-induced TGFβ activation to 
occur through Gαq (128).  
RhoA and its effector ROCKI/II have long been described as central 
to TGFβ activation in multiple cell types (128, 175, 183). This thesis 
showed that ROCKI/II are required for LPA-induced TGFβ activation 
in ASM cells. The Gα12/13 family have often been described as 
upstream of RhoA activation (337). Analysis of active RhoA after 
treatment with siRNA targeting Gαq/11 or Gα12/13 showed that Gα12/13 
and not Gαq/11 are upstream of LPA-induced RhoA activation in ASM 
cells. These data suggested that Gα12/13 would be a good candidate 
to prevent LPA-induced TGFβ activation. Moreover, rats subjected to 
repeated allergen exposure had increased expression of Gα12 and Gα13 
in bronchial smooth muscle (154). In this thesis, blocking Gα12/13 by 
siRNA had no effect on LPA-induced pSmad2, and therefore TGFβ 
activation. Moreover, targeting both Gαq/11 and Gα12/13 did not prevent 
LPA-induced pSmad2. However, knockdown of Gα13 protein was not 
achieved in this experiment, therefore it is only possible to conclude 
that Gαq/11 and Gα12 are not required for LPA-induced TGFβ activation. 
Despite knockdown of Gα13 not being complete at the protein level, 
siRNA appeared to functionally inhibit RhoA activation. It is important 
to note, however, that neither Gα12 nor Gα13 protein expression was 
measured while analysing RhoA activation, so protein knockdown 




inhibition of RhoA after Gα12/13 siRNA treatment, then it implies that 
RhoA is not required for LPA-induced TGFβ activation, but its effector 
ROCKI/II is. Indeed, this would be an interesting finding and set ASM 
cells apart from many other cell types that show RhoA to be central 
to integrin-dependent TGFβ activation (128, 175). This hypothesis 
was in the process of being tested by using a C3 exoenzyme to block 
RhoA, however experiments were halted by the onset of the COVID-
19 pandemic.  
There are a few proven mechanisms by which ROCKI/II can be 
activated independently of RhoA. Arachidonic acid has been shown 
to activate ROCKI/II by binding to its autoinhibitory PH domain and 
inducing contraction of smooth muscle fibres (298). LPA is able to 
increase arachidonic acid in monocytes, but this has not been shown 
in ASM cells (335). Another mechanism of RhoA-independent ROCK 
activation requires PDK1. ROCKI activation can be induced by PDK1 
binding in competition with its negative regulator RhoE (299). Many 
studies analysing ROCK focus on inhibiting both isoforms with the 
inhibitor Y27623. However, there are subtle differences between the 
roles of ROCKI and ROCKII. Analysis of the ROCKI/II in fibroblasts 
showed that siRNA depletion of ROCKI abrogated formation of stress 
fibres and focal adhesions, despite abundant ROCKII and active RhoA 
(338). Another study in vascular smooth muscle cells showed that 
ROCKII, but not ROCKI, was involved in cell contractility (339). 
Indeed, it would be interesting to inhibit ROCKI and ROCKII 
individually using small molecule inhibitors or siRNA to determine if 
one isoform regulates LPA-induced TGFβ in ASM cells. This could 
open up new avenues and narrow down the number of possible 
upstream activators that initiate TGFβ signalling. 
Another possible avenue that was not explored during this PhD was 




protein family. In a mouse and rat model of asthma both Gαi2 and 
Gαi3 expression was shown to be increased (160, 161). Moreover, LPA 
has been shown to activate RhoA and induce cytoskeletal 
reorganisation by a combination of Gαq and Gαi2 in ASM cells (279). It 
would have been interesting to test whether there is a role for the 
Gαi/o family of heterotrimeric G-proteins in LPA-induced TGFβ 
activation. Indeed, it is possible that inhibiting Gαi/o alone would not 
inhibit LPA-induced TGFβ because there is crosstalk and redundancy 
built in to G-protein signalling. However, it would be interesting to 
investigate in the future using both genetic approaches and pertussis 
toxin, which is a potent inhibitor of Gαi/0 (340).  
It is possible that a single heterotrimeric G-protein family is not 
responsible for LPA-induced TGFβ signalling. Initially, the fact that 
LPA receptors can couple to all of the heterotrimeric G-protein 
families seemed like an advantage. However, the inherent drawback 
of using such multisystem stimuli is that if there is a web of crosstalk 
built into the signalling pathways then trying to delineate a specific 
pathway becomes far more complex. Moreover, knockdown of 
heterotrimeric G-proteins using siRNA can alter expression of other 
G-proteins. For example, knockdown of Gαq/11 in HeLa cells caused an 
increase in expression of Gαi1 and Gα12 (296).  
Perhaps an alternative way of tackling the TGFβ signalling pathway 
would have been to adopt a top down approach. This could have 
involved analysing which LPA receptors were expressed in the human 
ASM cells used for experiments in this thesis. Subsequently, genetic 
knockdown of LPA receptors using siRNA or CRISPR could have been 
carried out to determine if a specific receptor was exclusively 
responsible for LPA-induced TGFβ activation. Then, a literature 
search of which heterotrimeric G-proteins are known to be coupled 




candidates. Of course, this method may have faced exactly the same 
challenges because LPA receptors often couple to multiple classes of 
heterotrimeric G-proteins (271).  
As for stretch-induced TGFβ activation in human ASM cells less 
conclusions can be drawn. 15% cyclical mechanical stretch is able to 
induce TGFβ signalling after 4 hours of stretch, and it appears that 
ASM cells from asthmatic patients activate more TGFβ than cells from 
non-asthmatics. This was expected because asthmatic ASM have 
been shown to activate more TGFβ than non-asthmatic ASM cells in 
response to methacholine and LPA (133). It is clear from data 
presented in this thesis that Gαq/11 alone are not responsible for 
stretch-induced TGFβ activation. Moreover, knockdown of Gα12 by 
siRNA showed that this heterotrimeric G-protein was also not 
responsible for stretch-induced TGFβ activation alone. Knockdown of 
Gα13 protein by siRNA was not successful in any stretch experiments, 
so the role of this protein remains unknown. 
RhoA activation was not assessed in response to stretch in this 
thesis. However, RhoA activation has been shown to increase after 1 
minute and peak after 5 minutes of 12% uniaxial stretch in human 
ASM cells (183). Inhibiting stretch-induced RhoA with a C3 
exonezyme abrogates TGFβ1 mRNA expression (183). In this thesis, 
inhibiting ROCKI/II abrogated a stretch-induced increase in pSmad2. 
These data suggest that the RhoA/ROCKI/II axis is important in ASM 
cells.  
This thesis hypothesised stretch-induced TGFβ activation in ASM cells 
was initiated by the release of a paracrine factor during stretch that 
binds to a GPCR. This was based on the observation that forced high-
pressure ventilation increased total lung TGFβ in mice, which was 
abrogated by epithelial knockout of Gαq/11 (127). This thesis neither 




Gα12 are required for stretch-induced TGFβ activation. Many factors 
are released from cells during stretch including angiotensin II, 
TGFβ1, endothelin-I, and matrix metalloproteinases (312-314, 322). 
MMP-9 has been shown to activate TGFβ in human lung fibroblasts 
cultured in collagen gels (341). Indeed this molecule was not 
specifically analysed in this thesis, however it may be interesting to 
see if inhibition of MMP-9 by siRNA reduced TGFβ signalling in ASM 
cells. The challenge with determining whether a paracrine factor 
released from cells activates TGFβ is that stretch itself induces the 
release of TGFβ. This makes media transfer experiments redundant 
because the TGFβ in the media would directly activate its receptor. 
Moreover, it isn’t possible to treat conditioned media with proteases 
or heat shock due to the presence of TGFβ. There are too many 
factors within the media to design a clearly defined experiment, 
without a panel of candidates, to determine which released mediator 
actives TGFβ.  A possible option to determine a panel of candidates 
could be to use mass spectrometry and compare the constituents of 
media from stretched versus unstretched ASM cells. 
It is possible that stretch-induced TGFβ activation may occur directly 
in response to force. Integrins in focal adhesion complexes that are 
bound to the collagen coated plates will transduce force directly to 
the cytoskeleton during a stretching regimen. This may then activate 
integrins that are able to liberate active TGFβ from its latent 
associated peptide. Therefore, it is possible that no GPCR is involved 
in stretch-induced TGFβ activation. There have been several studies 
in smooth muscle cells that have shown stretch to activate RhoA and 
therefore ROCKI/II (342-344). Moreover, RhoA/ROCKI/II pathway 
has been described as essential to the formation of stress fibres in 
response to stretch (344). Growth of focal adhesions have been 




via cell surface integrins (345). This thesis concludes that ROCKI/II, 
but not Gαq/11 nor Gα12, are required for stretch-induced TGFβ 
activation in ASM cells. It is therefore possible that cyclical stretch 
induced the activation of RhoA, ROCKI/II, and formation of focal 




Figure 7.1. Working hypothesis of LPA-induced TGFβ activation action 
pathway in human ASM cells. Results in this thesis have shown the 
importance of ROCKI/II in LPA-induced TGFβ activation. Moreover, 
inhibition of RhoA activation through knockdown of Gα12/13 by siRNA 
did not inhibit pSmad2. This suggests that ROCKI/II activation may 
occur independently of RhoA in human ASM cells. Thus the working 
hypothesis is that LPA activates a single or multiple heterotrimeric G-





7.2 Concluding Remarks 
This thesis was designed to test the hypothesis that the 
heterotrimeric G-proteins Gαq/11 are required for TGFβ activation in 
ASM cells. Data presented clearly demonstrated for the first time that 
there is no role for Gαq/11 in LPA- or stretch-induced TGFβ activation 
in ASM cells. Collectively, ROCKI/II have been shown to be central 
to TGFβ activation and further delineation of the individual roles of 
ROCKI and ROCKII would be interesting. LPA-induced RhoA 
activation has been shown, for the first time, to be regulated by 
Gα12/13 heterotrimeric G-proteins in ASM cells. Data in this thesis 
suggests that there is no role for Gα12 in LPA-induced TGFβ activation 
and hints that RhoA may not be required for LPA-induced TGFβ 
activation. If correct this could be essential to further delineate 











Appendix 1. Human asthmatic ASM cells mock transfected, 
transfected with control siRNA, Gαq siRNA, Gα11 siRNA, or Gαq and Gα11 
(n=1 cell line). Gαq protein was measured by western blot 48 and 72 
hours post-transfection. Gαq protein was reduced in Gαq and Gαq + Gα11 
siRNA treated cells at 72 hours but not at 48 hours. Bands in the 72 








































Stretch induced pSmad2 in PCLS is inhibited


















Appendix 2. This graph is from Amanda Tatler and is not my own 
work. Precision cut lung slices (PCLS) were taken from non-asthmatic 
human donors and attached to a Flexwell tissue culture plate. PCLS 
were subjected to 15% stretch for 48 hours at a frequency of 0.3Hz 
and pSmad2 was measured by ELISA (n=2 donors). PCLS were 
incubated with 10nM of the Gαq/11/14 inhibitor YM254890 for 45 minutes 
prior to stretch. Stretch induced an increase in pSmad2, which was 





8.2 Appendix 2: Buffer Recipes  
8.2.1  Western Blot Buffers 
Lysis Buffer:  
50mM Tris-HCL pH 6.8, 150mM NaCl, 1% TritonX 100, 0.1% 
SDS, 0.5% deoxycholic acid, 10µl/ml NaVO4, and 0.01M EDTA. 
Before use, 1µl/ml leupeptin, 20µl/ml PMSF, and 40µl/ml 
protease inhibitor cocktail and Phos-STOP were added. 
4x Laemmli Buffer: 
62.5mM Tris-HCL pH 6.8, 10% v/v glycerol, 1% w/v SDS, and 
0.01% bromophenol blue.  
Before use, 1% v/v β-mercaptoethanol was added. 
10x Transfer Buffer: 
50mM Tris base pH 8.3, 192mM glycine, and 20% v/v 
methanol. 
Buffer 1:  
 1.5M Tris-HCL, 0.4% SDS, pH 8.8. 
Buffer 2:  
 0.5M Tris-HCL, 0.4% SDS, pH 6.8. 
Tris Buffered Saline, and Tween (TBST): 
24.2g Tris Base, 87.6g NaCl, 1L dH20, pH 7.4-7.6, 10ml Tween 
20. 
10% Resolving Gel: 
 6.66ml 30% Bis/acrylamide, 5.2ml buffer 1, 7.92ml dH20. 






 1.3ml 30% bis/acrylamide, 2.5ml buffer 2, 6.1ml dH20. 
Before use, 50µl 10% ammonium persulphate and 10µl temed 
was added. 
8.2.2 Primer Sequences 
Gene Primer sequence 5’ -> 3’ 
GNAQ GGA CAG GAG AGA GTG GCA 
TGG GAT CTT GAG TGT GTC CA 
GNA11 CCA CTG CTT TGA GAA CGT GA 
GCA GGT CCT TCT TGT TGA GG 
GNA12 TTG AGG ACC GTG TTG TGT GT 
GCG TGC ACT GGA TGT CTA GA 
GNA13 GAC TCC AGT GAG GGC TCA AG 
AGC AGG GAA GAA AAC TGC AA 
PAI1 TCT GCA GAC CTG GTT CCC AC 
AGC CCC CGT AGT TCC ATC CTG 
Cre CGA GTG ATG AGG TTC GCA AG 
CCG GTA TTG AAA CTC GAG GG  
β2-M AAT CCA AAT GCG GCA TCT 








pSmad2 3108S Cell 
Signalling 
1mg/ml 1:1000 
Smad2/3 3102S Cell 
Signalling 
1mg/ml 1:1000 




Gα11 ab192507 Abcam 1mg/ml 1:1000 
Gα12 ab154004 Abcam 1mg/ml 1:1000 
Gα13 ab227494 Abcam 1.29mg/ml 1:1000 
Cre ab24607 Abcam 1mg/ml 1:1000 
GAPDH ab181603 Abcam 1.485mg/ml 1:10,000 
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